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ABSTRACT 
Information about viral etiologies of acute respiratory infections (ARIs) is essential 
for prevention, diagnosis and treatment but limited in developing tropical countries. This 
study described the clinical and epidemiological characteristics of viral ARIs in hospitalized 
children in Vietnam. Clinical data and nasopharyngeal samples were collected from children 
with ARIs at Ho Chi Minh City, Vietnam from April 2010 to May 2011. Four multiplex PCR 
assays were performed to detect 13 respiratory viruses. Viruses were detected in 64.6% of 
1,082 cases, with 12% of co-detection. The leading detected viruses were rhinovirus (HRV) 
(30%), respiratory syncytial virus (RSV) (23.8%), and human bocavirus (HBoV) (7.2%). 
HRV was detected all year round, while RSV epidemic occurred mainly in the rainy season. 
Influenza A virus (FLUA) was found in both seasons with H3N2 in the rainy season and 
pandemic H1N1 2009 in the dry season. Other viruses were predominant in the dry season. 
HRV was detected in all age groups. RSV predominantly affected children < 6 months, 
parainfluenza virus (PIV) 1 6 – 12 months, PIV3 and HBoV 12 – 24 months, and FLUA > 24 
months. PIV1 detection was associated with croup (p<0.005) and RSV detection was 
associated with bronchiolitis (p<0.005). HBoV and HRV were associated with hypoxia 
(p<0.05) and RSV was associated with chest retraction (p<0.05). RSV subgroup A had 
severity score higher than subgroup B (p<0.05). Pandemic H1N1 2009 virus and co-detection 
of other viruses did not lead to severer symptoms. In conclusion, HRV, RSV, and HBoV 
were the most commonly detected viruses and may increase the severity of ARIs in children. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Acute respiratory infections 
Acute respiratory infections (ARIs) are the most common illness in children that 
frequently lead to consultation in general practice and hospitalization. Young children 
experience about 4-8 respiratory tract infection episodes per year, and in older children the 
incidence is slightly lower with 2-6 episodes per year (1, 2). In developing countries, ARIs 
are still one of the leading causes of childhood mortality. Nearly 1 million children under five 
years old die from pneumonia in 2013, accounting for 15% of all deaths in this age group (3). 
In addition, ARIs cause a substantial burden on patients and their families, including the 
direct medical costs and the indirect costs of missed workdays or absences from school and 
day care (4).  
Although Streptococcus pneumoniae and Haemophilus influenzae type b are the 
major bacterial causes of pneumonia worldwide, viruses also have a significant role (5). 
Either involving in the upper or the lower respiratory tract, respiratory syncytial virus (RSV), 
parainfluenza viruses (PIV), influenza (FLU) A and B viruses, and human rhinovirus (HRV) 
were being the most commonly identified (6). Other pathogens such as human coronavirus 
(HCoV), adenovirus (AdV), and enterovirus infected the respiratory tract at a lower 
frequency (7). Since 2001, five newly discovered respiratory viruses have emerged including 
human metapneumovirus (hMPV) (8), human bocavirus (HBoV) (9), HCoV NL63 (10), 
HCoV HKU1 (11), and severe acute respiratory syndrome (SARS) CoV (12).  
The clinical significance of most respiratory viruses was well described. However, 
they usually have overlapping clinical manifestations so that it is difficult to distinguish the 
etiologic agents without a laboratory diagnosis. Most respiratory viral infections are confined 
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to the upper respiratory tract with symptoms such as coryza and cough. One third of ARIs in 
children develops lower respiratory tract symptoms such as wheezing, tachypnea and 
respiratory distress (13).  
Respiratory viruses 
Historically, viruses associated with ARIs were RSV, PIV, FLU, AdV, HCoV and 
HRV. Of these, the latter two viruses were primarily associated with upper respiratory tract 
infections (URTIs). The former viruses were mainly responsible for lower respiratory 
infections (LRTIs) (6, 7). 
RSV is one of the most important pathogen of childhood and is associated with 
significant morbidity and mortality. RSV is generally considered as the main cause of 
bronchiolitis in young children. Most children will develop antibodies against RSV by the 
age of 2 years. Despite much effort, there is no safe vaccine available. Risk factors for severe 
RSV infections are young age, prematurity, chronic lung disease, congenital heart disease, 
Down syndrome, and immunodeficiency. Early infection with RSV during infancy is 
associated with increased development of asthma in children. RSV has a clear seasonal 
pattern, with peak of infection occurring annually in the winter season of temperate countries. 
RSV is a negative-sense single-stranded RNA virus belongs to the Paramyxoviridae family. 
There are two major antigenic subgroups, A and B, with a single RSV serotype. Strains of 
both subgroups often co-circulate, but usually one subgroup predominates (14).  
FLU is a negative-sense single-stranded segmented RNA virus belonging to the 
family Orthomyxoviridae. The high rate of HA and NA gene mutation results in antigenic 
drift and causes the recurrent annual influenza epidemics seen in cold season in temperate 
climates. Since 1977, two FLU A subtypes H3N2 and H1N1 have been co-circulating with 
FLU B (15). In addition, the segmented nature of the influenza genome allows the re-
assortment of genetic materials between two different influenza A viruses co-infecting the 
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single host cell (antigenic shift), which gives FLU A the potential for the development of 
global pandemics (7). In 2009, the WHO declared the influenza pandemic caused by the 
novel H1N1 influenza A virus which originated from the triple-reassortant swine influenza 
(H1) virus circulating in Northern America pigs (16). Influenza is a febrile illness 
characterized by respiratory and systemic symptoms that result in a significant number of 
hospitalizations in all age groups. Among children, those younger than 2 years of age or those 
with underlying diseases are most susceptible to severe consequences of influenza infection. 
Influenza activity peaks in the winter season of temperate zone but throughout the year in 
tropical countries (17). In the hospital setting, the identification of influenza virus is 
important, as appropriate infection control measures are crucial in preventing the outbreaks.  
HRV is a positive-sense single-stranded RNA virus belonging to the family 
Picornaviridae. HRVs have been divided into 3 species A, B, and C, and further subdivided 
into more than 150 types. HRV C, which was described in recent years, has been associated 
with more severe diseases than the earlier identified ones. HRVs were long considered as 
only “the common cold” agent and were ignored by the medical community until recently, 
when their clinical spectrum of diseases expanded. Recent reports showed the infection rates 
higher than expected of HRVs among children hospitalized with LRTI. HRVs have gained 
more interests as the main cause of asthma exacerbations, severe LRTIs and wheezing in 
young children. HRV infections occur year round, but most frequently in late spring and early 
fall (18, 19). 
PIV is a negative-sense single-stranded RNA virus and belongs to the family 
Paramyxoviridae. Four serotypes of PIV were known to infect humans. PIV1 mainly causes 
acute croup in infants and young children but also causes ARIs in all age groups. PIV1 
outbreaks usually occur in fall in temperate climates. PIV2 is generally associated with mild 
URTI, croup in children, and occasionally, LRTI in fall months but less often than PIV1 and 
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PIV3. PIV3 is a common cause of severe LRTI in young children with a peak incidence in 
the first year of life. Infections with PIV3 occur all year round with high prevalence in winter 
and spring months in temperate climates. PIV4 is the least common of this group and is 
generally associated with mild URTI (7). 
AdV is a double-stranded DNA virus belonging to the family Adenoviridae. More 
than 50 serotypes of adenovirus have been described and categorized into six subgenera (A to 
F). Serotypes 1-5, 7, 14, 19, and 37 infect the respiratory tract most often, and cause diseases 
vary from mild URTIs to severe LRTIs. Following infection, AdV can remain in the host for 
a long time. AdV can be shed from the upper respiratory tract for a week in adults and up to 6 
weeks in children (7). 
Over the past decade, several new viruses have been discovered as respiratory viruses. 
HBoV, a single-stranded DNA virus within the family Parvoviridae, was discovered for the 
first time in 2005 by Allander and colleagues in Sweden but then occurs globally (9, 20). 
HBoV has been detected in children with LRTI, mainly acute wheezing, and has been 
associated with abnormal chest radiographic findings. However, the causative role of HBoV 
was not clearly established since HBoV was often detected concurrently with other viral 
pathogens in one- to two-thirds of cases (20). In several studies, HBoV is rarely detected in 
asymptomatic individuals (20, 21). This is the evidence that HBoV can cause LRTI, in 
particular, acute wheezing. 
Human metapneumovirus is a negative-sense single-stranded RNA virus that was 
discovered in the Netherlands in 2001 and belongs to the family Paramyxoviridae, and the 
genus Pneumovirus (8). hMPV causes both URTI and LRTI with the signs and symptoms are 
very similar to those caused by RSV. hMPV is also one of the common viruses detected in 
ARI patients with the prevalence has ranged from 3 to 25% in children <5 years old 
hospitalized with ARIs (7). 
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 HCoV is a positive-sense single-stranded RNA virus within the family Coronaviridae. 
Up to now, five HCoVs have been identified including 229E, OC43, SARS-CoV, NL63, and 
HKU1. HCoV-OC43 and HCoV-229E, which were identified in the mid-1960s as a cause of 
one-third common cold cases, have associated with both URTI and LRTI (7). HCoV-NL63 
which was discovered in the Netherlands in 2004 associated with croup and other symptoms 
of URTI and LRTI (10). HCoV-HKU1 was discovered in 2004 in Hong Kong and mostly 
associated with LRTIs (11). 
Acute respiratory infections in Vietnam and rationale for this thesis 
Vietnam is a developing country with the population of 90 million people as of 2012.  
Children under 15 years old accounted for 23% of the population (22). Together with the 
development of socioeconomics, the health care system of the country has been much 
improved. The under-five mortality rate which was 39.1 in 2000 had fallen rapidly to 24.1 per 
1,000 live births in 2013 (3). According to the national health insurance policy, children <6 
years of age receive the medical care free of charge in the public sector. The expanded 
program on immunization is also considered a successful child health care program, where 
children can receive free vaccination against tuberculosis, pertussis, measles, Hemophilus 
influenzae type b, etc. Pneumococcal and influenza vaccines are also available but on the fee-
for-service basis.  
However, ARIs are still a major burden on the families and the health care system in 
Vietnam. Pneumonia is the third leading cause of death among children aged less than 5 years 
in this country, representing 11.4% of all deaths in this age group (3). One third of hospital 
admissions among children are due to pneumonia. Furthermore, the average cost for 
childhood pneumonia treatment in Vietnam was estimated approximately one-tenth of the 
per-capita gross national product (GNP), in which the cost of medicament represented more 
than a half of the total treatment costs (23). Antibiotic resistance, usually as a consequence of 
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the unnecessary or inappropriate use of antibiotics in treatment of ARIs, is also a particular 
problem in Vietnam, which has one of the highest rates of penicillin and macrolide resistant 
pneumococci of all Asian countries (24, 25). Therefore, data on the causative agents of ARIs 
are extremely important and necessary in this country. Since it provides insight into the 
etiology, specific treatment can be applied and preventive measures can be implemented. As 
a result, the relative burden of disease caused by different respiratory pathogens can be better 
defined. 
However, viral etiology data for ARIs in Vietnam and Southeast Asia, where recently 
occurred severe outbreaks of SARS-coronavirus as well as avian and H1N1 pandemic 2009 
(H1N1pdm09) influenza, are scarce. During 2004-2008, Do et al. conducted a study to 
identify the viral etiology of ARIs among hospitalized children in Ho Chi Minh City (26). 
From 2007 to 2008, Yoshida et al. carried out another study in central Vietnam indicating the 
diversity of viruses causing ARIs in Vietnamese children (27). However, these studies did not 
describe the clinical impact between different kinds of viruses. Moreover, the temporal 
characteristics may influence the yearly epidemic of respiratory viruses. Therefore, this study 
was conducted to identify the common viral pathogens and describe their epidemiological 
and clinical features as well as evaluate their effect on disease severity of ARIs. 
Previous studies and the primary result of this study showed that HRV, RSV, HBoV, 
PIV, and FLU A were the leading detected viruses among hospitalized children with ARIs in 
Vietnam (26, 27). However, these studies did not describe the molecular characteristics of 
respiratory viruses. During 2001 – 2006, Li et al. analyzed the evolutionary patterns of H1N1 
and H3N2 viruses in Vietnam and found that the genetic evolution of HA, NA, M genes 
occurred independently and new strains in Vietnam may be appear earlier than in temperate 
zones (28). Vuong et al. analyzed the influenza viruses in Vietnam from 2001 to 2009 and 
found varying degrees of genetic similarity with vaccine strains of the Northern or Southern 
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Hemisphere (29). Since then, especially after the pandemic period, there is no updated 
information about the genetic characteristics of influenza viruses in Vietnam. 
Being considered as the main causes of ARIs but having no or limited information on 
molecular characteristics in Vietnam, the four viruses mentioned above, HRV, RSV, HBoV 
and FLU A, were targeted in my studies. In addition to clinical features, the molecular 
epidemiology of these viruses was further characterized. Due to limit of time, PIVs and other 
minor viruses detected in this study were not analyzed further. 
Aims of the thesis 
While the specific research objectives were described in each of the research chapters 
from 2 through 6, the comprehensive objectives of this thesis were to describe the 
epidemiological and clinical features of common viruses detected from hospitalized children 
with ARIs at Ho Chi Minh City, Vietnam during 2010-2011, as well as to analyze the 
molecular characteristics of major viruses identified from this study. 
Outline of the thesis 
 This thesis was organized into five major research chapters (chapters 2 through 6) 
together with the introductory and summary chapters. In chapter 2, the clinical and 
epidemiological characteristics of ARIs in Vietnamese children were described. Then, the 
typing, genetic characteristics and clinical features of FLU A, RSV, HBoV and HRV were 
described in the following chapters from 3 to 6. 
Patient recruitment 
Study site and patients 
 The study was conducted from April 1, 2010 to May 31, 2011 at the Respiratory 
Ward, the Children’s Hospital 2, Ho Chi Minh City, Vietnam. The Children’s Hospital 2 is a 
1,400-bed tertiary referral and university-affiliated hospital, receiving pediatric patients from 
most parts of the city as well as other provinces in the south and southern central, Vietnam. 
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Since Children’s Hospital 2 is one of the three national pediatric hospitals and usually in the 
patient overload situation, the inpatient admission criteria are strictly followed (Table 1).  
Table 1. Admission criteria for ARIs at Children’s Hospital 2 Ho Chi Minh City. 
Indications for hospital admission 
• Persistent SpO2 ≤92% in room air 
• Cyanosis 
• Markedly elevated respiratory rate (>70 breaths/min) 
• Dyspnea and intercostal retractions 
• Risk factores: Chronic lung disease, Congenital heart disease (especially if 
associated with cyanosis or pulmonary hypertension), Immunocompromised 
diseases, Prematurity, Severe malnutrition  
• Age less than 3 months 
• Inability to maintain oral hydration in patients younger than 6 months 
• Difficulty in feeding as a consequence of respiratory distress 
• Parent unable to care for child at home 
 
This area has a tropical climate with two distinct seasons: rainy season (May-October) 
and dry season (November-April). The temperature does not change much during the year, 
and varied between 24-32 oC during the time conducting this study.  
Under-15-year-old children admitted for an ARI condition with an onset of illness less 
than 7 days before hospitalization were eligible for enrollment in the study. An ARI case was 
defined as any child presenting with cough and/or difficult breathing (30). Patients who had 
underlying chronic diseases (e.g. cystic fibrosis, bronchopulmonary dysplasia, congenital 
heart disease, immunodeficiency) or who were discharged from the hospital within the 
previous 7 days, or who had coexisting acute systemic illnesses (e.g. sepsis), or proven or 
suspected non-infectious respiratory symptoms (e.g. asthma), were all excluded from the 
study. Patients with previous respiratory infection within 3 weeks from the current 
hospitalization were also excluded to avoid prolonged viral shedding. Clinical samples and 
data were obtained on 2 fixed days (Monday and Thursday) each week from all the admitted 
children who satisfied the above criteria. During 14-month period from April 2010 to May 
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2011, a total of 11,777 patients admitted to Respiratory Ward of the Children’s Hospital 2 
and 1,082 cases of ARI were enrolled in this study. 
 
         
Figure 1. Map of Vietnam with location of Ho Chi Minh City and the south and 
southern center of Vietnam [source from (31)]. 
Clinical data 
 The research pediatricians explained and collected the signed consent from the 
participant’s parent or guardian. Then, he or she examined the patient and recorded the 
demographic and clinical data on a standardized questionnaire (Appendix 7-8).  
Demographic parameters included gender, age at diagnosis, birth weight, gestational 
age, personal history (day-care attendance, atopy, breastfeeding, previous wheezing episodes, 
exposure to tobacco smoke), family history (parental atopy, simultaneous respiratory 
infection in a family member), number of persons in household. Breastfeeding was defined as 
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being given mother milk up to the age of six months (32). Atopy was defined as a history of 
medical diagnosis of asthma, allergic rhinitis, eczema, or anaphylaxis. Exposure to tobacco 
smoke was considered positive if either parent smoked any number of cigarettes in the house. 
Clinical observations at admission included vital signs, symptoms and signs contributory to 
the diagnosis of ARIs, the presence of wheezing and chest retraction, and the trans-cutaneous 
oxygen saturation as measured by a portable pulse oxymeter (Siemens MicroO2, Siemens 
Medical Systems Inc., USA) using a pediatric sensor (Nellcor, CA, USA).  
The laboratory workup included complete blood counts (CBC), C-reactive protein 
(CRP), and chest X-ray (CXR). In cases where more than one CBC had been affected, only 
the first count was recorded. Blood cultures were done only on patients with complications of 
pneumonia (pleural effusion, empyema, lung abscess, etc) or clinical deterioration after initial 
antibiotic therapy. Sputum samples for culture and Gram stain were only obtained from 
patients who could produce sputum, which was not common in young children. Treatment 
course (type and duration of O2 support, antibiotic therapy) and outcome (duration of 
hospitalization and complications) were noted.  
The diagnosis was made on the basis of clinical findings and CXR. ARI patients with 
the presence of an infiltrate on CXR were categorized as pneumonia (33). Bronchiolitis was 
defined as ARI patient under 2 years old presenting with wheezing or crackles and 
hyperaeration, or atelectasis, or peribronchial thickening on CXR (34). 
Laryngotracheobronchitis (croup) was characterized by hoarseness, cough, and stridor (35). 
Upper respiratory tract infection (URTI) was defined as ARI with no abnormalities on CXR. 
The disease severity was assessed by using the previously published severity score as 
described in Table 2 (36-39). Patients were managed and discharged according to routine 
clinical practice. 
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Table 2. Clinical severity score. 
Symptom Point score 
Fever (>38oC) 1 
Cough  
      Mild 1 
      Moderate 2 
      Severe 3 
Rhinorrhea  
      Milda 1 
      Moderate to severeb 2 
Hoarseness 1 
Duration of illness >4 days 1 
Apnea 3 
Wheezing 5 
Cyanosis 5 
Chest retraction 5 
Tachypnea 5 
Severity score (sum)c 0-31 
 
aSuction 0–4 times/day or wipe every 2 hr or less. 
bSuction 5 times/day or 1 wipe/hr. 
cA higher severity score indicates severer disease. 
Clinical samples 
 Nasopharyngeal (NP) flocked swabs (MicroRheologics, Brescia, Italia) were obtained 
by trained personnel on 2 fixed days each week from all enrolled children within 24 hr after 
admission. The specimens were immediately placed in tubes containing 2 ml sterile 
physiological saline fluid and stored at - 20oC until further analysis at the laboratory. 
Ethical approval 
 This study was a collaborated project between Department of Developmental Medical 
Sciences, the University of Tokyo and Nihon University School of Medicine and Children’s 
Hospital 2. The experiments were mainly taken place at Nihon University School of 
Medicine laboratory. The study was approved by the Scientific and Ethical Committee of the 
Children’s Hospital 2, Ho Chi Minh City (#25A/QD-ND2) and Nihon University School of 
Medicine (#25-15-0). Written informed consent was obtained from parents or legal guardians 
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of all children enrolled in the study. Children under 6 years of age received treatment free of 
charge and this was not limited to study participants. Withdrawal of participants from the 
study did not affect the health care services they received. 
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CHAPTER 2 
CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF 
ACUTE RESPIRATORY INFECTIONS  
IN VIETNAMESE CHILDREN 
1. INTRODUCTION 
Acute respiratory infections (ARIs) are leading cause of morbidity and mortality 
among infant and young children worldwide. About 1 million children under 5 years of age 
died from pneumonia in 2013, accounting for 15% of all deaths in this age group and most of 
these deaths occurred in developing countries (3). In addition, ARIs cause a substantial 
burden on patients and their families, including the direct medical costs and the indirect costs 
of missed workdays or absences from school and day care (4). In Southeast Asia, several 
severe outbreaks such as SARS-coronavirus, avian and H1N1 pandemic 2009 influenza have 
recently occurred that makes ARIs become a more serious public health problem. Viruses are 
the most common cause of ARIs and the major reason for hospitalization among young 
children (7). However, due to limited resources and facilities, the role of individual 
respiratory virus in these settings has not been well documented. Better understanding of 
clinical and epidemiological characteristics of ARIs is essential for predicting the epidemics, 
estimating the etiologic agents, and establishing an effective prevention and treatment 
measures. Therefore, this study was conducted to identify the common viral pathogens 
among Vietnamese children hospitalized for ARIs, to describe the epidemiological and 
clinical features of ARIs, and to investigate the associations between detected specific viruses 
and the severity of ARIs. 
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2. MATERIALS AND METHODS 
Patients and samples 
 The clinical samples and data collection was described in detail in chapter 1. 
Virus detection 
Nucleic acids extraction  
Viral genomes were extracted directly from the respiratory specimens by using the 
QIAamp Viral RNA minikit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions and stored at -80oC. 
Reverse transcription (RT)  
For RT, 5 µl of extracted RNA was added to the reagent mixture consisting of 3 µl of 
5× First-Strand Buffer (Invitrogen, Carlsbad, CA), 0.8 µl of 10 mM dNTPs (Roche, 
Mannheim, Germany), 0.8 µl of 0.1 M DTT (Invitrogen), 0.8 µl of (200 U/µl) SuperScript 
Reverse Transcriptase III (Invitrogen), 0.8 µl of (1 µg/µl) random primer (hexa-
deoxyribonucleotide mixture) (Takara, Shiga, Japan), 0.5 µl of (33 U/µl) RNase Inhibitor 
(Toyobo, Osaka, Japan), and distilled water. The total volume of reaction mixture was 15 µl. 
The reaction was carried out at 50oC for 1 hr, followed by heating at 95oC for 5 min to 
inactivate the enzyme and then rapidly cooled on ice. cDNAs were stored at -20oC until 
further analysis. 
Screening for target viruses by multiplex (semi)-nested PCR 
Four separate sets of multiplex (semi)-nested PCR were used to detect 13 respiratory 
viruses in each NP sample (Table 3). Set 1 was to detect FLU A and B, RSV and hMPV. Set 
2 was to detect PIV type 1, 2, 3 and 4. Set 3 was to detect HRV, HCoV OC43 and 229E. Set 
4 was to detect AdV and HBoV. To increase the specificity, only samples positive on the first 
PCR assay were performed on the second PCR for confirmation. Samples positive for both 
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PCR assays were determined as positive. PCR assays for RNA pathogens (set 1-3) were 
performed as previously described (27). Test for DNA viruses was developed in this study 
using primers from published studies (40, 41). Briefly, 3 µl of (c)DNA was added to 22 µl the 
first-round PCR reaction mixture consisting of 5 µl of 5× Taq DNA polymerase buffer 
(Promega, Madison, WI, USA), 2.5 mM MgCl2, 0.4 mM dNTPs, 0.4 µM each of the first-
round primers, 1.25 U of (5 U/µl) Taq DNA polymerase (Promega, Madison, WI, USA),  and 
distilled water. The PCR was performed at 94oC for 3 min, followed by 40 cycles of 95oC for 
30 sec, 57 oC for 30 sec, 72 oC for 60 sec, and a final extension at 72 oC for 7 min, and then 
held at 10 oC. For the second PCR, 1 µl of the first-round product was used as the template in 
the PCR mixture as described above containing the second round primers and the same PCR 
cycling program was followed. Positive templates and buffer sample as negative control were 
added in each test run. 
 Electrophoresis  
The PCR products were run on 1.5% agarose gel, and the bands were visualized by 
SYBR Safe (Invitrogen, Tokyo, Japan) staining under blue LED (light-emitting diode). The 
results were recorded by photographer. The length of the PCR fragments was indicative of 
the putative pathogen. 
Statistical analysis 
Descriptive analyses for discrete variables were performed by using frequency 
distributions or rates. For continuous variables, medians with interquartile range (IQR) were 
used to describe the demographic and patients’ characteristics. 
Demographic and clinical characteristics of patients with virus positive were 
compared with those negative for virus. Patients with viral co-detection were also compared 
with those with mono-detection. Values were given as percentages for categorical variables, 
and as median with interquartile range (IQR) for continuous variables. Bivariate associations 
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were assessed by using χ2 test or Fisher’s exact test for categorical variables, and by using the 
Mann-Whitney U test for continuous variables. A two-sided value of p<0.05 was considered 
statistically significant.  
Multivariate logistic regression analyses were performed to determine the association 
of specific type of detected virus (HRV, RSV, HBoV, PIV1, PIV3, and FLU A) with severe 
symptoms and diagnostic classification. The outcomes were tachypnea, chest retraction, SpO2 
≤92% (for severe symptoms) and URTIs, croup, bronchiolitis, pneumonia (for diagnostic 
classification). Initially, univariate models were performed introducing as independent 
variables age, gender, prematurity, malnutrition, co-detection with other viruses, and type of 
detected virus. Subsequently, these variables (known as potential confounders) were 
introduced in a multivariate model with a step-wise approach, to eliminate the possibility of 
mutual confounding and interaction. Results were presented as odds ratio (OR) with 95% 
confidence interval (95% CI). ORs and 95% CIs that did not contain 1 were considered 
significant. The Hosmer-Lemeshow test was used to determine the goodness-of-fit of the 
model. 
All analyses were conducted using the Statistical Package for Social Sciences version 
16.0 (SPSS, Inc., Chicago, IL, USA). 
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Table 3.  Primers and PCR assays for multiplex PCR and (semi)-nested multiplex PCR. 
Assay Virusa Direction              Sequence (5’ – 3’)b Target genec Amplicon (bp) 
Set 1 
1st   
 
 
 
 
 
 
 
 
 
 
 
2nd   
 
 
 
 
FLU A 
 
 
FLU B 
 
 
RSV 
 
 
hMPV 
 
 
FLU A 
FLU B 
RSV 
Hmpv 
 
sense 
antisense 
 
sense 
antisense 
 
sense 
antisense 
 
sense 
antisense 
 
antisense 
antisense 
sense 
antisense 
 
CCTTCTAACCGAGGTCGAAACG 
GCATTTTGGACAAAGCGTCTACG 
 
AGACACAATTGCCTACCTGCTTTC 
CTGAGCTTTCATGGCCTTCTGC 
 
CATGACTCTCCTGATTGTGGGATG 
CCTTCAACTCTACTGCCACCTC 
 
TGAAGTCAATGCGACTGTAGCAC 
ATGCCTTTGGGATTGTTCATGGTC 
 
ACAGGATTGGTCTTGTCTTTAGCC 
AGTCTAGGTCAAATTCTTTCCCACC 
AGCAGCAGGGGATAGATCTGGTC 
TCACTGCTTATTGCAGCTTCAACAG 
 
Matrix  protein 
 
 
Matrix protein 
 
 
Nucleocapsid 
 
 
Matrix  protein 
 
 
Matrix protein 
Matrix protein 
Nucleocapsid 
Matrix  protein 
 
    241 
 
 
    352 
 
 
    271 
 
 
    371 
 
 
    151 
    106 
    201 
    287 
Set 2 
1st  
 
 
 
 
 
 
 
 
 
 
 
2nd   
 
 
 
 
PIV1 
 
 
PIV2 
 
 
PIV3 
 
 
PIV4 
 
 
PIV1 
PIV2 
PIV3 
PIV4 
 
sense 
antisense 
 
sense 
antisense 
 
sense 
antisense 
 
sense 
antisense 
 
sense 
antisense 
antisense 
antisense 
 
ATGATTTCTGGAGATGTCCCGTAGG 
TTCCTGTTGTCGTTGATGTCATAGG 
 
CAATCAATCCTGCAGTCGGAAGC 
AAAGCGATGCAGACCACCAAG 
 
GACACAACAAATGTCGGATCTTAGG 
ATACAGCCATCAACAGTCGTTGG 
 
CTGAACGGTTGCATTCAGGT 
TTGCATCAAGAATGAGTCCT 
 
CCACCACAATTTCAGGATGTGTTAG 
TAACATAGAGCCTACCTTCTGCACC 
GAAGACCAGACGTGCATCTCCA 
GTCTGATCCCATAAGCAGC 
 
HA-NA 
 
 
HA-NA 
 
 
HA-NA 
 
 
Phosphoprotein 
 
 
HA-NA 
HA-NA 
HA-NA 
Phosphoprotein 
 
    300 
 
 
    386 
 
 
    230 
 
 
    451 
 
 
    210 
    329 
    148 
    390 
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Table 3.  Primers and PCR assays for multiplex PCR and (semi)-nested multiplex PCR (continued). 
Assay Virusa Direction              Sequence (5’ – 3’)b Target genec Amplicon (bp) 
Set 3 
1st  
 
 
 
 
 
 
 
 
2nd  
 
 
 
HRV 
 
 
HCoV 229E 
 
 
HCoV OC43 
 
 
HRV 
HCoV 229E 
HCoV OC43 
 
sense 
antisense 
 
sense 
antisense 
 
sense 
antisense 
 
antisense 
antisense 
antisense 
 
CCCACAGTAGACCTGGCAGATG 
ACGGACACCCAAAGTAGTTGGT 
 
GGTTTTGACAAGCCTCAGGAAAAAGA 
GTGACTATCAAACAGCATAGCAGCTGT 
 
GCTAGTCTTGTTCTGGCAAAACTTGGC 
TGAATTGCGCTATAACGGCGC 
 
CAGGGTTAAGGTTAGCCGCATTC 
CCATTGGCCACAACACCTGC 
CTCAGCAAGTAACTAAGCATACTGCC 
 
5'-noncoding  region 
 
 
Membrane glycoprotein 
 
 
Membrane glycoprotein 
 
 
5'-noncoding region 
Membrane glycoprotein 
Membrane glycoprotein 
 
    254 
 
 
    573 
 
 
    335 
 
 
    175 
    230 
    170 
Set 4 
1st  
 
 
 
 
 
2nd   
 
AdV 
 
 
HBoV 
 
 
AdV 
 
 
HBoV 
 
sense 
antisense 
 
sense 
antisense 
 
sense 
antisense 
 
sense 
antisense 
 
TACATGCACATCKCSGGVCAGGA 
CCRGCCARHACHCCCATRTTDCCHGT 
 
CGCCGTGGCTCCTGCTCT  
TGTTCGCCATCACAAAAGATGTG 
 
TGGCYWSCACNTWCTTTGACATYMG 
GCRWAWGAHCCRTARCAKGGYTDCAT  
 
GGCTCCTGCTCTAGGAAATAAAGAG 
CCTGCTGTTAGGTCGTTGTTGTATGT 
 
Hexon gene 
 
 
VP1/2 
 
 
Hexon gene 
 
 
VP1/2 
     
    983 
 
 
    608 
 
 
    426 
     
 
    575 
 
aFLU, influenza virus; RSV, respiratory syncytial virus; hMPV, human metapneumovirus; PIV, parainfluenzavirus; HRV, human rhinovirus;  
HCoV, human coronavirus; AdV, adenovirus; HBoV, human bocavirus. 
bDegenerate primer abbreviations are as follows: M, A/C; R, A/G; W, A/T; S, C/G; Y, C/T; K, G/T; V, A/C/G; H, A/C/T; D, A/G/T; N, A/C/G/T. 
cHA-NA, Hemagglutinin-Neuraminidase. 
 
20 
 
3. RESULTS 
Characteristics of study population 
 The demographic characteristics and medical history data of the study population are 
shown in Table 4. Overall, the median age was 9 months (ranged from 0 to 161 months), 86% 
of patients were under 2 years old. Male were more commonly affected than female and the 
male to female ratio was 1.8:1. A half of patients (50.6%) were living in urban areas from the 
south of Vietnam. Fourteen of 446 (3%) patients over 1 year old had been received the 
seasonal influenza vaccine.  
Table 4. Demographic characteristics and medical history data of study population and 
virus positive and negative groups. 
 
Characteristics (%) Total N=1,082 Virus Pos. 
N=699 
Virus Neg. 
N=383 
p-valuec OR (95% CI) 
Male 64.7 66.7 61.1 0.073 1.27(0.98-1.65) 
Age (m)a 9 (4-18) 9 (4-17) 10 (4-19) 0.250d  
Age group    0.046  
<6m 33.0 32.3 34.2   
6-<12m 23.9 26.6 19.1 0.030e 1.48 (1.05-2.09) 
12-<24m 27.4 26.0 29.8 0.685 0.92(0.67-1.27) 
≥24m 15.7 15.0 17.0 0.773 0.93(0.64-1.36) 
Live in urban area 50.6 51.6 48.8 0.409 0.89(0.69-1.14) 
Prematurity 9.2 10.0 7.8 0.273 1.31(0.83-2.04) 
Breastfeeding  89.9 89.0 91.6 0.171 0.73(0.47-1.13) 
Daycare 22.2 21.5 23.5 0.445 0.88(0.66-1.19) 
Malnutrition 9.5 8.4 11.5 0.105 0.71(0.47-1.07) 
Family sizea 4 (3-5) 4 (3-5) 4 (3-5) 0.407d  
Siblings 47.8 46.2 50.7 0.181 0.83(0.65-1.07) 
Passive smoking 58.7 59.8 56.7 0.333 1.13(0.88-1.46) 
ARIs exposure 32.0 32.6 31.0 0.633 1.07(0.82-1.41) 
Family atopy 42.1 41.3 43.3 0.502 0.92(0.71-1.18) 
Days before hos.(d)a 3 (2-5) 3 (2-4) 3 (2-6) 0.003d  
Antibiotics before hos. 47.5 47.5 47.5 1.000 0.99(0.78-1.28) 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; ARI, acute respiratory infection; 
Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets. 
cComparison between virus positive and negative groups used chi-squared test except dMann-
Whitney-U test was applied for continuous variables. 
eAge group <6m was used as a reference and compared to other age groups. 
At admission, most patients had fever, cough, and runny noses (Table 5). On 
examination, the percentage of patients who had fast breathing, wheezing and chest retraction 
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were 44.5%, 58.9% and 55.3%, respectively. All patients were performed CBC and CXR. 
Among 110 patients who were tested for CRP, 16 (14.5%) had the level of CRP ≥ 40 mg/L. 
Diagnoses at admission were based on clinical and laboratory information and CXR 
interpretation. Nearly four-fifths of cases were diagnosed as lower respiratory tract infections 
(LRTIs). Laboratory investigation for bacterial pathogens was not systematically performed. 
However, 76% of patients received antibiotic treatment during hospitalization. No patients 
either required mechanical ventilation or had complications. All patients were fully recovered 
and discharged. 
Table 5. Clinical features, diagnosis and treatment characteristics of study population 
and virus positive and negative groups. 
 
Characteristics (%) Total N=1,082 Virus Pos. 
N=699 
Virus Neg. 
N=383 
p-
valuec 
OR (95% CI) 
Fever 67.2 66.7 68.1 0.636 0.93(0.71-1.22) 
High fever 6.7 6.9 6.5 0.899 1.05(0.64-1.74) 
Cough 90.9 92.3 88.3 0.036 1.59 (1.05-2.41) 
Runny noses 73.4 78.3 64.5 <0.001 1.98 (1.50-2.61) 
SpO2 ≤92% 8.5 8.4 8.6 0.910 0.97(0.62-1.52) 
Tachypnea 44.5 42.5 48.3 0.073 0.79(0.61-1.01) 
Chest retraction 55.3 58.9 48.3 0.001 1.54 (1.20-1.97) 
Wheezing 58.9 60.7 55.6 0.121 1.23(0.95-1.58) 
Rales 66.0 68.0 62.4 0.070 1.27(0.98-1.65) 
Clinical Severity Scorea 12 (8-13) 12 (8-13) 11 (7-13) 0.029d  
WBC (×103/mm3)a 11.6 (9.392-15) 11.4 (9.39-14.6) 12.2 (9.40-15.5) 0.037d  
Elevated Neutrophilb 36.5 34.1 40.8 0.034 1.33 (1.03-1.72) 
Abnormal chest X-ray 77.6 81.3 70.7 <0.001 1.80 (1.35-2.42) 
Diagnosis    0.007  
URTIs 21.6 21.6 21.7 1.000 0.99(0.73-1.34) 
Croup 6.1 4.7 8.6 0.016 0.53 (0.32-0.87) 
Bronchiolitis 33.2 36.1 27.9 0.007 1.45 (1.11-1.91) 
Pneumonia 39.1 37.6 41.8 0.193 0.84(0.65-1.08) 
Oxygen 8.0 8.2 7.8 0.907 1.05(0.66-1.66) 
Antibiotics 76.0 76.0 76.0 1.000 0.99(0.75-1.33) 
Steroids 15.7 16.3 14.6 0.486 1.13(0.80-1.61) 
Bronchodilator 51.8 56.9 42.6 <0.001 1.79 (1.39-2.30) 
Hos. duration (d)a 6 (4-8) 6 (4-8) 5 (3-8) 0.203d  
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; URTI, upper respiratory infection; WBC, white blood cell.  
Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets. 
bNeutrophil >5,800/mm3 according to Nelson Textbook of Pediatrics (42). 
cComparison between virus positive and negative groups used chi-squared test except dMann-
Whitney-U test was applied for continuous variables. 
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Viral detection and seasonal patterns 
 One or more respiratory viruses were detected in 64.6% (699/1,082) of patients (Table 
6). Viruses could be found in all months and the monthly detection rate ranged from 47.4% to 
90.2% during the studied period (Fig. 2). The ARI activity reached peak from August to 
October and the detection rate was also high during this time. HRV which used to be thought 
as a “mild common cold” agent was the most common identified virus in hospitalized 
patients with the overall detection rate of 30%. RSV was the second most in frequency, 
followed by HBoV, PIV3, PIV1, and FLU A. Other viruses such as hMPV, AdV, FLU B and 
HCoV were detected in a small proportion of patients. Neither PIV type 2 nor type 4 could be 
found in this study. Mixed detection of more than one respiratory virus was found in 129 
patients (12%), in which, co-detection between HRV and RSV was the most frequent (48 
cases) followed by the combinations of HRV and HBoV (16 cases). It is noted that 66.7% 
(52/78) of HBoV and 4 out of 7 (42.9%) HCoV OC43 found in this study were mixed 
detection with other viruses. Six patients had triple detection. 
 Regarding seasonal patterns, HRV was detected all year round with no distinct 
seasonality (Fig. 3). RSV epidemic occurred during the rainy season from May to October 
with the peak in October 2010. In contrast, PIV1, PIV3 and HBoV were predominant during 
the dry season. FLU A could be found in both rainy and dry seasons with the peaks usually 
lagged after the changing of seasons. The numbers of remaining viruses were insufficient to 
detect the seasonal patterns. However, 11 out of 13 hMPVs in this study were identified in 
the rainy season, 6 cases occurred in October 2010, and had a similar seasonal pattern with 
RSV. 
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Figure 2. Number of hospitalized, enrolled and virus positive patients. 
 
Figure 3. Monthly distribution of leading respiratory viruses among hospitalized 
children with ARIs from April 2010 to May 2011.  
Abbreviation: HRV, human rhinovirus; RSV, respiratory syncytial virus; FLU, influenza 
virus; PIV, parainfluenza virus; HBoV, human bocavirus; 
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Table 6. Virus detected from 1,082 ARI patients. 
Virus HRV RSV HBoV PIV3 PIV1 FLU A hMPV AdV FLU B HCoV 229E 
HCoV 
OC43 
HRV 234           
RSV 48 184          
HBoV 16 15 26         
PIV3 11 1 6 38        
PIV1 3 1 2  29       
FLU A 3 1 4   26      
hMPV 1  2  1  9     
AdV 2       9    
FLU B 1  2      4   
HCoV 229E          7  
HCoV OC43  3         4 
HRV+RSV+HBoV 3           
HRV+RSV+AdV 1           
HRV+FLU A+HBoV 1           
HRV+PIV3+HBoV 1           
Totala 325 (30%) 
257 
(23.8%)
78 
(7.2%) 
57 
(5.3%) 
36 
(3.3%) 
35 
(3.2%) 
13 
(1.2%) 
12 
(1.1%) 
7 
(0.6%) 
7 
(0.6%) 
7 
(0.6%) 
 
Abbreviation: HRV, human rhinovirus; RSV, respiratory syncytial virus; PIV, parainfluenza virus; FLU, influenza virus; HBoV, human 
bocavirus; hMPV, human metapneumovirus; AdV, Adenovirus; HCoV, human coronavirus. 
aPercentages are calculated based on the positive number of each virus. 
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Description and comparison of clinical features of the detected viruses 
 To figure out the difference between virus positive and negative groups, demographic 
and clinical data were compared (Table 4 and 5). With regard to age, infants aged from 6 to 
12 months had a higher risk of viral detection compared with infants <6 months of age 
(OR=1.48, 95% CI: 1.05-2.09). Patients with virus positive were likely to admit to the 
hospital earlier in the course of their disease than those with virus negative (p=0.003). They 
also had the rates of cough (92.3 vs. 88.3%, p=0.036), runny noses (78.3 vs. 64.5%, p<0.001), 
chest retraction (58.9 vs. 48.3%, p=0.001), and most important, the clinical severity score (12 
vs. 11, p=0.029) higher significantly than virus negative group. However, the latter group was 
likely to have higher number of WBC (12,200 vs. 11,400, p=0.037) and elevated neutrophil 
(40.8 vs. 34.1%, p=0.034). The radiograph was more abnormal in virus positive group than 
the virus negative group (81.3 vs. 70.7%, p<0.001). Regarding the diagnosis, virus positive 
patients were more likely to have bronchiolitis (36.1 vs. 27.9%, p=0.007) but less likely to 
have croup (4.7 vs. 8.6%, p=0.016). As a result, they received bronchiodilators more often 
than the latter group (56.9 vs. 42.6%, p<0.001). There were no significant differences in other 
characteristics as shown in Table 5. 
 To address the question of whether children with multiple virus detection have 
different characteristics to those with single virus detection, attempts were done to compare 
the two groups (Table 7 and 8). However, the differences were not statistically significant 
except that children with mono-detection have siblings with a significant higher percentage 
than those with co-detection (48.2 vs. 37.2%, p=0.025). 
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Table 7. Demographic characteristics and medical history associated with viral mono- 
and co-detection. 
 
Characteristics (%) Mono-detection N=570 Co-detection  N=129 p-valuec OR (95% CI) 
Male 67.4 63.6 0.410 0.85(0.56-1.26) 
Age (m)a 9 (4-18) 9 (4-15) 0.429d  
Live in urban area 51.6 51.9 1.000 0.98(0.67-1.44) 
Prematurity  9.5 12.4 0.330 1.35(0.74-2.45) 
Breastfeeding  88.6 90.7 0.640 1.25(0.65-2.39) 
Daycare 21.2 22.5 0.812 1.07(0.68-1.70) 
Malnutrition 8.8 7.0 0.601 0.78(0.37-1.63) 
Family sizea 4 (3-5) 4 (3-6) 0.344d  
Siblings 48.2 37.2 0.025 0.64 (0.43-0.94) 
Passive smoking 59.6 60.5 0.921 1.03(0.70-1.52) 
ARIs exposure 31.5 37.2 0.214 1.28(0.86-1.91) 
Family atopy 40.9 43.4 0.621 1.11(0.75-1.63) 
Days before hos.a 3 (2-4) 2 (2-4) 0.303d  
Antibiotics before hos. 46.7 51.2 0.380 1.19(0.81-1.75) 
 
Abbreviation: OR, odds ratio; CI, confidence interval; d, day; m, month; hos, hospitalization; 
ARI, acute respiratory infection; 
Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets. 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
Table 8. Clinical features, diagnosis and treatment characteristics associated with viral 
mono- and co-detection. 
 
Characteristics (%) Mono-detection N=570 Co-detection  N=129 p-valuec OR (95% CI) 
Fever 65.4 72.1 0.179 1.36(0.89-2.08) 
High Fever 6.7 7.8 0.699 1.17(0.57-2.42) 
Cough 92.1 93.0 0.856 1.14(0.54-2.40) 
Runny noses 78.6 76.7 0.638 0.89(0.57-1.41) 
SpO2 ≤92% 7.5 12.4 0.080 1.73(0.94-3.19) 
Tachypnea 42.8 41.1 0.768 0.93(0.63-1.37) 
Chest retraction 58.4 61.2 0.620 1.12(0.76-1.66) 
Wheezing 61.4 57.4 0.425 0.84(0.57-1.24) 
Rales 67.0 72.1 0.297 1.27(0.83-1.94) 
Clinical Severity Scorea 12 (8-13) 12 (8-13) 0.801d  
WBC (×103/mm3)a 11.4 (9.47-14.4) 11.5 (9.20-15.0) 0.898d  
Elevated Neutrophilb 33.7 36.2 0.605 0.89(0.59-1.33) 
Abnormal chest X-ray 81.2 82.2 0.900 1.07(0.65-1.75) 
Diagnosis   0.552  
URTIs 22.3 18.6 0.408 0.79(0.49-1.29) 
Croup 5.1 3.1 0.490 0.59(0.20-1.72) 
Bronchiolitis 35.8 37.2 0.762 1.06(0.71-1.58) 
Pneumonia 36.8 41.1 0.367 1.19(0.81-1.76) 
Oxygen 7.2 12.4 0.073 1.82(0.99-3.37) 
Antibiotics 74.6 82.2 0.069 1.57(0.96-2.56) 
Steroids 16.5 15.5 0.895 0.92(0.54-1.57) 
Bronchodilator 56.8 57.4 0.922 1.02(0.69-1.50) 
Hos. durationa 6 (4-8) 6 (4-8) 0.195d  
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Abbreviation: OR, odds ratio; CI, confidence interval; d, day; m, month; hos, hospitalization; 
URTI, upper respiratory infection; WBC, white blood cell. 
Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets. 
bNeutrophil >5,800/mm3 according to Nelson Textbook of Pediatrics (42). 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
The association of each type of respiratory virus with specific demographic and 
clinical features was also found. In terms of age distribution, most viral agents could be 
detected in all age groups. The age distributions of patients were specific for each type of 
viruses (Fig. 4). In particular, HRV was detected in all age groups. RSV was usually 
associated with diseases in children younger than 6 months while FLU A was mostly found 
in children over 2 years old. PIV3 developed ARIs frequently in children from 6 to 11 
months, in contrast to PIV1 and HBoV being predominant in the second year of life. 
 
Figure 4. Age distribution of leading respiratory viruses. 
 
Abbreviation: HRV, human rhinovirus; RSV, respiratory syncytial virus; FLU A, influenza A 
virus; PIV, parainfluenza virus; HBoV, human bocavirus; 
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The association between HRV, RSV, HBoV, PIV1, PIV3 and FLU A detection with 
demographic and clinical features is shown in Tables 9-20. The clinical features of FLU A, 
RSV, HBoV and HRV are further characterized in chapters 3-6. In this chapter, the 
symptoms and diagnostic classification associated with severe ARIs were focused.  
In brief, patients with HRV positive were more likely to have hypoxia (12.3 vs. 6.9%, 
p=0.003), chest retraction (60.9 vs. 52.7%, p=0.013) and wheezing (63.7 vs. 56.8%, p=0.035) 
but less likely to have fever (56.0 vs. 72.0%, p<0.001) and to be diagnosed as croup (2.8 vs. 
7.5%, p=0.002) than those negative for HRV (Table 9 and 10).  
Table 9. Demographic characteristics and medical history associated with HRV 
detection. 
 
Characteristics (%) HRV(+) N=325 HRV(-) N=757 p-valuec OR (95% CI) 
Male 69.8 62.5 0.020 1.39(1.05-1.84) 
Age (m)a 9(4-18) 10(4-18) 0.392d  
Live in urban area 50.5 50.7 0.936 1.01(0.77-1.31) 
Prematurity 11.1 8.5 0.172 1.34(0.87-2.07) 
Breastfeeding  87.4 91.0 0.069 0.68(0.45-1.03) 
Daycare 22.2 22.2 1.000 0.99(0.73-1.36) 
Malnutrition 8.9 9.8 0.661 0.90(0.57-1.41) 
Family sizea 4(3-5) 4(3-6) 0.542d  
Siblings 46.5 48.3 0.569 0.92(0.71-1.20) 
Passive smoking 56.3 59.7 0.298 0.87(0.66-1.13) 
ARIs exposure 31.1 32.4 0.668 0.94(0.71-1.24) 
Family atopy 40.0 42.9 0.370 0.88(0.68-1.15) 
Days before hos.(d)a 3(1-4.5) 3(2-5) 0.209d  
Antibiotics before hos. 44.0 49.0 0.130 0.81(0.63-1.06) 
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; ARI, acute respiratory infection; HRV, human rhinovirus. Note: All results are 
expressed in percentages except for (a) in median with interquartile range between brackets. 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
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Table 10. Clinical features, diagnosis and treatment characteristics associated with 
HRV detection. 
 
Characteristics (%) HRV(+) N=325 HRV(-) N=757 p-valuec OR (95% CI) 
Fever 56.0 72.0 <0.001 0.50(0.38-0.65) 
High fever 4.6 7.7 0.067 0.58(0.32-1.05) 
Cough 91.1 90.8 0.865 1.04(0.66-1.63) 
Runny noses 74.2 73.1 0.707 1.05(0.78-1.42) 
SpO2 ≤92% 12.3 6.9 0.003 1.90(1.23-2.94) 
Tachypnea 40.9 46.1 0.116 0.81(0.62-1.05) 
Chest retraction 60.9 52.7 0.013 1.40(1.07-1.82) 
Wheezing 63.7 56.8 0.035 1.33(1.02-1.74) 
Rales 65.5 66.2 0.838 0.97(0.73-1.27) 
Clinical Severity Scorea 12(8-13) 11(8-13) 0.341d  
WBC (×103/mm3)a 11.7(9.8-15.1) 11.6(9.2-15.0) 0.236d  
Elevated Neutrophilb 37.7 36.0 0.595 0.92(0.70-1.21) 
Abnormal chest X-ray 82.4 75.6 0.014 1.52(1.09-2.11) 
Detection with other viruses 28.3 49.4 <0.001 0.40(0.31-0.54) 
Diagnosis   0.004  
URTIs 24.9 20.2 0.084 1.31(0.96-1.78) 
Croup 2.8 7.5 0.002 0.35(0.17-0.72) 
Bronchiolitis 36.3 31.8 0.152 1.22(0.92-1.60) 
Pneumonia 36.0 40.4 0.172 0.82(0.63-1.08) 
Oxygen 12.0 6.3 0.002 2.01(1.29-3.14) 
Antibiotics 68.9 79.0 <0.001 0.59(0.44-0.79) 
Steroids 17.8 14.8 0.206 1.25(0.88-1.77) 
Bronchodilator 56.9 49.7 0.029 1.34(1.03-1.74) 
Hos. duration (d)a 5(3-8) 6(4-8) 0.784d  
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; URTI, upper respiratory infection; WBC, white blood cell; HRV, human 
rhinovirus. Note: All results are expressed in percentages except for (a) in median with interquartile 
range between brackets. 
bNeutrophil >5,800/mm3 according to Nelson Textbook of Pediatrics (42). 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
Patients with RSV positive were younger (7 vs. 11 months, p<0.001) and were more 
likely to have chest retraction (68.5 vs. 51.0%, p<0.001) and bronchiolitis (47.1 vs. 28.8%, 
p<0.001) compared with RSV negative patients (Table 11 and 12).  
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Table 11. Demographic characteristics and medical history associated with RSV 
detection. 
 
Characteristics (%) RSV(+) N=257 RSV(-) N=825 p-valuec OR (95% CI) 
Male 63.0 65.2 0.550 0.91(0.68-1.21) 
Age (m)a 7(3-14) 11(4.5-19) <0.001d  
Live in urban area 53.3 49.8 0.329 0.87(0.65-1.15) 
Prematurity 11.3 8.6 0.265 1.35(0.85-2.13) 
Breastfeeding  91.1 89.6 0.493 1.18(0.73-1.91) 
Daycare 17.1 23.8 0.025 0.66(0.46-0.95) 
Malnutrition 6.2 10.5 0.039 0.56(0.32-0.98) 
Family sizea 4(3-5) 4(3-6) 0.229d  
Siblings 44.4 48.8 0.208 0.83(0.63-1.11) 
Passive smoking 65.0 56.7 0.019 1.42(1.06-1.89) 
ARIs exposure 36.3 30.7 0.089 1.29(0.96-1.73) 
Family atopy 40.9 42.4 0.657 0.93(0.70-1.24) 
Days before hos.(d)a 2(2-4) 3(2-5) 0.017d  
Antibiotics before hos. 54.4 45.3 0.010 1.44(1.09-1.91) 
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; ARI, acute respiratory infection; RSV, respiratory syncytial virus. Note: All 
results are expressed in percentages except for (a) in median with interquartile range between brackets. 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
Table 12. Clinical features, diagnosis and treatment characteristics associated with RSV 
detection. 
 
Characteristics (%) RSV(+) N=257 RSV(-) N=825 p-valuec OR (95% CI) 
Fever 72.8 65.5 0.033 1.41(1.03-1.92) 
High fever 8.2 6.3 0.297 1.32(0.78-2.24) 
Cough 93.8 89.9 0.064 1.68(0.96-2.93) 
Runny noses 82.5 70.5 <0.001 1.97(1.38-2.81) 
SpO2 ≤92% 5.8 9.3 0.095 0.60(0.34-1.06) 
Tachypnea 41.6 45.5 0.314 0.85(0.64-1.13) 
Chest retraction 68.5 51.0 <0.001 2.09(1.55-2.81) 
Wheezing 59.9 58.5 0.717 1.05(0.79-1.40) 
Rales 75.1 63.2 <0.001 1.76(1.28-2.41) 
Clinical Severity Scorea 12(8-13) 11(7-13) 0.003d  
WBC (×103/mm3)a 10.9(8.7-13.8) 11.9(9.5-15.2) 0.001d  
Elevated Neutrophilb 25.1 40.0 <0.001 1.99(1.45-2.73) 
Abnormal chest X-ray 83.2 75.9 0.014 1.57(1.09-2.27) 
Detection with other viruses 28.4 53.6 <0.001 0.34(0.25-0.47) 
Diagnosis   <0.001  
URTIs 16.0 23.4 0.012 0.62(0.43-0.90) 
Croup 0.8 7.8 <0.001 0.09(0.02-0.38) 
Bronchiolitis 47.1 28.8 <0.001 2.19(1.65-2.93) 
Pneumonia 36.2 40.0 0.305 0.85(0.63-1.13) 
Oxygen 5.1 9.0 0.044 0.54(0.30-0.99) 
Antibiotics 79.8 74.8 0.103 1.32(0.94-1.87) 
Steroids 10.9 17.2 0.015 0.59(0.38-0.91) 
Bronchodilator 63.4 48.2 <0.001 1.86(1.40-2.48) 
Hos. duration (d)a 6(4-8) 5(4-8) 0.067d  
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; URTI, upper respiratory infection; WBC, white blood cell; RSV, respiratory 
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syncytial virus. Note: All results are expressed in percentages except for (a) in median with 
interquartile range between brackets. 
bNeutrophil >5,800/mm3 according to Nelson Textbook of Pediatrics (42). 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
Patients positive for HBoV were more likely to have hypoxia (SpO2 ≤92%) (16.7 vs. 
7.9%, p=0.007) and pneumonia (50.0 vs. 38.2%, p=0.04) compared with HBoV negative 
patients (Table 13 and 14).  
Table 13. Demographic characteristics and medical history associated with HBoV 
detection. 
 
Characteristics (%) HBoV(+) N=78 HBoV(-) N=1004 p-valuec OR (95% CI) 
Male 62.8 64.8 0.714 0.91(0.56-1.47) 
Age (m)a 12(6-18) 9(4-18) 0.106d  
Live in urban area 57.7 50.1 0.196 0.73(0.46-1.17) 
Prematurity 10.3 9.2 0.684 1.13(0.52-2.42) 
Breastfeeding  88.5 90.0 0.656 0.84(0.41-1.75) 
Daycare 26.8 21.8 0.295 1.32(0.78-2.22) 
Malnutrition 12.8 9.3 0.314 1.44(0.71-2.89) 
Family sizea 4(3-6) 4(3-5) 0.809d  
Siblings 42.3 48.2 0.315 0.78(0.49-1.25) 
Passive smoking 53.8 59.1 0.367 0.80(0.51-1.28) 
ARIs exposure 30.8 32.1 0.808 0.94(0.57-1.54) 
Family atopy 46.2 41.7 0.446 1.19(0.75-1.90) 
Days before hos.(d)a 3(2-4) 3(2-5) 0.663d  
Antibiotics before hos. 46.2 47.6 0.804 0.94(0.59-1.49) 
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; ARI, acute respiratory infection; HBoV, human bocavirus. Note: All results are 
expressed in percentages except for (a) in median with interquartile range between brackets. 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
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Table 14. Clinical features, diagnosis and treatment characteristics associated with 
HBoV detection. 
 
Characteristics (%) HBoV(+) N=78 HBoV(-) N=1004 p-valuec OR (95% CI) 
Fever 73.1 66.7 0.263 1.35(0.80-2.27) 
High fever 6.4 6.8 0.902 0.94(0.36-2.41) 
Cough 92.3 90.7 0.838 1.22(0.51-2.89) 
Runny noses 75.6 73.2 0.692 1.13(0.66-1.94) 
SpO2 ≤92% 16.7 7.9 0.007 2.43(1.24-4.43) 
Tachypnea 46.2 44.4 0.813 1.07(0.67-1.70) 
Chest retraction 55.1 55.2 1.000 0.99(0.62-1.58) 
Wheezing 62.8 58.6 0.477 1.19(0.74-1.92) 
Rales 76.9 65.1 0.034 1.78(1.04-3.07) 
Vomiting 55.1 57.4 0.723 0.91(0.57-1.45) 
Diarrhea 30.8 27.0 0.509 1.20(0.72-1.98) 
Clinical Severity Scorea 12(8-13) 12(8-13) 0.359d  
WBC (×103/mm3)a 12.7(10.4-15.0) 11.6(9.3-15.0) 0.093d  
Elevated Neutrophilb 45.5 35.8 0.090 0.66(0.42-1.06) 
Abnormal chest X-ray 82.1 77.3 0.398 1.34(0.74-2.44) 
Detection with other viruses 66.7 62.0 0.467 0.81(0.49-1.32) 
Diagnosis   0.115  
URTIs 23.1 21.5 0.747 1.09(0.63-1.89) 
Croup 3.8 6.3 0.620 0.59(1.18-1.94) 
Bronchiolitis 23.1 34.0 0.060 0.58(0.33-1.01) 
Pneumonia 50.0 38.2 0.040 1.62(1.02-2.56) 
Oxygen 16.7 7.4 0.004 2.51(1.32-4.77) 
Antibiotics 85.9 75.2 0.033 2.01(1.05-3.86) 
Steroids 14.1 15.8 0.685 0.87(0.45-1.68) 
Bronchodilator 52.6 51.8 0.896 1.03(0.65-1.63) 
Hos. duration (d)a 6(4-9) 5(4-8) 0.020d  
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; URTI, upper respiratory infection; WBC, white blood cell; HBoV, human 
bocavirus. Note: All results are expressed in percentages except for (a) in median with interquartile 
range between brackets. 
bNeutrophil >5,800/mm3 according to Nelson Textbook of Pediatrics (42). 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
The detection of PIV3 had no significant association with severe symptoms such as 
hypoxia (SpO2 ≤92%), retraction and tachypnea or specific diagnostic classification (Table 15 
and 16).  
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Table 15. Demographic characteristics and medical history associated with PIV3 
detection. 
 
Characteristics (%) PIV3(+) N=57 PIV3(-) N=1025 p-valuec OR (95% CI) 
Male 71.9 64.3 0.258 1.42(0.78-2.57) 
Age (m)a 9(6-15) 10(4-18) 0.759d  
Live in urban area 57.9 48.9 0.221 1.43(0.83-2.46) 
Prematurity 8.8 9.3 1.000 0.94(0.36-2.41) 
Breastfeeding  94.7 89.7 0.264 2.07(0.63-6.75) 
Daycare 10.5 22.8 0.032 0.40(0.17-0.94) 
Malnutrition 8.8 9.6 1.000 0.91(0.35-2.33) 
Family sizea 4(3-6) 4(3-5) 0.435d  
Siblings 42.1 48.1 0.415 0.78(0.45-1.34) 
Passive smoking 59.6 58.6 1.000 1.04(0.60-1.79) 
ARIs exposure 36.8 31.7 0.466 1.25(0.72-2.18) 
Family atopy 42.1 42.0 1.000 1.01(0.58-1.72) 
Days before hos.(d)a 2(1-3) 3(2-5) 0.035d  
Antibiotics before hos. 33.3 48.3 0.029 0.54(0.31-0.94) 
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; ARI, acute respiratory infection; PIV3, parainfluenza virus 3. Note: All results 
are expressed in percentages except for (a) in median with interquartile range between brackets. 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
Table 16. Clinical features, diagnosis and treatment characteristics associated with 
PIV3 detection. 
 
Characteristics (%) PIV3(+) N=57 PIV3(-) N=1025 p-valuec OR (95% CI) 
Fever 68.4 67.1 0.886 1.06(0.59-1.88) 
High fever 5.3 6.8 1.000 0.75(0.23-2.48) 
Cough 96.5 90.5 0.158 2.87(0.69-11.96) 
Runny noses 80.7 73.0 0.221 1.54(0.79-3.03) 
SpO2 ≤92% 3.5 8.8 0.223 0.37(0.09-1.57) 
Tachypnea 33.3 45.2 0.100 0.60(0.34-1.06) 
Chest retraction 45.6 55.7 0.171 0.66(0.39-1.13) 
Wheezing 66.7 58.4 0.269 1.42(0.80-2.50) 
Rales 64.9 66.0 0.886 0.95(0.54-1.66) 
Clinical Severity Scorea 8(7-13) 12(8-13) 0.192d  
WBC (×103/mm3)a 11.2(8.9-14.1) 11.7(9.5-15.0) 0.182d  
Elevated Neutrophilb 33.3 36.7 0.673 1.15(0.65-2.04) 
Abnormal chest X-ray 80.7 77.5 0.628 1.21(0.62-2.38) 
Detection with other viruses 33.3 62.6 <0.001 0.30(0.17-0.52) 
Diagnosis   0.667  
URTIs 15.8 22.0 0.323 0.66(0.32-1.37) 
Croup 7.0 6.0 0.773 1.17(0.41-3.34) 
Bronchiolitis 38.6 32.9 0.388 1.28(0.74-2.22) 
Pneumonia 38.6 39.1 1.000 0.98(0.56-1.69) 
Oxygen 3.5 8.3 0.312 0.40(0.09-1.67) 
Antibiotics 75.4 76.0 0.875 0.97(0.52-1.80) 
Steroids 21.1 15.4 0.262 1.46(0.75-2.82) 
Bronchodilator 52.6 51.8 1.000 1.03(0.60-1.76) 
Hos. duration (d)a 5(4-7) 6(4-8) 0.550d  
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; URTI, upper respiratory infection; WBC, white blood cell; PIV3, parainfluenza 
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virus 3. Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets. 
bNeutrophil >5,800/mm3 according to Nelson Textbook of Pediatrics (42). 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
Patients with PIV1 positive were older (13 vs. 9 months, p=0.038), had more fever 
(91.7 vs. 66.3%, p=0.001) but lower rate of chest retraction (36.1 vs. 55.8%, p=0.026) 
compared with those negative for PIV1. They were more likely to be diagnosed as croup 
(38.9 vs. 5.0%, p<0.001) compared with PIV1 negative patients (Table 17 and 18).  
Table 17. Demographic characteristics and medical history associated with PIV1 
detection. 
 
Characteristics (%) PIV1(+) N=36 PIV1(-) N=1046 p-valuec OR (95% CI) 
Male 69.4 64.5 0.599 1.24(0.60-2.56) 
Age (m)a 13(9-18) 9(4-18) 0.038d  
Live in urban area 52.8 50.6 0.866 0.91(0.47-1.78) 
Prematurity 2.8 9.5 0.244 0.27(0.04-2.01) 
Breastfeeding  91.7 89.9 1.000 1.24(0.37-4.11) 
Daycare 22.2 22.2 1.000 1.01(0.45-2.22) 
Malnutrition 2.8 9.8 0.245 0.26(0.04-1.95) 
Family sizea 4(3-5.5) 4(3-5) 0.753d  
Siblings 36.1 48.2 0.176 0.60(0.30-1.21) 
Passive smoking 44.4 59.2 0.086 0.55(0.28-1.07) 
ARIs exposure 25.0 32.2 0.468 0.70(0.32-1.50) 
Family atopy 44.4 42.0 0.864 1.10(0.56-2.15) 
Days before hos.(d)a 2.5(2-5.5) 3(2-5) 0.827d  
Antibiotics before hos. 61.1 47.0 0.126 1.76(0.89-3.49) 
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; ARI, acute respiratory infection; PIV1, parainfluenza virus 1. Note: All results 
are expressed in percentages except for (a) in median with interquartile range between brackets. 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
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Table 18. Clinical features, diagnosis and treatment characteristics associated with 
PIV1 detection. 
 
Characteristics (%) PIV1(+) N=36 PIV1(-) N=1046 p-valuec OR (95% CI) 
Fever 91.7 66.3 0.001 5.58(1.70-18.32) 
High fever 19.4 6.3 0.008 3.58(1.51-8.49) 
Cough 94.4 90.7 0.766 1.73(0.41-7.34) 
Runny noses 77.8 73.2 0.702 1.27(0.57-2.84) 
SpO2 ≤92% 2.8 8.7 0.357 0.30(0.04-2.21) 
Tachypnea 52.8 44.3 0.394 1.40(0.72-2.73) 
Chest retraction 36.1 55.8 0.026 0.45(0.22-0.89) 
Wheezing 50.0 59.2 0.303 0.69(0.35-1.34) 
Rales 36.1 67.0 <0.001 0.28(0.14-0.56) 
Clinical Severity Scorea 10.5(7.5-13) 12(8-13) 0.625d  
WBC (×103/mm3)a 10.4(8.9-12.9) 11.7(9.4-15.0) 0.099d  
Elevated Neutrophilb 44.4 36.2 0.379 0.71(0.36-1.38) 
Abnormal chest X-ray 66.7 78.0 0.151 0.56(0.27-1.14) 
Detection with other viruses 19.4 63.4 <0.001 0.14(0.06-0.32) 
Diagnosis   <0.001  
URTIs 16.7 21.8 0.543 0.71(0.29-1.74) 
Croup 38.9 5.0 <0.001 12.16(5.89-25.14) 
Bronchiolitis 11.1 33.9 0.003 0.24(0.09-0.69) 
Pneumonia 33.3 39.3 0.603 0.77(0.38-1.56) 
Oxygen 5.6 8.1 0.762 0.66(0.15-2.81) 
Antibiotics 86.1 75.6 0.169 1.99(0.76-5.19) 
Steroids 38.9 14.9 0.001 3.63(1.82-7.25) 
Bronchodilator 38.9 52.3 0.128 0.58(0.29-1.14) 
Hos. duration (d)a 5(4-6.5) 6(4-8) 0.599d  
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; URTI, upper respiratory infection; WBC, white blood cell; PIV1, parainfluenza 
virus 1. Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets. 
bNeutrophil >5,800/mm3 according to Nelson Textbook of Pediatrics (42). 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
Patients positive for FLU A were older (15 vs. 9 months, p=0.002), were more likely 
to have fever (88.6 vs. 66.5%, p=0.005) but less wheezing (40.0 vs. 59.5%, p=0.024) 
compared with those without FLU A (Table 19 and 20). The detection of FLU A was less 
associated with bronchiolitis (14.3 vs. 33.8%, p=0.017). 
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Table 19. Demographic characteristics and medical history associated with FLU A 
detection. 
 
Characteristics (%) FLUA(+) N=35 FLUA(-) N=1048 p-valuec OR (95% CI) 
Male 62.9 64.8 0.858 0.92(0.45-1.85) 
Age (m)a 15(9-31.5) 9(4-18) 0.002d  
Live in urban area 51.4 50.6 1.000 0.96(0.49-1.89) 
Prematurity 5.7 9.4 0.764 0.58(0.13-2.48) 
Breastfeeding  88.6 90.0 0.773 0.86(0.29-2.49) 
Daycare 34.3 21.8 0.096 1.87(0.91-3.82) 
Malnutrition 8.6 9.6 1.000 0.88(0.26-2.95) 
Family sizea 4(3.5-6) 4(3-5) 0.384d  
Siblings 45.7 47.9 0.864 0.91(0.46-1.80) 
Passive smoking 60.0 58.6 1.000 1.05(0.53-2.10) 
ARIs exposure 34.3 31.9 0.854 1.11(0.54-2.26) 
Family atopy 40.0 42.1 0.863 0.91(0.46-1.82) 
Days before hos.(d)a 3(2-4) 3(2-5) 0.677d  
Antibiotics before hos. 54.3 47.3 0.492 1.32(0.67-2.60) 
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; ARI, acute respiratory infection; FLU A, influenza A virus. Note: All results are 
expressed in percentages except for (a) in median with interquartile range between brackets. 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
Table 20. Clinical features, diagnosis and treatment characteristics associated with FLU 
A detection. 
 
Characteristics (%) FLUA(+) N=35 FLUA(-) N=1048 p-valuec OR (95% CI) 
Fever 88.6 66.5 0.005 3.91(1.37-11.16) 
High fever 5.7 6.8 1.000 0.83(0.19-3.54) 
Cough 88.6 90.9 0.553 0.77(0.26-2.23) 
Runny noses 80.0 73.2 0.441 1.46(0.63-3.39) 
SpO2 ≤92% 5.7 8.6 0.762 0.64(0.15-2.73) 
Tachypnea 60.0 44.0 0.083 1.90(0.95-3.79) 
Chest retraction 48.6 55.4 0.491 0.76(0.38-1.49) 
Wheezing 40.0 59.5 0.024 0.45(0.23-0.90) 
Rales 74.3 65.7 0.366 1.50(0.69-3.25) 
Clinical Severity Scorea 12(7-13) 12(8-13) 0.827d  
WBC (×103/mm3)a 11.6(8.6-14.7) 11.6(9.4-15.0) 0.695d  
Elevated Neutrophilb 45.7 36.2 0.285 0.67(0.34-1.32) 
Abnormal chest X-ray 82.9 77.5 0.541 1.40(0.57-3.42) 
Detection with other viruses 25.7 63.4 <0001 0.20(0.09-0.43) 
Diagnosis   0.593  
URTIs 22.9 21.6 0.836 1.07(0.48-2.40) 
Croup 8.6 6.0 0.468 1.46(0.43-4.91) 
Bronchiolitis 14.3 33.8 0.017 0.33(0.13-0.85) 
Pneumonia 54.3 38.6 0.077 1.98(0.96-3.71) 
Oxygen 5.7 8.1 1.000 0.68(0.16-2.90) 
Antibiotics 94.3 75.4 0.008 5.40(1.29-22.64) 
Steroids 17.1 15.7 0.813 1.11(0.45-2.72) 
Bronchodilator 42.9 52.1 0.305 0.68(0.34-1.35) 
Hos. duration (d)a 5(4-9) 6(4-8) 0.576d  
 
Abbreviation: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; d, day; m, month; 
hos, hospitalization; URTI, upper respiratory infection; WBC, white blood cell; FLU A, influenza A 
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virus. Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets. 
bNeutrophil >5,800/mm3 according to Nelson Textbook of Pediatrics (42). 
cChi-squared test was used except dMann-Whitney-U test was applied for continuous variables. 
 
The effect of respiratory virus detection on the risk of having severe clinical 
symptoms is shown in Table 21. In univariate analyses, HRV (Table 10) and RSV (Table 12) 
were positively associated with retraction, while HRV (Table 10) and HBoV (Table 14) were 
positively associated with hypoxia. In multivariate analyses adjusting for age, gender, 
prematurity, malnutrition and other viral co-detection (Table 21), HRV (AOR=1.49, 95% CI: 
1.13-1.96, p=0.005) and RSV (AOR=1.96, 95% CI: 1.44-2.68, p<0.001) were the significant 
predictors of retraction. On the other hand, HRV (AOR=1.78, 95% CI: 1.14-2.79, p=0.012) 
and HBoV (AOR=2.32, 95% CI: 1.22-4.41, p=0.011) were the significant predictors for 
hypoxia. Detection of any specific type of viruses was not associated with tachypnea. 
Regarding diagnosis, RSV positive was positively associated with bronchiolitis in 
both univariate (Table 12) and multivariate analyses (AOR=1.89, 95% CI: 1.37-2.61, 
p<0.001) (Table 22). Detection of PIV1 was less likely to have bronchiolitis (AOR=0.33, 
95% CI: 0.11-0.97, p=0.045) but more associated with croup (AOR=8.31, 95% CI: 3.88-
17.81, p<0.001) (Table 22). On the other hand, detection of HRV (AOR=0.31, 95% CI: 0.15-
0.64, p=0.002) and RSV (AOR=0.08, 95% CI: 0.02-0.35, p=0.001) were less likely to be 
diagnosed as croup (Table 22). HBoV positive was positively associated with pneumonia in 
the univariate analysis (Table 14) but this association became borderlined in multivariate 
analysis  (AOR: 1.59, 95% CI: 0.99 – 2.55, p=0.053) (Table 22). 
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Table 21. Association between specific respiratory virus and severe clinical signs. 
Category PCR Tachypnea n(%) AOR (95% CI) 
Yes No
HRV Positive 133(40.9) 192(59.1) 0.81(0.61-1.08)
Negative 349(46.1) 408(53.9) 1 
RSV Positive 107(41.6) 150(58.4) 1.07(0.78-1.46) 
Negative 375(45.5) 450(54.5) 1 
HBoV Positive 36(46.2) 42(53.8) 0.99(0.60-1.61) 
Negative 446(44.4) 558(55.6) 1 
PIV3 Positive 19(33.3) 38(66.7) 0.61(0.33-1.12) 
Negative 463(45.2) 562(54.8) 1 
PIV1 Positive 19(52.8) 17(47.2) 1.21(0.60-2.44) 
Negative 463(44.3) 583(55.7) 1 
FLU A Positive 21(60.0) 14(40.0) 1.28(0.60-2.73) 
Negative 461(44.0) 586(56.0) 1 
Category PCR Retraction n(%) AOR (95% CI) 
Yes No
HRV Positive 198(60.9) 127(39.1) 1.49(1.13-1.96)
Negative 399(52.7) 358(47.3) 1 
RSV Positive 176(68.5) 81(31.5) 1.96(1.44-2.68) 
Negative 421(51.0) 404(49.0) 1 
HBoV Positive 43(55.1) 35(44.9) 1.01(0.63-1.62) 
Negative 554(55.2) 450(44.8) 1 
PIV3 Positive 26(45.6) 31(54.4) 0.70(0.40-1.21) 
Negative 571(55.7) 454(44.3) 1 
PIV1 Positive 13(36.1) 23(63.9) 0.55(0.27-1.13) 
Negative 584(55.8) 462(44.2) 1 
FLU A Positive 17(48.6) 18(51.4) 1.05(0.52-2.13) 
Negative 580(55.4) 467(44.6) 1 
Category PCR SpO2 ≤92% n(%) AOR (95% CI) 
Yes No
HRV Positive 40(12.3) 285(87.7) 1.78(1.14-2.79)
Negative 52(6.9) 705(93.1) 1 
RSV Positive 15(5.8) 242(94.2) 0.64(0.35-1.14) 
Negative 77(9.3) 748(90.7) 1 
HBoV Positive 13(16.7) 65(83.3) 2.32(1.22-4.41) 
Negative 79(7.9) 925(92.1) 1 
PIV3 Positive 2(3.5) 55(96.5) 0.39(0.09-1.63) 
Negative 90(8.8) 935(91.2) 1 
PIV1 Positive 1(2.8) 35(97.2) 0.33(0.04-2.48) 
Negative 91(8.7) 955(91.3) 1 
FLU A Positive 2(5.7) 33(94.3) 0.71(0.17-3.05) 
Negative 90(8.6) 957(91.4) 1 
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Abbreviation: HRV, human rhinovirus; RSV, respiratory syncytial virus; FLU A, influenza A 
virus; PIV, parainfluenza virus; HBoV, human bocavirus; AOR, adjusted odds ratio; CI, 
confidence interval; 
The multivariate analyses included the virus status and all these variables known as potential 
confounders (Age, Gender, Prematurity, Malnutrition, and Co-detection with other viruses) to 
calculate adjusted ORs. The results of the Hosmer-Lemeshow test indicated high goodness-
of-fit for the final model (p >0.05). 
 
Table 22. Association between specific respiratory virus and diagnosis categories. 
 
Category PCR URTIs n(%) AOR (95% CI) Yes No
HRV Positive 81(24.9) 244(75.1) 1.32(0.96-1.83)
Negative 153(20.2) 604(79.8) 1 
RSV Positive 41(16.0) 216(84.0) 0.73(0.49-1.07) 
Negative 193(23.4) 632(76.6) 1 
HBoV Positive 18(23.1) 60(76.9) 1.08(0.62-1.90) 
Negative 216(21.5) 788(78.5) 1 
PIV3 Positive 9(15.8) 48(84.2) 0.76(0.36-1.60) 
Negative 225(22.0) 800(78.0) 1 
PIV1 Positive 6(16.7) 30(83.3) 0.73(0.29-1.81) 
Negative 228(21.8) 818(78.2) 1 
FLU A Positive 8(22.9) 27(77.1) 0.88(0.38-2.03) 
Negative 226(21.6) 821(78.4) 1 
Category PCR Croup n(%) AOR (95% CI) Yes No
HRV Positive 9(2.8) 316(97.2) 0.31(0.15-0.64)
Negative 57(7.5) 700(92.5) 1 
RSV Positive 2(0.8) 255(99.2) 0.08(0.02-0.35) 
Negative 64(7.8) 761(92.2) 1 
HBoV Positive 3(3.8) 75(96.2) 0.63(0.19-2.05) 
Negative 63(6.3) 941(93.7) 1 
PIV3 Positive 4(7.0) 53(93.0) 0.92(1.32-2.67) 
Negative 62(6.0) 963(94.0) 1 
PIV1 Positive 14(38.9) 22(61.1) 8.31(3.88-17.81) 
Negative 52(5.0) 994(95.0) 1 
FLU A Positive 3(8.6) 32(91.4) 1.16(0.34-3.97) 
Negative 63(6.0) 984(94.0) 1 
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Table 22. Association between specific respiratory virus and diagnosis categories 
(continued). 
Category PCR Bronchiolitis n(%) AOR (95% CI) Yes No
HRV Positive 118(36.3) 207(63.7) 1.27(0.93-1.73)
Negative 241(31.8) 516(68.2) 1 
RSV Positive 121(47.1) 136(52.9) 1.89(1.37-2.61) 
Negative 238(28.8) 587(71.2) 1 
HBoV Positive 18(23.1) 60(76.9) 0.64(0.36-1.14) 
Negative 341(34.0) 663(66.0) 1 
PIV3 Positive 22(38.6) 35(61.4) 1.31(0.72-2.39) 
Negative 337(32.9) 688(67.1) 1 
PIV1 Positive 4(11.1) 32(88.9) 0.33(0.11-0.97) 
Negative 355(33.9) 691(66.1) 1 
FLU A Positive 5(14.3) 30(85.7) 0.50(0.18-1.42) 
Negative 354(33.8) 693(66.2) 1 
Category PCR Pneumonia n(%) AOR (95% CI) Yes No
HRV Positive 117(36.0) 208(64.0) 0.85(0.64-1.12)
Negative 306(40.4) 451(59.6) 1 
RSV Positive 93(36.2) 164(63.8) 0.93(0.69-1.26) 
Negative 330(40.0) 495(60.0) 1 
HBoV Positive 39(50.0) 39(50.0) 1.59(0.99-2.55) 
Negative 384(38.2) 620(61.8) 1 
PIV3 Positive 22(38.6) 35(61.4) 0.99(0.57-1.74) 
Negative 401(39.1) 624(60.9) 1 
PIV1 Positive 12(33.3) 24(66.7) 0.76(0.37-1.57) 
Negative 411(39.3) 635(60.7) 1 
FLU A Positive 19(54.3) 16(45.7) 1.68(0.84-3.37) 
Negative 404(38.6) 643(61.4) 1 
 
Abbreviation: HRV, human rhinovirus; RSV, respiratory syncytial virus; FLU A, influenza A 
virus; PIV, parainfluenza virus; HBoV, human bocavirus; AOR, adjusted odds ratio; CI, 
confidence interval; 
The multivariate analyses included the virus status and all these variables known as potential 
confounders (Age, Gender, Prematurity, Malnutrition, and Co-detection with other viruses) to 
calculate adjusted ORs. The results of the Hosmer-Lemeshow test indicated high goodness-
of-fit for the final model (p >0.05). 
 
The clinical severity score was higher in RSV, HRV, FLU A and HBoV single 
detection but this difference was not significant (Kruskal-Wallis test, p>0.05). Median 
duration of hospitalization of HBoV and RSV single detection was longer than that of other 
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viruses, however, the difference was not statistically significant (Kruskal-Wallis test, p>0.05). 
Other viruses such as FLU B, hMPV, HCoV, and AdV were not included in this analysis 
because of the small number of cases in each such category. 
4. DISCUSSION 
 The contribution of disease associated with respiratory viruses in developing and 
tropical countries is currently poorly described. The present study focused on the contribution 
of 13 respiratory viruses to children hospitalized with ARIs in the south of Vietnam, and 
elucidated the impact of each viral detection on the disease severity and the burden of ARIs.  
Viral detection and seasonal patterns 
In this study, a wide variety of viral agents associated with ARIs in children in 
southern Vietnam was described. Identifying 11 different respiratory viruses associated with 
high positive percentage of hospitalized patients in this study was in concordance with the 
previous studies conducted in Vietnam (26, 27). Altogether, by using PCR methods, these 
studies confirmed the diversity of respiratory viruses and the burden of viral ARIs in this area.  
One or more viruses were detected in 64.6% of ARI cases in this study. Since 2000, 
the introduction of PCR has increased the ability to detect respiratory viruses, including those 
are difficult to culture. Viruses accounted for 43-67% of ARI cases in studies during this time 
(43). The detection rate in the current study was higher than that in previous studies from 
surrounding countries such as Cambodia (44), Thailand (45), China (46), India (47), and 
Nepal (48). The differences in detection rates may be attributed to inclusive criteria, or the 
broader spectrum of studied viruses, or the more sensitive detection method such as PCR 
using in this study. It is obvious that a wider panel of target viruses is necessary to get the 
better possible yield of virus in hospitalized patients with ARIs. 
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HRV was the most common virus detected in this study with the rate of 30% of all 
ARI cases followed by RSV and HBoV. These 3 viruses accounted for 83.1% of viral 
positive patients, suggesting the significant burden of these viruses associated with ARIs 
among hospitalized children in this location. Using the high sensitivity method as PCR, HRV 
has been increasingly detected and shown to cause LRTIs among children (49, 50). This 
result is consistent with previous findings suggesting that HRV is one of the most frequent 
detected viruses of ARIs in children (37, 51-55). 
The positive rates for virus detection in this study varied dramatically from month to 
month, ranging from 47.4% (May 2010) to 90.2% (October 2010) (Fig. 2). The viral 
detection rates were highest during months when there were the most hospitalized patients 
with ARI (from August to October). Simultaneously, RSV detection also reached the peak 
during this time. Therefore, it could be inferred that the ARIs epidemics to some extent were 
driven by the respiratory viruses, especially the RSV. 
Although the detection rate was high, viruses were still not able to be identified in 
nearly 35% of enrolled children with ARIs. Several factors may account for this phenomenon. 
First, the utilization of nasopharyngeal flocked swab may have led to the poorer recovery of 
viruses compared with nasopharyngeal aspiration. However, the difference in yield rate was 
not significant (56). Moreover, the nasopharyngeal swab was less invasive for children and 
more acceptable for parents. Second, frozen specimens using for RT-PCR may have reduced 
the yield of viral detection since RNA may have degraded during freezing, thawing, and 
storing of the samples. Third, it is possible that some children may have had infection with 
bacteria or other viruses not included in the assays of this study (eg, enteroviruses, other 
types of HCoV such as NL63 and HKU1), or with agents yet to be discovered. Finally, 
despite the high sensitivity and specificity of PCR, the number of viral detection may have 
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been underestimated by using multiplex instead of monoplex assays, as some loss of 
sensitivity is an inherent limitation of multiplex PCR assays. 
Since this study spanned only 14 months, this duration is short to have any 
conclusions regarding seasonal patterns of different respiratory viruses. However, some 
interesting points were found. First, the RSV epidemic peaked in relation to the rainy season. 
This seasonal pattern is distinct from that in temperate countries where RSV infections 
usually occur in the winter (57). Second, different from temperate zone, FLU A activity in 
Vietnam was found in both rainy and dry seasons. Unlike in many temperate countries, where 
PIV infections were prevalent during autumn or spring (7), and other tropic countries, where 
PIVs did not show significant annual seasonality (58), PIV in this study was detected mainly 
during the dry season and filled in for the weak RSV season. Although the reasons for the 
seasonality are almost unclear, determining the seasonality of respiratory viruses is very 
important in guiding appropriate preventive strategies and clinical management.  
Clinical features of respiratory viruses and their association with severe disease 
In the current study, statistical significance was achieved for the detection of virus and 
its association with clinical severity (Table 4). The virus-positive patients tended to have 
more severe symptoms and higher severity score so that they sought the hospital care earlier 
than the virus-negative patients. Although the WBC count was found higher in the virus-
negative group, its sensitivity and specificity is not sufficient to differentiate bacterial from 
viral infection (59). Age from 6 to 12 months was a risk factor for virus detection, since 
maternal antibodies decrease dramatically but the immune system is not mature enough to 
protect the infants from infection at this age. Regarding diagnosis, potential viruses known to 
cause bronchiolitis such as RSV, HRV, and PIV3 accounted for a relatively large part in this 
study and explained why this diagnosis was seen significant more often in virus-positive 
group than in virus-negative group.  
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In this study, the relationship between overall co-detection and increasing disease 
severity could not be established. Recent studies have shown that co-detection are not 
uncommon events (43), however their effect on severity depends on the combination of 
different viruses (60).  
 Many viruses are responsible for ARIs and it is believed that the virus type may 
influence the clinical manifestations of infection. In this study, different age distributions of 
each virus type were found. This information may be useful in clinical practice. It is noted 
that more than one third of HRV positive cases occurred in infants under 6 months of age. 
This finding implies that HRV can cause a burden at a very early stage of life. 
As in previous literature, RSV is always associated with bronchiolitis. The fact that 
most of RSV positive cases were diagnosed as either bronchiolitis or pneumonia and 
associated with chest retraction demonstrated that RSV by far the most important pathogen in 
children, which is comparable to the results of other studies (55, 61, 62). Croup was a clinical 
picture associated uniquely to PIV1 as seen in other study (63). In addition, RSV and HRV 
were less likely to be detected from patients diagnosed as croup in this study. Similarly, PIV1 
was less likely to be detected from patients with bronchiolitis. This information is useful for 
physician in estimating the possible cause when the clinical diagnosis is made.  
 Of note, HRV was the most common virus detected from patients hospitalized for 
ARIs in this study and LRTIs also occupied two-thirds of HRV positive cases. In addition, 
HRV detection was also associated with the development of severe symptoms such as 
hypoxia and retraction. Moreover, majority of the patients with HRV detection (75%) had the 
onset of symptoms within 5 days before admission, suggesting HRV may be responsible for 
the symptom rather than bacterial superinfection in later presentation. HRV has also 
previously been demonstrated the ability to infect the lower respiratory tract (50, 64-66). 
Despite all these supporting data for the pathogenesis of HRV, caution must be considered 
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when interpreting the role of HRV since it could be found in approximately 15% 
asymptomatic individuals, compared with <5% of most other respiratory viruses (67). 
The newly discovered HBoV were detected in a substantial number of cases and 
representing the third most common virus in this study. Although HBoV detection was 
significantly associated with hypoxia, HBoV was frequently detected in combination with 
other pathogens. HBoV was also often detected from asymptomatic individuals. However, 
several studies showed that identification of single HBoV was more common in sick patients 
than in control subjects (20). Therefore the role of HBoV as the true pathogen remains to be 
determined.  
Although clinical signs and symptoms of various respiratory viruses are usually 
overlapping, this work found different clinical characteristics associated with common 
respiratory viruses. Taken together with the differences in seasonal patterns and the age 
distribution, it is possible to speculate the probability of diseases being caused by a specific 
virus. This may contribute to clinical benefits in developing country settings since facilities 
for virus detection are not available there. To document and analyze the demographic and 
clinical information is important, since it enables to put the results themselves into the 
practical context and allow them to be applied in clinical practice. On the other hand, 
knowledge of clinical information allows medical practitioners to link the potential risk 
factors and causes to the clinical outcomes, and helps to confirm the accuracy and reliability 
of the results.  
Antibiotics were used in three quarters of children hospitalized with ARIs. This 
probably reflects the reluctance of physicians to manage sick patients while having no 
effective tools to support the diagnosis. The availability of viral diagnostic tests might 
decrease the number of subjects who receive antibiotics for viral infections or decrease the 
duration of initially empiric antibiotic administration in patients hospitalized with ARIs. 
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Strengths and limitations 
The major strengths of this pediatric clinical study were the use of a highly sensitive 
multiplex (RT)-PCR for a wide range of respiratory viruses, the evaluation of important 
clinical characteristics, the high number of patients enrolled in the study, and the inclusion of 
whole spectrum of ARI disease severity, from mild URTI to severe cases of bronchiolitis and 
pneumonia, requiring oxygen supplementation. 
However, this study still has some limitations. First of all, the clinical diagnosis was 
sometimes not accurate. Differentiating between bronchiolitis and pneumonia was sometimes 
difficult and tended to be subjective assessment since the signs shown in each condition were 
overlapped. Despite this limitation, these two categories reflect the severe condition of LRTI 
and represent of what happen in real clinical situations. Second, although a wide spectrum of 
diseases and severities were included, a large number of outpatients were not recruited. 
Therefore, the results of this study cannot be applied to the general pediatric population. 
Since the study included only hospitalized children, the results may have the selection bias 
towards more severe diseases. However, the comparison clinical features of specific type 
virus with each other may still be valid since the groups being compared share the same 
selection bias of being hospitalized. Third, the detection of viruses in nasopharyngeal samples 
is not enough to confirm the cause of ARIs. The samples were not examined the viral load by 
quantitative PCR. The high viral load may have association with the cause of ARIs (68). 
Information regarding bacterial infection was also not available in this study since obtaining 
appropriate sputum from the lower respiratory tract is not feasible in young children and 
blood culture usually reveals low positive rates due to high rate of antibiotic usage before 
hospitalization. Moreover, the study lacked a control group. Due to the sensitivity of PCR, it 
is able to detect the remnant material of old pathogens along with current active pathogens. 
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Using control samples to detect pathogens in asymptomatic children would help determine 
the likelihood of these viruses being a true pathogen. 
Conclusions 
The results of this study confirmed the diversity of viruses found among the children 
were associated with ARIs among them in the south of Vietnam. HRV, RSV and HBoV were 
the most commonly detected viruses and may increase the severity of ARIs in children. 
Specific viruses were frequently associated with specific clinical syndromes, specific 
seasonal patterns and age distributions. The ARIs epidemics to some extent were driven by 
the respiratory viruses, especially the RSV. The findings of this study emphasize the 
important role of viruses associated with ARIs in both aspects: magnitude and severity. Up to 
now, while bacterial ARIs is able to put under control by antibiotics or vaccine against 
Streptococcus pneumoniae and Hemophilus influenzae type b, there are no effective measures 
to control ARIs caused by viruses. Sooner or later, when bacterial ARIs are well controlled, 
viruses will become more fatal threat to child life. So far, only vaccine against influenza is 
available. In addition, the cost for treatment of viral ARIs is high. Therefore, to prevent viral 
ARIs in developing country setting, the ability of early diagnosis and treatment as well as 
basic preventive measures such as nutrition and hygiene should be improved. Similar 
surveillances on common viral agents should be continued in the future in order to know the 
fluctuation of these viruses. Especially, the control group should be added so that the 
causative role of each virus could be explained more accurately. Identification of bacteria 
causing ARIs should be done. More knowledge on viruses causing ARIs in children would 
help to decrease the disease burden, not only for Vietnam but also for other countries. Better 
understanding of the epidemiology of viral ARIs is essential to enable prediction of outbreaks 
and for planning of preventive and therapeutic control measures. 
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CHAPTER 3 
MOLECULAR EPIDEMIOLOGY AND CLINICAL 
CHARACTERISTICS OF INFLUENZA A VIRUS IN VIETNAM 
DURING POST-PANDEMIC PERIOD 
1. INTRODUCTION 
Influenza virus infection is the major cause of morbidity and mortality in humans 
worldwide. The influenza epidemics lead to approximately 3 to 5 million severe illness cases 
and 250,000 to 500,000 deaths every year  (69). The ability to acquire genetic changes makes 
the virus to overcome the immunity from previous infections and causes yearly epidemics. 
The hemagglutinin (HA) and neuraminidase (NA) genes of influenza A (FLU A) viruses 
usually mutate at high frequencies (70). As a result, the accumulation of these mutations at 
critical positions may lead to alter the antigenic characteristics of surface glycoproteins and 
the antiviral drug susceptibility. Therefore, monitoring these genetic changes of influenza 
virus is important for vaccine strain selection as well as identification of the drug resistant 
strains.  
In addition, the influenza activity has been well described in temperate countries with 
outbreaks usually occurring during winter seasons (70). Thus, influenza vaccine is delivered 
annually to protect against the newly emerged influenza strains. In contrast, influenza virus 
circulates throughout the year with no clear seasonality in tropical regions. However, little 
epidemiological information about influenza makes it more difficult to develop the 
prevention and control programs in these settings (71). Moreover, it has been proposed that 
Southeast and East Asia are regions where influenza virus A/H3N2 first evolved before 
spreading worldwide (72, 73). Therefore, influenza virological surveillance in these areas is 
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necessary not only to understand the circulation of influenza viruses but also to identify the 
virus strains which may be included in the annual influenza vaccine composition. 
In this study, the molecular, clinical, and epidemiological characteristics of influenza 
A viruses circulating during the post-pandemic season 2010 – 2011 in Vietnam were 
described. These data may improve the understanding of the temporal and geographic 
circulation of influenza viruses and provide important information to develop the public 
health vaccination policies throughout the region. 
2. MATERIALS AND METHODS 
Patients and samples 
 The clinical samples and data collection was described in detail in chapter 1. 
Influenza virus detection and subtyping 
Samples positive for FLU A by screening PCR as described in chapter 1 were further 
subtyped as seasonal H1N1, seasonal H3N2, or pandemic H1N1 2009 by multiplex nested 
PCR (74). 
Sequencing and phylogenetic analysis 
 The HA, NA, and M genes of H1N1pdm09 and H3N2 viruses were amplified using 
gene-specific primers recommended by the World Health Organization (75). PCR products 
were then sequenced by the commercial company (Macrogen Japan Corp., Tokyo, Japan). 
Sequences were assembled by using Cap3 Sequence Assembly program (76). Vaccine strain 
and reference sequences used for the phylogenetic trees were obtained from the NCBI 
GenBank Database (www.ncbi.nlm.nih.gov/genbank) and GISAID EpiFluTM 
(www.gisaid.org). The sequence data and the phylogenesis were analyzed using BioEdit 
v.7.0.5 (77). Phylogenetic analysis was performed using MEGA 5.0.5 (78). The neighbor-
joining method (79) with maximum composite likelihood model (80) and 1,000 bootstrap 
50 
 
replicates was used to construct the phylogenetic trees. Deduced amino acid sequences were 
analyzed and compared with the vaccine strains A/California/7/2009 (H1N1pdm09) and 
A/Perth/16/2009 (H3N2). HA and NA numbering are accordant with the respective subtype. 
The HA, NA and M sequences in this study have been deposited in the GenBank 
database under accession numbers KJ955501-KJ955605. 
Antigenic site mapping of HA and NA 
The HA and NA protein sequences of influenza virus in this study were compared 
with the vaccine strains. The amino acid changes were mapped to the previously reported HA 
(81-83) and NA antigenic sites (84, 85). Protein structures were rendered by PyMol software 
v1.3 (http://www.pymol.org) using the HA (PDB: 3LZG for H1, 1MQL for H3) and NA 
(PDB: 3NSS for N1, 1IVG for N2) structures from Protein Data Bank (RCSB PDB, 
http://www.pdb.org) (86).  
Statistical analysis 
Demographic and clinical characteristics of patients singly detected with H1N1pdm09 
were compared to those with H3N2. Categorical variables between groups were compared by 
using χ2 test or Fisher’s exact test, and continuous variables were compared by using the 
Mann-Whitney U test. A two sided P-value <0.05 was considered statistically significant. All 
analyses were conducted using SPSS 16.0 software (Chicago, IL, USA). 
3. RESULTS 
Epidemiological characteristics of FLU A 
 Between April 2010 and May 2011, FLU A was detected in 35 of 1,082 samples 
(3.2%). Nine samples were found mixed detection with other respiratory viruses, such as 
human bocavirus (n=4), human rhinovirus (n=3), respiratory syncytial virus (n=1), and triple 
detection with human bocavirus and rhinovirus (n=1). FLU A subtyping was performed, and 
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14 samples were H1N1pdm09 and 21 were H3N2. Seasonal H1N1 subtype was not found in 
any samples. Co-detection was more common among H3N2 cases (7/21) than H1N1pdm09 
cases (2/14). Male positive for FLU A was more often than female (male:female = 1.7). The 
median age of children detected with FLU A was 15 months (range from 1 to 60 months). 
Children younger than 6 months had the lowest FLU A detection rate (1.4%) while those 
aged from 24 to 59 months had the highest detection rate (7.1%). It is noted that among 
children less than 5 years old, there is a progressive increase in FLU A positive rate with 
increasing age (Fig. 4). Of note, FLU A was detected in both seasons of this tropical country 
(Fig. 5). Right after the pandemic period, only seasonal H3N2 subtype was detected in the 
rainy season (May – October) of 2010. This was also the time when the Southern Hemisphere 
vaccine was typically available. Then, the H3N2 virus was replaced completely by the 
H1N1pdm09 virus in the following dry season (November – April), the typical time for the 
Northern Hemisphere vaccine being available. 
 
Figure 5. Seasonal pattern of FLU A from April 2010 to May 2011. 
Abbreviation: ssH3N2, seasonal H3N2; H1N1pdm09, H1N1 pandemic 2009; 
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Clinical characteristics of FLU A 
 To exclude the confounding that co-detection may cause, only samples with single 
detection of H3N2 and H1N1pdm09 were compared (Table 23). However, there were no 
statistically significant differences between the two groups. The median age of patients 
detected with H1N1pdm09 was higher than those with H3N2 (26.5 vs. 20.5 months). H3N2 
subtype was associated with LRTI more than H1N1pdm09 subtype (71.4 vs. 50%). One case 
of H1N1pdm09 (8.3%) had hypoxia and required oxygen supplementation. Patients with 
H1N1pdm09 detection had longer duration of hospitalization than those with H3N2 (5.5 vs. 
4.5 days). No influenza-positive cases in this study were severe enough to require mechanical 
ventilation or become fatal. None of them had vaccinated against influenza before or received 
any antiviral treatment. 
 
Table 23. Demographic and clinical characteristics of children detected with 
H1N1pdm09 and H3N2 viruses. 
Characteristics (%)  H1N1pdm09 N=12 H3N2 N=14  p-value 
Male  50.0 71.4  0.422 
Age (m)(IQR)a 26.5(13.5-32) 20.5(10-33)  0.757 
Flu vaccination  0.0 0.0  NA
Fever  83.3 100.0  0.203 
Cough  100.0 92.9  1.000 
Tachypnea  66.7 57.1  0.701 
Retraction  50.0 50.0  1.000 
SpO2≤92%  8.3 0.0  0.462 
Diagnosis   0.422
URTIs 50.0 28.6  
LRTIs  50.0 71.4  
Oxygen  8.3 0.0  0.462 
Antiviral drugs  0.0 0.0  NA
Hospitalization length (d)a  5.5 (5-10) 4.5 (3-9)  0.090 
 
Abbreviation: d, day; m, month; URTI, upper respiratory infection; LRTI, lower respiratory 
infection; NA, not applicable;  
Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets. 
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Molecular characterization and phylogenetic analysis 
Sequences in this study were blast searched in the NCBI Influenza Virus Resource 
and the GISAID EpiFlu database in order to find the similar sequences. Other strains from 
Vietnam, reference and vaccine strains were also analyzed together. Genetic groups in this 
study were named according to the WHO Influenza Centre London classification (87). 
a. H1N1pdm09 virus 
Phylogenetic analysis showed the simultaneous co-circulation of three influenza virus 
groups in Vietnam (Fig. 6). In detail, one Vietnamese strain (A/HoChiMinh/962.11/2010) 
clustered with other strains from Vietnam, Cambodia, Singapore, and Australia in 2009-2010. 
These strains were characterized by the double mutations A197T and S203T and formed an 
additional genetic group which had not been named in the WHO Influenza Centre London 
classification (87). Another strain (A/HoChiMinh/1137.2/2011) belonged to genetic group 6, 
characterized by the mutations D97N, S185T in the HA1 region and E374K, S451N in the 
HA2 region. This strain clustered with the European and North American strains in 2011. 
Finally, the rest of Vietnamese strains in this study formed a distinct cluster within genetic 
group 7, characterized by the mutations S143G, S185T, A197T, E374K and S451N. They 
clustered with strains isolated in East and Southeast Asia, Australia, Europe in 2010-2011 
and strains isolated in North and Central America in 2011-2012. Of note, all the Vietnamese 
strains in this study (except A/HoChiMinh/1137.2/2011 carried only L420V) carried all the 
substitutions L420V, D436E, and S539F that had not been reported in other influenza viruses 
before. These changes formed a unique signature for the 2010-2011 Vietnamese H1N1pdm09 
sequences. 
The HA protein of Vietnamese H1N1pdm09 showed some amino acid mutations with 
respect to the vaccine strain A/California/7/2009. Some of them located within the major 
antigenic sites Ca (H138Q, S203T), Cb (S71A), Sa (L161I), and Sb (S185T) of the HA 
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molecule (Fig. 8). Moreover, other mutations S143G and A197T were also found in the 
vicinity of the Ca and Sb antigenic sites. 
 
Figure 6. Phylogenetic analysis of HA (A) and NA (B) genes of influenza H1N1pdm09 
viruses circulating in southern Vietnam during 2010-2011.  
Phylogenetic trees were constructed with MEGA 5 software using the neighbor-joining 
method. Bootstrap values of greater than 70 % are shown at the branch nodes. Characteristic 
mutations of a particular branch are indicated on the left side nodes. Drug resistant mutations 
are shown in bold on the right of strains. The genetic group assignment is indicated by the 
brackets on the right. The influenza strains in this study are marked with solid round. The 
influenza strains from Vietnam are marked with solid triangles. Vaccine strain is shown in 
bold and italic. 
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The NA phylogenetic tree was generally compatible with the HA tree (Fig. 6). 
Compared with the vaccine strain, some of the amino acid substitutions of the NA protein 
involved in the antigenic sites J (S340F), L (S366N, N369K), and M (N386K). Additionally, 
none of the NA proteins contained the mutation H275Y, which are resistant to oseltamivir. 
However, two strains in this study carried the D199N and S247N mutations which were 
known to reduce the neuraminidase inhibitor susceptibility. 
b. H3N2 virus 
The phylogenetic analysis of the HA gene of H3N2 indicated that the 2010 
Vietnamese sequences formed a distinct cluster, most closely related to the A/Perth/10/2010 
subclade of the A/Victoria/208/2009 clade (Fig. 7). They did not group with the 
A/Perth/16/2009 clade (the vaccine strain). However, these two clades had similar 
antigenicity. These Vietnamese strains shared some similar key amino acid substitutions with 
the genetic groups 5 and 6 (D53N, Y94H, I230V, and E280A). They also carried the 
substitutions N389I, T485I, which had not been reported before. These mutations made the 
Vietnamese strains form the separate cluster from group 5 and 6. 
When compared with the vaccine strain (A/Perth/16/2009), the Vietnamese strains 
had some mutations within the antigenic sites A (K144N, R150I), C (D53N, S54R, N278Y, 
E280A, N310H), D (R208K, T212A, S214I, I230V), and E (K62E, G78D, Y94H) on the HA 
protein (Fig. 8). 
The NA phylogenetic tree was generally in agreement with that of the HA (Fig. 7). 
The NA protein also showed some mutations compared with the vaccine strain, in which 6 
located at 3 antigenic sites F’ (D339N), I’ (S367N, K369T), L’ (I464L, L466F, L466I) (Fig. 
8). 
The M gene analysis showed that all strains were resistant to Amantadine due to 
possession of the S31N substitution in the M2 ion-channel protein. 
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Figure 7. Phylogenetic analysis of HA (A) and NA (B) genes of influenza H3N2 viruses 
circulating in southern Vietnam during 2010-2011.  
Phylogenetic trees were constructed with MEGA 5 software using the neighbor-joining 
method. Bootstrap values of greater than 70 % are shown at the branch nodes. Characteristic 
mutations of a particular branch are indicated on the left side nodes. The genetic group 
assignment is indicated by the brackets on the right. The influenza strains in this study are 
marked with solid round. The influenza strains from Vietnam are marked with solid triangles. 
The Perth/10/2010 sub-clade is boldfaced. Vaccine strains for the Northern (N) and Southern 
(S) Hemisphere are shown in bold and italic and corresponding years are enclosed in boxes. 
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Figure 8. Mapping of mutations in antigenic sites of HA, NA proteins of influenza 
viruses in Vietnam during 2010-2011.  
Three dimensional structures of HA and NA were downloaded from the Protein Data Bank 
(RCSB PDB, http://www.pdb.org) and visualized using PyMol (http:www.pymol.org). The 
amino acids in the antigenic sites of Vietnamese strains were compared with vaccine strains 
A/California/07/2009 (H1N1pdm09) and A/Perth/16/2009 (H3N2). Amino acid substitutions 
at each antigenic site are color-coded. The drug resistant mutations in NA of H1N1pdm09 are 
also shown. PDB entry: 3LZG (HA, H1N1pdm09), 3NSS (NA, H1N1pdm09), 1MQL (HA, 
H3N2), 1IVG (NA, H3N2). 
 
Interestingly, one patient in this study was detected with the swine influenza H3N2 
variant (A/HoChiMinh/459.6/2010). This variant clustered together with other swine 
influenza viruses from Binh Duong province (Vietnam), Hong Kong and China. 
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4. DISCUSSION 
 Influenza virus is a major pathogen that causes epidemics with thousands of human 
deaths every year. Worldwide influenza epidemics were considered to be seeded by viruses 
originated from Southeast and East Asia (73). The lack of information about temporal and 
geographic circulation of influenza virus in these areas can threaten human health and 
compromise the prevention and control strategies. In this study, the seasonal, clinical and 
molecular characteristics of influenza A viruses circulating in Vietnam during the post-
pandemic period 2010-2011 were reported. 
 Unlike in temperate countries where a single peak of influenza infections is usually 
observed during winter seasons, in this study, influenza viruses were circulated throughout 
the year with 2 peaks occurring in the rainy and dry seasons. Not as expected, during the 
rainy season right after the pandemic period, no H1N1pdm09 virus was detected. Only H3N2 
virus was detected in this rainy season (May – October), which coincides with the winter 
season in the Southern Hemisphere. During the following dry season (November – April), 
which coincides with the winter season in the Northern Hemisphere, H3N2 virus was 
completely replaced by H1N1pdm09. The national surveillance in Vietnam from 2006 to 
2009 also revealed two peaks of seasonal influenza each year, one between June and October, 
and an additional minor peak during the winter time of the Northern Hemisphere (88, 89). 
Similar bimodal seasonal pattern of influenza activity was also reported in Thailand, 
Indonesia and India (90). Determining the onset and the duration of influenza epidemics in 
the community is critical in guiding the appropriate timing for influenza vaccination, 
especially for high risk individuals, as well as guiding the use of antiviral agents. 
 Vietnam has issued guidelines for the use of seasonal influenza vaccines and has been 
using the Northern Hemisphere formulation vaccine in the private sector (91). Due to 
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limitation of data on influenza seasonality, the usage of influenza vaccine composition was 
historically based on its hemispheric location. However, the phylogenetic analysis showed 
that the mid-2010 Vietnamese H3N2 viruses grouped with viruses from other countries in the 
winter 2010 – 2011 and belonged to the A/Perth/10/2010 subclade (Fig. 7). This subclade 
was antigenically similar to vaccine strain A/Perth/16/2009 in the 2010 winter season of the 
Southern Hemisphere and in the 2010 – 2011 winter season of the Northern Hemisphere. The 
Vietnamese H3N2 viruses did not group with the vaccine strain A/Brisbane/10/2007 in 2009 
– 2010. These data proved that the influenza activity in Vietnam appeared earlier than in 
other temperate climate countries in the Northern Hemisphere, and the current Northern 
Hemisphere vaccine usage may be too late to provide the optimal protection. These findings 
are consistent with the recent genetic relatedness analysis of seasonal influenza A viruses 
circulating in Vietnam from 2001 to 2009, which showed the high match with the Southern 
Hemisphere vaccine strains (29). Therefore, these results, taken together with previous 
studies (29, 88-90), suggest that the Southern Hemisphere formulation and timing should be 
considered for use in Vietnam instead of the current Northern Hemisphere one. This is in 
accordance with reports from Brazil emphasizing that the adoption of seasonal influenza 
vaccine based on hemispheric location may not apply to tropical countries (92). 
 It is also noted that the sub-clade A/Perth/10/2010, to which the strains in this study 
belonged, emerged and spread worldwide in the winter season of 2010 – 2011 (93). Some of 
the amino acid changes of this sub-clade were located in the globular head of the HA, with 
Y94H being exposed at the surface of the trimer. The I230V substitution was located within 
the receptor binding pocket. These mutations may contribute to the lower reactivity of this 
sub-clade to antiserum raised against the vaccine strain A/Perth/16/2009 (93). 
 Regarding H1N1pdm09, phylogenetic analysis showed that there was co-circulation 
of different genetic groups in Vietnam during the post-pandemic period. None of these 
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genetic groups were considered antigenically distinct from the vaccine strain. Most of the 
Vietnamese strains belonged to group 7, clustered with contemporary strains from East and 
Southeast Asia, Australia during 2010 – 2011. Moreover, they also tended to group with the 
North and Central American strains during the 2011-2012 season. These observations suggest 
that the American influenza viruses in 2011 – 2012 may have an Asian origin.  
Some of the amino acid substitutions were observed to locate within the major 
antigenic sites of the HA globular head. The S203T located within the Ca antigenic site but 
its buried position near the monomer-monomer interface makes its role unclear (82). The 
S185T located within the receptor binding site and the A197T located nearby may affect the 
binding of HA with its receptor (94). The E374K located in the HA oligomerization interface 
may have role in membrane fusion (95). The mutation D222G associated with more virulent 
genotype was not present in these samples (96). Recent studies have also found some 
important antigenic sites in the stem of HA, of which, the 2 unique mutations L420V and 
D436E in Vietnamese strains were located in the R1 and R2 antigenic sites (97). However, 
the antigenic properties of these viruses against the vaccine strain were not examined in this 
study. Therefore, whether these changes affect the vaccine effectiveness needs to be 
elucidated.  
In addition, the mutation associated with oseltamivir-resistant H275Y was not 
detected in this study. Instead, 2 mutations D199N and S247N on the NA, which reduced the 
neuraminidase inhibitor susceptibility, were found. It should be noted that none of the 
patients in this study were treated with antiviral drugs. The S247N was observed in viruses 
from Australia and Southeast Asia with mild reduction in oseltamivir and zanamivir 
susceptibility (98). The D199N mutation has recently detected from patients with oseltamivir 
resistance (99, 100) and exhibited to reduce susceptibility to oseltamivir and zanamivir (101). 
Although the D199E/G/N mutations have respectively shown to reduce susceptibility to 
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oseltamivir in seasonal H1N1, H5N1, and B influenza viruses, the effect of D199N mutation 
among H1N1pdm09 needs further investigation (99). It is also important to note that the 
viruses in this study were not cultured to avoid the generation of adaptive mutations in vitro. 
 In this study, the detection rate was lowest in infant younger than 6 months, increased 
with increasing age and reached the highest rate among children 24 – 59 months. This 
phenomenon implies that maternal antibodies may provide protection against influenza 
during infancy. Previous research has demonstrated that this protection lasted up to one year 
after maternal influenza immunization (102). When the children become older, the involved 
influenza virus strains have drifted far apart and therefore the previous protection could not 
cross-protect against the new strains. Although the H1N1pdm09 caused significant concern 
and increased recognition of influenza as an important public health issue, H1N1pdm09 was 
not associated with more severe disease than seasonal influenza in this study. This result was 
also supported by similar reports from Australia (103), Canada (104), Netherlands (105), and 
United States (106). 
The data reported in this study have several limitations. First, only 14 months of data 
were available. Additional surveillance data are needed to confirm the seasonality and the 
circulation of influenza viruses. Second, a small number of both H1N1pdm09 and H3N2 
influenza cases may hamper the ability to reveal the significantly clinical differences among 
them. According to the hospital’s triage process, patients with suspected influenza infections 
will be referred to Infectious Diseases ward for isolation and treatment. As only samples from 
Respiratory ward were collected, the number of influenza detection in this study may be 
underrepresented. However, this result was in line with the finding of recent systematic 
review indicating that influenza detection rate was 3% (2.2% - 4.0%) among children under 5 
years of age hospitalized with acute respiratory infection (107). Moreover, the detection rate 
might depend on different types of influenza virus affecting individuals of different ages, 
62 
 
with school-aged children were the most commonly affected (89, 108). Most of patients in 
this study were < 2 years of age might explain for the low influenza detection rate. Third, the 
data were only collected on patients seeking hospital care, thus the results may not reflect 
episodes of milder disease occurring simultaneously in the community. Finally, the study was 
lack of the antigenic assay against vaccine strains and the antiviral drug susceptibility tests. 
Therefore, the inferences regarding the protection of vaccine strains or of antiviral drugs are 
limited. However, the genetic data are also useful since amino acid mutations in some 
important regions usually correlate with significant antigenic changes (109). 
 Although safe and effective influenza vaccines have been used for more than 60 years, 
they are still not available as a part of public health programs in many Asian tropical 
countries. Nevertheless, the recent pandemic influenza in 2009 as well as the ongoing 
outbreaks of emerging avian influenza H5N1 and H7N9 have increased the awareness about 
the public health importance of influenza and the need to control influenza in this area. 
Currently, Vietnam and some other countries are developing their domestic capacity to 
produce influenza vaccine in response to pandemic preparedness. The findings in this study 
may help to understand better the influenza seasonality and the viral circulation, which are 
essential for deciding the optimal time for vaccination as well as the suitable vaccine 
formulation. These data may help policy-makers to inform and develop the influenza 
prevention and control strategies, not only in Vietnam but may also be applied throughout the 
region with similar influenza seasonal pattern. Continuing surveillance and characterization 
of circulating viruses in order to identify the emergence of genetic, antigenic, and drug-
sensitivity changes is critical to sustain the prevention and control policy. 
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CHAPTER 4 
MOLECULAR EPIDEMIOLOGY AND DISEASE SEVERITY OF 
HUMAN RESPIRATORY SYNCYTIAL VIRUS IN VIETNAM 
1. INTRODUCTION 
Respiratory syncytial virus (RSV) is the major cause of ARIs among infants and 
young children worldwide (110). The clinical presentations can vary from mild URTIs to life 
threatening bronchiolitis and pneumonia which result in significant pediatric hospitalization 
and economic burden (111). Primary RSV infections occur during the first year of life in 
more than 50 % of infants, and by 2 years of age, almost all children have been infected at 
least once (112). RSV can cause re-infections throughout life with milder disease, indicating 
that either RSV infection induces an inadequate immune response or genetic variability of 
RSV is extensive (113). RSV is a negative-sense single-stranded RNA virus that belongs to 
the Paramyxoviridae family. RSV is divided into two major groups, A and B, initially based 
on the reaction of the virus with monoclonal antibodies against the major structural 
glycoproteins G and F (114) and later by genetic analysis (115). Each group can be further 
subdivided into genotypes by nucleotide sequence variability. The attachment glycoprotein G 
is the most divergent viral protein, both between and within the two groups, and a major 
target for neutralizing and protective antibody responses (116).  
Along with the F protein, the second variable region at the C-terminal of the G protein 
that contains much of the G gene variability is commonly used in molecular epidemiological 
studies (117). So far, RSV group A is divided into 8 genotypes (GA1 to GA7, and SAA1), 
and so is RSV group B (GB1 to GB4, SAB1 to SAB3, and BA) (118). BA, which was first 
isolated in Buenos Aires in 1999, is a new genotype of group B with a 60-nucleotide 
duplication in the second variable region of the G protein gene (119). The two groups 
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circulate independently, but often at the same time, although group A viruses tend to 
predominate (112, 120). The presence of two groups has led to the speculation that there 
might be a relationship between the RSV-group infections and clinical severity. A number of 
studies were carried out but such a relationship has not been fully elucidated (121). 
Although RSV has been recognized as an important pathogen in childhood, there is no 
published information regarding the molecular epidemiology and clinical characteristics of 
RSV in Vietnam. The aims of this study were to investigate the molecular epidemiology of 
RSV, as well as to compare the clinical characteristics of diseases associated with the 
detection of group A and B strains in hospitalized children in Ho Chi Minh City, Vietnam. 
2. MATERIALS AND METHODS 
Patients and samples 
 The clinical sample and data collection was described in detail in chapter 1.  
Virus detection 
 All specimens were screened for RSV and other respiratory viruses such as influenza 
virus A and B, human metapneumovirus, parainfluenza virus types 1 to 4, human 
rhinoviruses (HRV), human coronaviruses (229E and OC43), adenovirus and human 
bocavirus by using multiplex semi-nested (RT)-PCR as described in chapter 1. The detection 
primers were targeted to the conserved region of nucleoprotein gene of RSV. 
Genotyping of RSV 
 All samples positive for RSV by screening test were then subjected to grouping and 
genotyping by a semi-nested PCR as described previously (117). The second hypervariable 
region of the G protein gene of RSV was the target for the outer and inner PCRs. The final 
product sizes were possible for differentiating RSV group A, group B, and genotype BA with 
each other. The genotypes within each group were further identified by sequence analysis.  
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The products of nested PCR were sequenced bi-directionally by the commercial 
company (Macrogen Japan Corp., Tokyo, Japan). The nucleotide sequences were analyzed 
and compared with the reference strains available in the GenBank database. The sequence 
data and the phylogenesis were analyzed using BioEdit v.7.0.5 (77). A parsimony analysis 
was also conducted using MEGA version 3.1 (122). The method was performed using close-
neighbor interchange with a random option and with 1,000 bootstrap repetitions. 
The sequences of RSVs detected in this study have been submitted to GenBank and 
assigned accession numbers JX079948-JX079993. 
Statistical analysis 
Demographic and clinical characteristics were compared between patients with RSV 
positive and those negative for RSV, between patients with RSV mono-detection and those 
with RSV co-detection, and among patients with RSV A, RSV B and mixed detection of both 
RSV A and B. Values were given as percentages for categorical variables, and as median 
with interquartile range (IQR) for continuous variables. Bivariate associations were assessed 
by using χ2 test or Fisher’s exact test for categorical variables, and by using the Mann-
Whitney U test or Kruskal-Wallis test for continuous variables, when appropriate. A two-
sided value of p<0.05 was considered statistically significant. All analyses were conducted 
using the Statistical Package for Social Sciences version 16.0 (SPSS, Inc., Chicago, IL, USA). 
3. RESULTS 
RSV detection and seasonal pattern 
 RSV was identified in 23.8% (257/1,082) of patients, represented the second most 
common virus following HRV. Additionally, RSV was co-detected with other viruses in 
28.4% (73/257) of all RSV positive samples. Co-detection between RSV and HRV was the 
most frequent (48 cases), followed by HBoV (15 cases). RSV A was the dominant subgroup 
66 
 
with 91.4% (235/257). RSV subgroup B had 5.1% (13/257). Of note, 9 cases (3.5%) 
contained both subgroup A and B. The RSV epidemic occurred during the rainy season, from 
May to October (Fig. 3). 
Molecular epidemiology of RSV 
 Twenty-seven RSV A and 19 RSV B samples were selected randomly for sequencing.  
Twenty-seven of the group A strains clustered into one genotype, GA2 (Fig. 9).  Of these, 9 
sequences were found only once. Of the remaining 18 sequences, 5 sequence groups were 
found, with 2 to 9 isolates per group. The rates of divergence between prototype strain A2 
and the Vietnamese strains were 12.2% to 14% at the nucleotide level and 24.2% to 28.8% at 
the amino acid level. Differences of up to 3.2% at the nucleotide level and 7.6% at the amino 
acid level were observed among the group A Vietnamese strains. The nucleotide and amino 
acid distances between the Vietnamese strains and the GA2 reference strains were up to 9% 
and 21.2%, respectively. The G protein gene of one of these strains, 1310-HCM/05.11-A, 
was identical to three sequences in GenBank, from Brazil (EU625712-SPIAL 1401/2006), 
Thailand (FJ489656-1359/BKK/07), and Scotland (HQ731741-R9061/07-08). 
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Figure 9. Phylogenetic tree for RSV-A nucleotide sequences based on 2nd variable region 
of G gene.  
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Phylogenetic tree was constructed with MEGA 3.1 software using the neighbor-joining 
method. Bootstrap values of greater than 70 % are shown at the branch nodes. The RSV 
strains in this study are marked with solid round. Prototype strain A2 (in bold face) for group 
A was also included. The genotype assignment is indicated by the brackets on the right. 
 
 All 19 of the group B strains belonged to the recently identified BA genotype, with a 
60-nucleotide duplication in the second variable region of the G protein gene (119). These 
BA genotype strains were further clustered into 2 recently described subgenotypes BA9 and 
BA10 (123) (Fig. 10). The nucleotide and amino acid variations among the Vietnamese BA 
genotype strains were up to 7% and 12.9%, respectively.  There was 2.5% to 6% divergence 
at the nucleotide level and 4.8% to 11.3% divergence at the amino acid level between the 
Vietnamese strains and the prototype genotype BA. Regarding the BA9 subgenotype, 
differences of up to 6% at the nucleotide level and 8.1% at the amino acid level were 
observed when comparing Vietnamese strains with reference strains. The nucleotide and 
amino acid distances between Vietnamese BA10 strains and BA10 reference strains were up 
to 5.5% and 11.2%, respectively. 
The deduced amino acid sequences of the group A and group B isolates were 
compared to those of the prototype A2 and BA strains, respectively (Fig. 11). Twenty-seven 
of the Vietnamese group A viruses exhibited changes in the stop codon position compared 
with that of prototype strain A2, which had 298 amino acids in the deduced G-protein 
sequence. Among these, 26 Vietnamese group A strains had a predicted G protein of 297 
amino acids, while 1 strain (763-HCM/09.10-A) had a premature stop codon that shortened 
the G polypeptide to 286 amino acids. 
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Figure 10. Phylogenetic tree for RSV-B nucleotide sequences based on 2nd variable 
region of G gene.  
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Phylogenetic tree was constructed with MEGA 3.1 software using the neighbor-joining 
method. Bootstrap values of greater than 70 % are shown at the branch nodes. The RSV 
strains in this study are marked with solid round. Prototype strain of BA genotype is marked 
with solid triangle. Prototype strain 18537 for group B was also included. The genotype 
assignment is indicated by the brackets on the right. 
 
The G protein genes of the BA genotype were predicted to encode proteins of 2 
different lengths, 312 (16/19 isolates) and 319 (3/19 isolates) amino acids. A serine (S) to 
proline (P) substitution was found within the 20-amino acid duplicated region at position 247 
in all the Vietnamese BA strains. In addition, 14 of the 15 BA9 strains had a V271A 
substitution relative to the BA prototype strain, whereas all 4 BA10 strains had an E292G 
change. The majority (11/15) of the BA9 isolates also had amino acid substitutions at 
positions 270 (T270I) and 287 (H287Y).  
The G protein is heavily glycosylated with both N-linked and O-linked sugars. Two 
putative N-glycosylation sites (NXT, where X is not proline) were identified in the second 
variable region of the G protein among the majority of the RSV A strains. The amino acid 
substitutions at some positions made these strains gain or lose the N-glycosylation sites. 
Similarly, two N-glycosylation sites were found to be conserved in all BA strains examined. 
Two of the BA10 isolates, 960-HCM/11.10-BA10 and 566-HCM/07.10-BA10, each acquired 
an additional N-glycosylation site as a result of amino acid substitutions at P231S and K258N, 
respectively. 
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Figure 11. Amino acid alignments of 2nd variable region of G protein from RSV-A (A) 
and RSV-B (B).  
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Alignments are shown relative to the sequences of prototype strain A2 (GenBank accession 
number M11486) (A) and genotype BA strain BA4128/99B (GenBank accession number 
AY333364) (B). The amino acids shown correspond to strain A2 G protein positions 221 to 
299 for the group A viruses or to strain BA4128/99B G protein positions 213 to 320 for the 
group B viruses. Identical residues are indicated by dashes. The two copies of the duplicated 
20-amino-acid region in group B viruses are indicated by rectangles. Stop codons are 
indicated by asterisks. Potential N-glycosylation sites (NXT, where X is not proline) are 
underlined. 
 
Disease severity associated with RSV detection 
To examine the disease severity in the RSV positive and negative groups, clinical and 
demographic data were compared (Table 11 and 12). With regard to age, RSV positive 
children were significantly younger than RSV negative ones (7 vs. 11 months, p<0.001).  
RSV positive patients were admitted to the hospital earlier in the course of their disease than 
RSV negative patients (2 vs. 3 days, p=0.017). They also had higher rates of fever (72.8 vs. 
65.5%, p=0.033), runny nose (82.5 vs. 70.5%, p<0.001), and chest retraction (68.5 vs. 51.0%, 
p<0.001). Most importantly, the clinical severity score of the RSV positive children was 
significantly higher than the RSV negative group (12 vs. 11, p=0.003). Regarding the 
diagnosis, RSV positive patients were more likely to have bronchiolitis (47.1 vs. 28.8%, 
p<0.001). 
To address the question of whether children with RSV co-detection have different 
characteristics to those with RSV mono-detection, attempts were made to compare these two 
groups (Table 24 and 25). Patients with RSV co-detection were more likely to be hypoxia 
than those with RSV single detection (Table 25). 
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Table 24. Demographic characteristics and medical history associated with RSV- mono-, co-detection and subgroups. 
Characteristics (%) RSV mono N=184 RSV co N=73 p-valueb RSV A N=163 RSV B N=12 RSV A&B N=9 p-valueb 
Male 64.1 60.3 0.570 65.6 41.7 66.7 0.244 
Age (m)a 7(3-13.5) 8(2-14) 0.914c 7 (3-13.5) 8.5 (3-16) 8 (2-11) 0.733d 
Age group 0.266 0.836 
<6m 41.8 45.2 42.3 33.3 44.4  
6-<12m 29.3 19.2 28.2 33.3 44.4  
12-<24m 17.9 26.0 17.8 25.0 11.1  
≥24m 10.9 9.6 11.7 8.3 0.0  
Prematurity (<37 wk) 10.3 13.7 0.512 9.8 16.7 11.1 0.751 
Malnutrition 6.5 5.5 1.000 4.9 25.0 11.1 0.021 
Days before hos.a 2(2-4) 3(2-4) 0.952c 2 (2-4) 2 (1-2) 3 (3-5) 0.065d 
 
Abbreviation: d, day; m, month; wk, week; hos, hospitalization; RSV, respiratory syncytial virus; NA, not applicable; mono, mono-detection; co, 
co-detection;  
Note: All results are expressed in percentages except for (a) in median with interquartile range between brackets;  
bChi-squared test was used except cMann-Whitney-U test and dKruskal-Wallis test were applied for continuous variables. 
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Table 25. Clinical features, diagnosis and treatment characteristics associated with RSV- mono-, co-detection and subgroups. 
Characteristics (%) RSV mono N=184 RSV co N=73 p-valueb RSV A N=163 RSV B N=12 RSV A&B N=9 p-valueb 
Fever 73.9 69.9 0.536 73.0 66.7 100.0 0.168 
Cough 93.5 94.5 1.000 92.6 100.0 100.0 0.437 
Runny nose 85.3 75.3 0.069 84.7 83.3 100.0 0.440 
SpO2≤92% 3.8 11.0 0.038 3.7 8.3 0.0 0.596 
Tachypnea 41.8 41.1 1.000 44.2 33.3 11.1 0.122 
Chest retraction 69.0 67.1 0.786 69.9 50.0 77.8 0.299 
Wheezingd 61.4 56.2 0.481 62.6 25.0 88.9 0.008 
Clinical Severity Scorea 12(8-13) 12(8-13) 0.326c 12 (8-13) 8 (7-8) 13 (8-14) 0.005d 
Diagnosis 0.234 0.854 
URTIs 18.5 9.6 19.6 16.7 0.0  
Croup 1.1 0.0 1.2 0.0 0.0  
Bronchiolitis 44.6 53.4 43.6 50.0 55.6  
Pneumonia 35.9 37.0 35.6 33.3 44.4  
Hos. durationa 6(4-8) 6(4-7) 0.983c 6 (4-8) 6.5 (3.5-8) 6 (3-6) 0.337d 
 
Abbreviation: d, day; m, month; wk, week; hos, hospitalization; URTI, upper respiratory infection; RSV, respiratory syncytial virus; NA, not 
applicable; mono, mono-detection; co, co-detection; 
Note: All results are expressed in percentages except for (a) in median with interquartile range between brackets;  
bChi-squared test was used except cMann-Whitney-U test and dKruskal-Wallis test were applied for continuous variables.  
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To assess the relationship between clinical severity and RSV subgroup, subjects that 
were co-detected with other viruses were excluded. One hundred and sixty-three cases with 
RSV A, 12 cases with RSV B, and 9 cases with mixed detection of both RSV A and B were 
compared (Table 24 and 25). No significant differences were found with respect to the 
presence of fever, cough, runny nose, tachypnea, chest retraction, and hypoxemia among the 
three groups. However, both wheezing and the clinical severity scores were greater in 
patients with group A and mixed A and B detection than those with group B detection 
(p<0.01). 
4. DISCUSSION 
 RSV is one of the most important respiratory pathogens among infants worldwide. 
The identification of RSV in about one fourth of cases in this study confirmed that this virus 
is a dominant agent of respiratory disease in children. This finding is in line with previous 
reports from Vietnam and other countries (26, 27, 45, 46, 61, 124).  
Regarding the seasonality in this study, the RSV epidemic peaked during the rainy 
season. RSV activity was completely absent for the 3 months of the dry season (February to 
April, 2011). The presence of RSV seasonality in relation to rainfall has been observed in 
India (125), Hong Kong (126), Thailand (62), the Philippines (62), Colombia (127), and 
Kenya (128). In tropical regions, children tend to be kept indoors during the rainy season, and 
the resultant crowding may account for the increased incidence of RSV infection. Another 
reason that has been suggested is that high humidity may help to prevent the virus from 
desiccation and loss of infectivity.  
RSV is the most common viral pathogen causing LRTIs among infants and young 
children. However, there has been no information about the molecular epidemiology of RSV 
in Vietnam. This report provides data on the molecular characteristics of RSV from 
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hospitalized children in Ho Chi Minh City and represents the first such study in Vietnam. 
Information from this study will contribute to the growing database on the molecular 
diversity of RSV circulating worldwide. The results of this study indicated that RSV 
subgroup A and B co-existed in one epidemic and cases with RSV subgroup A predominated 
over those with subgroup B. These findings are in agreement with majority of studies in 
many countries around the world including Germany (129), Belgium (130), Argentina (111), 
Kenya (131), Japan (132), and India (117), with various patterns of subgroup predominance. 
The identification of the GA2 as the predominant genotype in this study was 
consistent with the results of other reports. GA2 was the most common genotype of RSV 
group A found around the world and has persisted for many years (117, 129, 130, 132, 133). 
On the other hand, the G protein gene variable region of one Vietnamese strain was identical 
to strains from different parts of the world, including Thailand, Scotland, and Brazil.  
In this study, 26 out of 27 GA2 genotype strains were predicted to encode a G protein 
of 297 amino acids in length, while one strain was shorter, of 286 amino acids. This mutant 
strain was sequenced directly from the clinical sample. To my knowledge, there has been one 
previous report of such a mutant strain, by Cane and Pringle (134). In that report, an isolate 
with the G protein of 289 amino acids was obtained from virus culture. My strain was 
genotype GA2. The previously reported strain was genotype GA1 (data not shown). 
All Vietnamese subgroup B viruses fell  into a new genotype BA, which was first 
detected in Buenos Aires, Argentina during 1999 (119). The major characteristic of genotype 
BA is that the G protein gene contains a 60-nucleotide duplication in the second variable 
region. The BA genotype strains in this study were further clustered into 2 recently described 
subgenotypes, BA9 and BA10. These subgenotypes were first described from RSV isolates in 
Japan in 2006 (123) but have not been reported elsewhere until now. 
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The Vietnamese BA strains had two different G protein lengths, 312 and 319 amino 
acids, which were reported in previous studies (135). In addition, alterations had occurred so 
that the duplicated region was no longer identical to the original one. Since its first 
appearance, the BA genotype has spread globally and was reported from many regions 
around the world. Some recent reports also showed that genotype BA has gradually replaced 
the other group B genotypes (119). It is possible that these changes in the G protein enhance 
the attachment of the virus to the host cell, or result in the antigenic modification which 
allows this virus to escape the immune response. 
Potential N-glycosylation sites are thought to play an important role in helping viruses 
escape from the host immune response (136). The number and distribution pattern of 
glycosylation sites identified in this study were different between the 2 RSV subgroups. The 
group A strains in this study had 2 N-glycosylation sites within the second variable region of 
G protein while group B had 4 (Figure 11). Variations in the number and location of these 
sites can inhibit the recognition of RSV by antibodies to particular epitope (137).  
 The demographic and clinical information is important to put the results into a 
practical context and allow them to be applied in clinical practice. In the current study, 
statistical significance was achieved for the detection of RSV and its association with clinical 
severity. The RSV-positive patients tended to have more severe symptoms and a higher 
severity score that probably led them to seek hospital care earlier than the RSV-negative 
patients. 
The fact that nearly half of the RSV detection (42.8%) occurred in children under 6 
months showed that patients in this age group are the most vulnerable to RSV infections, 
despite the presence of maternal antibodies. Maternal antibodies are able to protect against 
severe RSV in children, however relatively high tilters are required (138). Unfortunately, 
with a half-life of 26 days antibodies received at birth quickly drop to unprotective levels 
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within the first month of life (138). The finding that RSV detection were mainly associated 
with bronchiolitis and pneumonia (47.1 and 36.2% of the cases, respectively), in which the 
diagnosis of bronchiolitis was significantly related to RSV, confirmed that this agent is 
important in LRTIs, as have other studies (139, 140). 
The co-detection has led to the speculation that the presence of several types of virus 
in one respiratory specimen may affect the clinical presentation of ARIs. Viruses might 
interact indirectly or directly, and the effect may depend upon which viruses are co-detecting. 
The co-detection of RSV with other viruses increased the risk of LRTIs or severe LRTIs were 
also observed in other studies (141, 142). No study specified the association of RSV co-
detection and hypoxia. In this study, most of RSV co-detections were in combination with 
HRV and HBoV, the 2 viruses that were associated with hypoxia in this population. That may 
explain for the increased rate of hypoxia in the RSV co-detection group. 
Regarding clinical manifestation of each group, by using a composite severity score, 
detection of RSV group A (either alone or mixed with RSV group B) were associated with 
more severe disease than detection with RSV group B. Besides virus factors, the clinical 
severity of RSV infection is also associated with epidemiological and host factors, which 
include socioeconomic status, age, prematurity, and underlying heart and/or lung disease. To 
exclude these confounding factors, patients with underlying diseases or having co-detection 
with other viruses were not included. 
Children with subgroup B were admitted to the hospital less frequently than those 
with subgroup A. Either subgroup B strains cause such a mild illness that there is no need to 
hospitalize the patient or the prevalence of subgroup B is truly low. However, in two studies, 
the proportions of children with subgroup A and subgroup B in the hospital and in the 
community were similar (143, 144). Although there was a small number of patients 
hospitalized with RSV B detection, 25% of them suffered from malnutrition. It could be 
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speculated that RSV B may cause mild diseases. Only on patients with risk factor such as 
malnutrition, RSV B may cause disease severe enough for hospitalization. 
Several studies have examined the relationship between clinical severity and RSV 
subgroups. In approximately half of these studies, group A seemed to be associated with 
more severe clinical disease (143, 145-149), whereas no such difference was found in the 
others (120, 150-155). In only two studies have group B infections been reported to cause 
more severe disease (156, 157). This inconsistency could be attributed to difference in study 
design and population, definition of disease severity, the distribution of RSV subgroups, etc. 
In the recent study, Houben et al. reported that disease severity correlated positively with 
viral load during primary RSV infection (36). 
The current study was limited to only one epidemic season. Because the predominant 
subgroups shift from year to year, the immunity against the previous circulating groups could 
have altered the severity of disease caused by specific subgroups. Therefore, continued 
observation and analysis of additional seasons is required to determine the association 
between subgroups and severity of disease. 
  In summary, RSV was found to be the agent most commonly and frequently 
associated with severe acute respiratory diseases in infants and children. Co-detection 
between RSV and other respiratory viruses were associated with hypoxia. The molecular 
characteristics of RSV were determined for the first time in Vietnam, and carried 
characteristics both similar to strains from other parts of the world and specific to Vietnam. 
Subgroup A and B of RSV were co-circulating and subgroup A was associated with more 
severe disease than subgroup B. Similar surveillance should be continued to follow the 
epidemiology of this virus. A better understanding of RSV epidemiology is essential to 
enable prediction of outbreaks and for planning preventive and therapeutic control measures. 
80 
 
CHAPTER 5 
HUMAN BOCAVIRUS IN CHILDREN WITH ACUTE 
RESPIRATORY INFECTIONS IN VIETNAM 
1. INTRODUCTION 
Acute respiratory infections are the leading cause of morbidity and mortality among 
children worldwide. Viruses are responsible for most of acute respiratory infections. Up to 
now, many viruses have been identified as the main cause of acute respiratory infections, 
such as respiratory syncytial virus, human metapneumovirus, influenza virus, parainfluenza 
virus, coronavirus, and adenovirus. However, a rather high percentage of acute respiratory 
infections still remains unknown the etiology. In recent years, several newly discovered 
viruses were reported to have association with respiratory infections, including human 
bocavirus (HBoV) (7). 
In 2005, HBoV was first identified in nasopharyngeal aspirate of children with acute 
respiratory infections in Sweden (9). This novel virus belongs to the family Parvoviridae, 
subfamily Parvovirinae, genus Bocavirus with the single-stranded linear DNA genome of 
about 5.3 kb. The genome contains three open reading frames encoding 2 non-structural 
proteins, NS1 and NP1, as well as 2 structural capsid proteins, VP1 and VP2. Up to now, four 
species of HBoV have been identified, namely HBoV1, HBoV2, HBoV3, and HBoV4. 
HBoV1 is predominantly detected in respiratory samples. On the contrary, HBoV2 – 4 have 
been found mainly in stool samples (20).  
Since its first discovery, HBoV has been widely detected in many countries. HBoV 
was mainly found in children with acute respiratory infections at the rate ranging from 1.5% 
to 19% (20, 158), indicating that HBoV is the third most common respiratory virus, after 
respiratory syncytial virus and human rhinovirus. However, in many epidemiological studies, 
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HBoV was co-detected frequently with other respiratory pathogens, as well as often seen in 
asymptomatic children, which raising the question about its causality. Despite of that, recent 
identification of HBoV in blood samples together with advances in serodiagnosis have 
provided the increasing evidence for a causal role of HBoV in respiratory illness (20). Most 
of the published studies so far emphasized on the prevalence and epidemiology of HBoV. 
Only a few reports provided data related to clinical characteristics of HBoV detection. 
Moreover, epidemiology of respiratory viruses seems to have the geographic and temporal 
characteristics. 
Therefore, this study was conducted on respiratory specimens obtained from 
hospitalized children with acute respiratory infections during a 14-month period in Vietnam 
to investigate the epidemiological features and specify the clinical characteristics associated 
with HBoV detection. A phylogenetic analysis of HBoV was also carried out. 
2. MATERIALS AND METHODS 
Patients and samples 
 The clinical sample and data collection was described in detail in chapter 1. 
Virus detection 
HBoV was detected by PCR method using pan-bocavirus primers as described 
previously (40). Briefly, a pair of primers AK-VP-F1 (5’-CGCCGTGGCTCCTGCTCT-3’) 
and AK-VP-R1 (5’-TGTTCGCCATCACAAAAGATGTG-3’) was used in the first PCR. 
Another pair of primers AK-VP-F2 (5’-GGCTCCTGCTCTAGGAAATAAAGAG-3’) and 
AK-VP-R2 (5’-CCTGCTGTTAGGTCGTTGTTGTATGT-3’) was used in the nested-PCR to 
amplify the partial VP1 gene of HBoV (576 basepairs). In addition, each sample was also 
screened for other respiratory viruses by using multiplex semi-nested PCR as described in 
chapter 1. 
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Sequencing and phylogenetic analysis 
 All HBoV positive PCR products were sequenced by the commercial company 
(Macrogen Japan Corp., Tokyo, Japan). The nucleotide sequences were analyzed and 
compared with the reference strains available in the NCBI GenBank database. The sequence 
data and the phylogenesis were analyzed using BioEdit v.7.0.5 (77). A parsimony analysis 
was also conducted using MEGA 5 (78). The method was performed using close-neighbor 
interchange with a random option and with 1,000 bootstrap repetitions. 
The sequences of HBoV detected in this study have been deposited in the GenBank 
database under accession numbers JX418234-JX418266, KF193582-KF193604. 
Statistical analysis 
Demographic and clinical characteristics were compared between patients with HBoV 
positive and those negative for HBoV, between patients with HBoV mono-detection and 
those with HBoV co-detection. Values were given as percentages for categorical variables, 
and as median with interquartile range (IQR) for continuous variables. Bivariate associations 
were assessed by using χ2 test or Fisher’s exact test for categorical variables, and by using the 
Mann-Whitney U test for continuous variables, when appropriate. A two-sided value of 
p<0.05 was considered statistically significant. All analyses were conducted using the 
Statistical Package for Social Sciences version 16.0 (SPSS, Inc., Chicago, IL, USA). 
3. RESULTS 
Epidemiological characteristics of HBoV 
 Between April 2010 and May 2011, HBoV was found in 78 samples (7.2%), 
representing the third most common agent after HRV (30%) and RSV (23.8%). Among these 
children positive with HBoV, 52 (66.7%) were mixed detection with other respiratory viruses, 
most frequently with HRV (n=16), followed by RSV (n=15). In addition, 5 cases had triple 
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detection of HBoV, HRV and RSV (n=3), FLU A (n=1), and PIV 3 (n=1). The male to 
female ratio of HBoV positive patients was similar to that of the enrolled patients (1.7 vs. 
1.8). The children with HBoV had a median age of 12 months (range from 1 to 62 months). 
Children younger than 6 months had the lowest detection rate (5.0%) while those aged from 
12 to 23 months had the highest HBoV detection rate (9.8%) (Fig. 4). HBoV was detected 
throughout the year. However, HBoV was detected more frequently during the dry season 
(December – April) than the rainy season (May – October) (9.8 vs. 5.7%, p=0.015, Fisher’s 
exact test) (Fig. 3). 
Clinical manifestations and disease severity 
The demographic and clinical characteristics at presentation of all enrolled patients 
are shown in Table 13 and 14. Patients with HBoV positive tended to be older than those 
negative for HBoV but the difference did not reach significance (median age 12 vs. 9 months). 
The difference on prematurity and malnutrition rates between HBoV-positive and HBoV-
negative children was also not significant. Fever, cough, runny nose, wheezing, and rales 
were the most frequently observed clinical signs among HBoV-positive patients. Patients 
with HBoV positive had a significantly higher rate of hypoxia (16.7 vs. 7.9%, p=0.007) 
which may result in longer hospitalized duration (median 6 vs. 5 days, p=0.02) than those 
were negative for HBoV. Rales were present in 76.9% of HBoV-positive patients, 
significantly higher than that of HBoV-negative patients, 65.1% (p=0.034). Vomiting and 
diarrhea were reported in 55.1% and 30.8% of patients with HBoV poitive, respectively. 
Abnormal findings on CXR were found in 82.1% of HBoV-positive patients. Regarding the 
diagnosis, HBoV was associated with diseases from the upper to the lower respiratory tract. 
In which, pneumonia was found more often in the children with HBoV positive than those 
negative (50.0 vs. 38.2%, p=0.04). No patient required mechanical ventilation. There was no 
fatal case. 
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Attempts were also made to compare the difference between HBoV mono- and co-
detection groups (Table 26 and 27). The median age of children with HBoV mono-detection 
was higher than those with co-detection (14.5 vs. 10.5 months). However, this difference was 
not statistically significant (p>0.05). The demographic characteristics and clinical symptoms 
or signs in HBoV mono-detection and co-detection children were similar, except for 
prematurity which was less common in HBoV mono-detection group (0 vs. 15.4%, p=0.047, 
Fisher’s exact test). 
Table 26. Demographic characteristics and medical history associated with HBoV-
mono- and co-detection groups. 
Characteristics (%) HBoV mono N=26 HBoV co N=52 p-valueb 
Male 65.4 61.5 0.807 
Age (m)a 14.5(9-17) 10.5(5.5-19.5) 0.461c 
Prematurity (<37 weeks) 0.0 15.4 0.047 
Malnutrition 19.2 9.6 0.287 
Days before hospitalization (d)a 3(2-5) 2(2-4) 0.596c 
 
Abbreviation: d, day; m, month; HBoV, human bocavirus; mono, mono-detection; co, co-
detection; Note: All results are expressed in percentages except for (a) in median with 
interquartile range between brackets.  
bChi-squared test was used except cMann-Whitney-U test was applied for continuous 
variables. 
Table 27. Clinical features, diagnosis and treatment characteristics associated with 
HBoV-mono- and co-detection groups. 
Characteristics (%) HBoV mono N=26 HBoV co N=52 p-valueb 
Fever 65.4 76.9 0.293 
Cough 92.3 92.3 1.000 
Runny nose 80.8 73.1 0.580 
Vomiting 46.2 59.6 0.336 
Diarrhea 26.9 32.7 0.795 
SpO2≤92% 11.5 19.2 0.526 
Tachypnea 53.8 42.3 0.349 
Chest retraction 53.8 55.8 1.000 
Wheezing 69.2 59.6 0.464 
Rales 73.1 78.8 0.580 
Abnormal chest X-ray 80.8 82.7 1.000 
Diagnosis   0.947 
URTIs 23.1 23.1  
Croup 3.8 3.8  
Bronchiolitis 19.2 25.0  
Pneumonia 53.8 48.1  
Hospitalization  duration (d)a 6(4-9) 6(4.5-10) 0.713c 
 
Abbreviation: d, day; m, month; URTI, upper respiratory infection; HBoV, human bocavirus; 
NA, mono, mono-detection; co, co-detection; 
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Note: All results are expressed in percentages except for (a) in median with interquartile range 
between brackets.  
bChi-squared test was used except cMann-Whitney-U test was applied for continuous 
variables. 
 
Molecular characterization and phylogenetic analysis 
The partial VP1 nucleotide sequences (454 basepairs) of all 78 positive specimens for 
HBoV were determined and compared with those of four established HBoV species 1 – 4 and 
the prototype strains ST1 and ST2 (DQ000495 and DQ000496). The phylogenetic analysis 
(Fig. 12) showed that all HBoV strains isolated in this study were clustered closely in the 
same branch with HBoV1 reference strains. This finding confirmed that HBoV1 was 
circulating in Vietnam. The sequence identity of 97.5 – 100% at the nucleotide level and 94.6 
– 100% at the amino acid level were observed among the HBoV positive strains isolated. All 
Vietnamese strains showed high nucleotide sequence identity of 97.5 – 100% and amino acid 
identity of 95.9 – 100% with HBoV1 reference strains. These sequences also shared 97.7 – 
99.6% and 98.0 – 100% nucleotide sequence identity as well as 95.9 – 99.3% and 96.6 – 
100% amino acid identity with the HBoV prototype strain ST1 and ST2, respectively. The 
partial VP1 sequences of three Vietnamese strains were identical to the HBoV prototype 
strain ST2.  
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Figure 12. Phylogenetic analysis of the partial VP1 nucleotide sequences of HBoVs.  
Phylogenetic tree was constructed with MEGA 5 software using the neighbor-joining method. 
Bootstrap values of greater than 70 % are shown at the branch nodes. The HBoV strains in 
this study are marked with solid round. Prototype strain ST1 and ST2 (in bold face) were also 
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included. Number of identical strains is indicated in the parentheses. The species assignment 
is indicated by the brackets on the right. 
4. DISCUSSION 
 HBoV is a newly discovered human parvovirus that was first described in 2005 in 
nasopharyngeal aspirate of children with respiratory infection (9). The discovery of this virus 
also raised the concerns about its causative role, as well as its community and clinical impact. 
Since then, HBoV has been detected frequently worldwide not only in the respiratory samples 
(21, 27, 124, 159-162) but also in human feces (161, 163, 164), serum (165, 166), saliva 
(167) and urine (168). The epidemiological status and genetic characteristics of HBoV 
circulating in children with acute respiratory infections in Vietnam, however, remains 
unknown. To understand better the epidemiology of HBoV, the presence of HBoV and other 
common respiratory viruses in patients with acute respiratory infections in this region was 
investigated. 
 In this study, the rate of HBoV detection was 7.2% among hospitalized children with 
acute respiratory infections. This rate is in accordance with previously published rates, 
ranging from 1.5% to 19% (20). The discrepancy observed in the rate of HBoV detection 
between these studies may be explained by the differences in study design affecting age, 
recruitment criteria, study settings, study periods; the differences between hospital-based and 
community-based study; the differences in clinical specimen examination, diagnostic 
methods with different sensitivity and specificity, or regional and temporal differences. In 
this study, HBoV was the third most common respiratory agent after HRV and RSV, and it 
was more frequent than FLU A, FLU B, and PIVs. Since the evidence of HBoV as a true 
respiratory pathogen becomes more convincing (9, 169, 170), the high detection rate implies 
that HBoV is responsible for a large burden of illness in young children with regard to health 
care utilization.  
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Regarding the season, although HBoV was detected throughout the year, its peak was 
in the dry season from December to April of this tropical area. However, no consistent 
seasonal distribution of HBoV was found in many previous reports. Most studies 
demonstrated that HBoV was detected year round with high prevalence in the winter and 
spring (9, 21, 161, 168, 171), while some other reports showed the increased HBoV detection 
in late spring and early summer (124, 162). On the other hand, some authors did not observe 
the obvious seasonal activity of HBoV (172-174). Since this study spanned for about one 
year, in order to get a clear view on seasonality of HBoV, the continuing surveillance is 
necessary. 
HBoV can be found in respiratory samples of all ages, but mainly in young children. 
In this study, the ages of HBoV-positive children ranged from 1 to 62 months, indicating that 
children over 5 years old were rarely detected with HBoV. The age group with the lowest 
detection rate was children younger than 6 months (5%). In contrast, the detection rate was 
highest among children 12 – 23 months (9.8%), the age at which most children have lost the 
maternal antibody protection, and decreased with the increasing age. These phenomena imply 
that maternal antibody against HBoV may protect the children during early infancy, and then, 
the immunity acquired from primary HBoV infection during early childhood may protect the 
children from getting later infection. The serological study in Japan revealed that nearly all 
individuals were seropositive for HBoV by the age of 5 years, and the seropositive rate was 
lowest in infants aged from 6 to 8 months and gradually increased with age (175). 
The main symptoms of HBoV detection were cough, runny nose, fever and signs of 
respiratory distress such as tachypnea, lower chest retraction, wheezing, and hypoxia, which 
are also commonly seen among patients with respiratory infections. Therefore, it is 
impossible to differentiate clinically the respiratory infections caused by HBoV and other 
pathogens. However, in this study some clinical features which were distinct for HBoV were 
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also observed. Hypoxia was seen more often among children with HBoV-positive than those 
with HBoV-negative, which may lead to longer hospitalization duration. Moriyama et al. also 
observed that hypoxia was more severe in HBoV-positive patients than in RSV-positive ones 
(176). In this study, half of HBoV-positive patients were diagnosed as pneumonia. The 
existing literatures, in which HBoV infection was confirmed by serum PCR or serodiagnosis, 
also noted the significant association between HBoV infection and pneumonia (160, 166, 177, 
178). 
Co-detection of HBoV with other respiratory pathogens was found frequently, with 
the rate of up to 83% (20). However, HBoV viremia has been documented to be significantly 
more frequent in children with acute respiratory infections than in the control group, which 
supports the causative role of HBoV in respiratory diseases (21, 160, 165, 173). In this study, 
66.7% of children with HBoV-positive were co-detected with other respiratory viruses. This 
result also confirmed that co-detection with other viruses was not an uncommon 
characteristic of HBoV. The overlapping seasonality of HBoV and other circulating viruses 
may explain for this phenomenon. Another explanation is the persistence, an interesting 
feature of HBoV (20). HBoV may persist in the airway rather long-lasting and the prolonged 
viral shedding may explain for the high co-detection rate observed in many studies.  
Unexpectedly, no correlation was found between co-detection and clinical symptoms. 
The rates of severe symptoms and lower respiratory tract infections did not increase in co-
detection group. Co-detection of HBoV and other respiratory viruses did not increase the 
disease severity. A quantitative PCR analysis may be helpful to clarify the role of HBoV to 
the respiratory diseases when being detected alone or together with other viruses. 
The phylogenetic analysis of HBoV strains in this study and the reference strains 
revealed that HBoV species 1 was circulating in pediatric patients with acute respiratory 
infections in Vietnam. The recent review summarized the current knowledge on HBoV 
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demonstrated that HBoV1 is predominantly found in respiratory samples, while the rest of 
HBoV species, including HBoV2, HBoV3, and HBoV4, have been found mainly in human 
stool (20). However, two studies of children with acute respiratory infections in Korea (179) 
and China (180) reported that the enteric HBoV2 was also identified in nasopharyngeal 
samples. Recently, the research from Japan reported the identification of all four HBoV 
species in respiratory samples from children with respiratory tract infections (181). To 
determine whether all HBoV species are involved with respiratory diseases, the pan-
bocavirus primers were used in this study. However, only HBoV1 was found in children with 
acute respiratory infections in Vietnam and is in line with the above review’s findings (20). 
The geographical differences may explain for the different distribution of HBoV species 
worldwide. The absence of HBoV2 – 4 in this study suggests these viruses may not directly 
involve in respiratory illnesses. The sequence analysis also revealed that the circulating 
HBoVs were closely related to the original strains. Most polymorphisms identified in this 
study did not result in amino acid changes at the corresponding protein. The high similarity 
suggests that HBoV1 genes may be highly conserved, and serological tests should be 
universal application and interpretation worldwide. 
In conclusion, this study provides the first data on the molecular background of HBoV 
among children with respiratory infections in Vietnam. Information from this study will 
contribute to the growing database on the molecular diversity of HBoV circulating worldwide. 
Moreover, these data indicated that HBoV seems to be an important and frequent pathogen in 
respiratory tract infection in children. Further surveillance and molecular characterization of 
HBoV including the healthy control group and using serology and/or PCR detection of HBoV 
in blood is essential to clarify the clinical impact as well as to provide further genetic 
information of HBoV. 
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CHAPTER 6 
HUMAN RHINOVIRUS IN HOSPITALIZED CHILDREN: 
CLINICAL, EPIDEMIOLOGICAL  
AND VIROLOGICAL FEATURES 
1. INTRODUCTION 
Human rhinovirus (HRV) is the most common cause of URTIs in humans and 
frequently causes a mild, self-limiting illness often known as common cold. The development 
of PCR methods has markedly increased the detection of HRV and revealed greater 
association of HRV with more severe diseases in children such as bronchiolitis, pneumonia 
and asthma exacerbation (19, 49, 182). Therefore, their impact on overall morbidity and 
substantial cost for health care is thought to be considerable (183). HRV belongs to the genus 
Enterovirus, family Picornaviridae with highly genetic diversity. More than 150 serotypes/ 
genotypes of HRV have been described so far and classified into 3 main species: HRV-A, 
HRV-B, and the recently recognized HRV-C (184). However, the association between HRV 
species and clinical outcomes are still controversial. Initially, the new HRV-C species was 
reported to cause more severe diseases than HRV-A and HRV-B (184, 185), but recent data 
exhibited similar clinical syndromes across all species (186). 
Moreover, HRV is not diagnosed routinely in clinical practice, and the clinical impact 
of HRV compared with other viruses such as influenza, RSV is still not known much. 
Therefore, the role of HRV in ARIs need hospitalization is also not well established, 
especially in tropical countries.  
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In this study, prospective viral surveillance among hospitalized children was 
performed to assess the incidence, clinical and epidemiological characteristics associated 
with HRV detection as well as genetic diversity of HRV. 
2. MATERIALS AND METHODS 
Patients and samples 
 The clinical sample and data collection was described in detail in chapter 1. 
Virus detection and Sequencing 
Multiplex nested PCR assays were used to screen for 13 respiratory viruses including 
HRV as described previously (187). HRV was identified by using PCR primers, targeting the 
highly conserved 5’ untranslated region (5’UTR), that can detect all known serotypes as well 
as the novel HRV-C species (188). For species and type determination, another RT-PCR was 
performed to amplify the VP4/VP2 region on every 5th HRV-positive sample (n=58) (189). 
Both strains of PCR products were then sequenced by the commercial company (Macrogen 
Japan Corp., Tokyo, Japan). 
Phylogenetic Analysis 
Nucleotide sequences of the VP4/VP2 coding region (616 – 1004, numbered by 
EF582385) (190) were aligned along with reference sequences (obtained from 
http://www.picornaviridae.com). Phylogenetic trees were constructed by maximum-
likelihood analysis using the MEGA5 software, with the most suitable model for nucleotide 
substitution estimated by MEGA5, and bootstrap analysis of 1000 replicates (78). Types were 
assigned when the sequences in this study had ≥90 % nucleotide similarity to a known 
prototype sequence or clustered with a reference sequence in phylogenetic analysis with a 
bootstrap value above 70%. VP4/VP2 sequences in this study are available at GenBank under 
accession numbers KM676336-KM676393. 
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Statistical analysis 
Demographic and clinical characteristics of patients with HRV mono-detection were 
compared with those negative for any virus, those positive for other viruses than HRV, and 
those with HRV co-detection. Patients with HRV-A mono-detection were also compared with 
those with HRV-C mono-detection. Values were given as percentages for categorical 
variables, and as median with interquartile range (IQR) for continuous variables. Bivariate 
associations were assessed by using χ2 test or Fisher’s exact test for categorical variables, and 
by using the Mann-Whitney U test for continuous variables. A two-sided value of p<0.05 was 
considered statistically significant. A two sided value of p<0.05 was considered statistically 
significant. All analyses were conducted using SPSS 16.0 (Chicago, IL, USA). 
3. RESULTS 
Epidemiological and clinical characteristics of HRV 
HRV was found in 325 patients (30%), with 91 (28%) were mixed detection with 
other viruses. Of these, RSV was the most commonly co-detected agent recorded (48/91, 
52.7%). HRV could be detected throughout the year with several peaks occurred in July, 
November (2010) and January, April (2011). HRV-A and C were detected in almost every 
month with no clear seasonal distribution (Fig. 13).  
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Figure 13. Monthly distribution of HRV types from April 2010 to May 2011 
 
Abbreviation: HRV, human rhinovirus 
 
To determine the clinical findings associated with the presence of HRV, demographic 
and clinical characteristics of patients with HRV mono-detection were compared with those 
were negative for all viruses, those positive with viruses other than HRV, and those with 
HRV co-detection (Table 28 and 29). The median age of HRV mono-detection patients was 9 
months and comparable to other groups. The difference on prematurity and malnutrition 
prevalence between HRV mono-detection children and other groups was not significant. 
Regarding clinical symptoms, fever occurred less often in HRV mono-detection than in other 
groups (p<0.001). In terms of severe symptoms, children with HRV mono-detection were 
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more likely to have chest retraction (57.3% vs. 48.3%, p=0.031) and abnormal findings in 
CXR (80.5% vs. 70.7%, p=0.003) than those with PCR negative.  
Of note, mono-detection with HRV had more hypoxia than other viruses significantly 
(12.4% vs. 5.1%, p=0.002). However, the former also had higher white blood cell and 
neutrophil counts than the latter (11900 vs. 11300, p=0.006 and 4895 vs. 4020, p=0.004, 
respectively). Compared with HRV co-detection, HRV mono-detection was less likely to 
have chest retraction (57.3% vs. 70.3%, p=0.032). Finally, the blood eosinophil count was 
significantly elevated among patients with HRV mono-detection as compared with those with 
PCR-negative, or detection with other virus, or HRV co-detection (p<0.001). Pneumonia was 
the most common diagnosis among HRV patients followed by bronchiolitis and URTIs. 
During the rainy season, HRV was the second most common detected virus among patients 
with pneumonia and bronchiolitis after RSV. However, during the dry season when the 
activity of RSV was low, HRV emerged as the most common virus associated with 
pneumonia and bronchiolitis that needed hospitalized (Fig. 14). 
Regarding the association of HRV species and clinical characteristics, the difference 
between HRV-A and HRV-C mono-detection was compared. The median age of cases with 
HRV-C detection was higher than those with HRV-A detection but not significant (17.5 vs. 
10, p=0.192). No significant differences were observed between HRV-A and HRV-C with 
regard to epidemiological and clinical characteristics (Table 28 and 29). 
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Figure 14. Proportions of pneumonia and bronchiolitis associated with HRV and RSV 
detection during rainy and dry seasons. 
Abbreviation: HRV, human rhinovirus; RSV, respiratory syncytial virus; FLU, influenza 
virus; hMPV, human metapneumovirus; HCoV, human coronavirus; PIV, parainfluenza 
virus; HBoV, human bocavirus; AdV, adenovirus; 
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Table 28. Demographic characteristics and medical history of patients with HRV mono-detection compare to those with no detected 
respiratory virus, or with respiratory viruses other than HRV, and HRV co-detection, and HRV-A compare to HRV-C. 
Characteristics (%) HRV mono-detection N=234 
PCR negative 
N=383 
p-
value
Other viruses  
N=374 
p-
value 
HRV co-
detection N=91 
p-
value 
HRV-A (mono) 
N=28 
HRV-C (mono) 
N=12 
p-
value 
Male 71.8 61.1 0.007 63.9 0.044 64.8 0.228 64.3 75.0 0.716 
Age (m)a 9(4-19) 10(4-19) 0.425 9(4-17) 0.913 9(3-14.5) 0.628 10(6-20) 17.5(8-31.5) 0.192 
Prematurity 12.0 7.8 0.090 8.8 0.215 8.8 0.555 17.9 0.0 0.298 
Malnutrition 9.8 11.5 0.594 8.0 0.426 6.6 0.516 7.1 8.3 1.000 
Days before hos(d).a 3(1-5) 3(2-6) 0.127 3(2-4) 0.534 2(2-4) 0.232 3(2-6) 2.5(1-4.5) 0.342 
 
Abbreviation: d, day; m, month; hos, hospitalization; HRV, human rhinovirus;  
Note: All results are expressed in percentages except for (a) in median with interquartile range between brackets. Categorical variables were 
compared by using Fisher’s exact test, and continuous variables were compared by using Mann-Whitney U test. 
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Table 29. Clinical features, diagnosis and treatment characteristics of patients with HRV mono-detection compare to those with no 
respiratory virus detected, or with respiratory viruses other than HRV, and HRV co-detection, and HRV-A compare to HRV-C. 
Characteristics 
(%) 
HRV mono-
detection N=234 
PCR negative 
N=383 
p-
value
Other viruses  
N=374 
p-
value 
HRV co-
detection N=91 
p-
value 
HRV-A (mono) 
N=28 
HRV-C (mono) 
N=12 
p-
value 
Fever 50.0 68.1 <0.001 75.9 <0.001 71.4 <0.001 64.3 50.0 0.490 
Cough 90.2 88.3 0.509 93.3 0.167 93.4 0.516 89.3 91.7 1.000 
Runny nose 72.6 64.5 0.041 81.8 0.009 78.0 0.397 71.4 83.3 0.693 
SpO2≤92% 12.4 8.6 0.132 5.1 0.002 12.1 1.000 7.1 0.0 1.000 
Tachypnea 40.6 48.3 0.067 43.9 0.449 41.8 0.900 35.7 50.0 0.490 
Chest retraction 57.3 48.3 0.031 57.2 1.000 70.3 0.032 57.1 50.0 0.738 
Wheezing 63.2 55.6 0.064 58.0 0.203 64.8 0.898 57.1 75.0 0.477 
Rales 64.5 62.4 0.607 70.1 0.180 68.1 0.604 60.7 75.0 0.484 
Abnormal CXR 80.5 70.7 0.003 80.4 0.751 84.6 0.627 85.7 91.7 1.000 
WBCa (cells/mm3) 11900(10000-15200) 
12200(9400-
15500) 0.933 
11300(8990-
13700) 0.006 
11400(9170-
15500) 0.242 
12500(10500-
14700) 
13900(10500-
16300) 0.738 
Neutrophila 
(cells/mm3) 4895(2883-7560) 
4748(2872-
7434) 0.933 
4020(2409-
6377) 0.004 
3860(2526-
8048) 0.322 
4334(2859-
7805) 
6036(5328-
8935) 0.457 
Eosinophila 
(cells/mm3) 239(109-482) 118(41-303) <0001 99(38-197) <0.001 127(62-268) <0.001 195(105-317) 383(187-437) 0.086 
Diagnosis   0.006  0.040  0.529   0.557 
URTIs 26.9 21.7 0.144 18.7 0.020 19.8 0.201 17.9 33.3  
Croup 3.0 8.6 0.006 6.4 0.087 2.2 1.000 3.6 0.0  
Bronchiolitis 34.6 27.9 0.087 35.8 0.794 40.7 0.369 32.1 16.7  
Pneumonia 35.5 41.8 0.127 39.0 0.391 37.4 0.797 46.4 50.0  
Hos. Duration(d)a 5(3-8) 5(3-8) 0.776 6(4-8) 0.084 6(4-8) 0.078 5(3.5-7.5) 4.5(3.5-7) 0.850 
 
Abbreviation: d, day; hos, hospitalization; URTI, upper respiratory infection; HRV, human rhinovirus;  
Note: All results are expressed in percentages except for (a) in median with interquartile range between brackets. Categorical variables were 
compared by using Fisher’s exact test, and continuous variables were compared by using Mann-Whitney U test. 
99 
 
Molecular characterization and phylogenetic analysis 
In all, 58 out of 325 samples were randomly selected for sequencing. By VP4/VP2 
sequence analysis, HRV-A was the major detection (44/58, 75.9%) followed by HRV-C 
(14/58, 24.1%). No HRV-B was found. There were 21 different HRV-A types and 10 
different C types. The most commonly detected types were A12 (n=9) and C40 (n=3) (Fig. 
15). Although partial samples were typed, it seems that the circulation of more types may be 
responsible for the peaks of HRV activity (Jul 2010: 4 types; Oct 2010: 7 types, Nov 2010: 5 
types; Apr 2011: 5 types). Some types were found across several months, such as A12, A78, 
and C40, suggesting that these types may circulate in the population over long time periods. 
On the other hand, the almost distinct type distributions from month to month have proved 
the rapid turnover and diversity nature of HRV populations. The mean nucleotide difference 
between HRV-A and HRV-C was 37.2%. The mean nucleotide variability within HRV-C 
was greater than that within HRV-A (23.9% vs. 19.7%).  
One HRV-A sequence (VNM308-MAY.2010) did not cluster with any previously 
known types and showed 13% nucleotide difference to the nearest reference types (A88, 
A89), suggesting the new type. By BLAST searching, only 3 sequences with 97 – 99% 
similarity were found in GenBank (as of 24 Sep 2014), and all were from neighbor countries 
(Thailand, Cambodia). These strains showed the pairwise-distances of at least 11.3% with all 
available A88, A89 sequences and formed a separate cluster with high bootstrap value (Fig. 
15). Following the criteria proposed by McIntyre et al. (pairwise-distance >10.5%), these 
strains could be assigned as new type. However, their VP1 sequences which are required for 
type assignment are not available, they may be designated as provisionally assigned type 
(numbered sequentially as HRV Apat5) (190).  
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Figure 15. Diversity of HRV types detected in the study.  
Phylogeny of the VP4/VP2 sequences of HRV-A, HRV-C, HRV-Apat5 detected in this study 
and reference strains were constructed with MEGA 5 software using the maximum-likelihood 
method. Data were bootstrap re-sampled 1000 times to assess the robustness of branches, 
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values of greater than 70 % are shown at the branch nodes. The HRV strains in this study are 
marked with solid round. HEV-D (HRV-87) (GenBank number AY040243) sequence was 
used to root the trees. 
 
4. DISCUSSION 
 This study documented a significant burden of HRV in children with ARIs. HRV was 
by far the most frequently detected, in the majority as mono-detection, among children ill 
enough to be hospitalized. HRV was also more common than RSV, which is well-known to 
be the major causes of hospitalization in children. Consistent with the findings of previous 
studies worldwide, where HRV detection rates varied from 26% to 33% in hospitalized 
children (51, 191-196), HRV was found in 30% of patients in this study. Although the 
clinical value of HRV detection was arguable due to the identification of HRV from 
asymptomatic individuals, there was still strong association of HRV detection with true 
infection, especially in children less than 2 years old (192, 197, 198).  
In addition, HRV has been shown experimentally the ability to infect the bronchial 
epithelium of immunocompetent individuals and replicate in the lower airways (50, 64-66). 
This contradicts previous assertion considered HRV as a “common cold” agent and causes 
mild diseases. When compared to children positive with other viruses, those hospitalized with 
HRV were equally to have predisposing underlying medical condition (prematurity and 
malnutrition). That means HRV detection is associated with severe diseases requiring 
hospitalization even in previously healthy children. 
Despite traditionally associated with mild URTIs, HRV in this study was responsible 
for up to three-quarters of serious LRTIs in hospitalized children. Moreover, HRV detection 
was more likely to associated with severe findings such as difficult breathing, abnormal CXR. 
When compared with other viruses, in which RSV was the most prevalent, HRV also had 
more hypoxia significantly. The WBC and neutrophil counts were found higher in the HRV 
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mono-detection group. However, their sensitivity and specificity are not sufficient to 
differentiate bacterial from viral infection (59). Moreover, HRV infection has been proved to 
stimulate neutrophil chemoattractants which result in increasing blood neutrophil circulation 
(50, 199-201). Therefore, neutrophil elevation in this study may not reflect secondary 
bacterial infection in HRV. In addition, eosinophil count was significantly increased in HRV-
detected children as compared with other groups. In some conditions, HRV can stimulate 
cytokine production such as eotaxin, eotaxin-2 to attract and stimulate eosinophils (50). Since 
blood eosinophil count is the predictor of reactive airway disease, this finding is consistent 
with previous reports indicating early infection of HRV as an important risk factor for asthma 
development (182, 202). 
The most common co-detection was found between HRV and RSV. The high 
incidence and overlapping of seasonal distribution of both agents might explain for this 
phenomenon. No significant differences were seen in clinical symptoms related to HRV co-
detection, except for the more prevalence of chest retraction, reflecting the decrease of lung 
compliance and severe difficult breathing. Similar findings were found in some studies (194) 
but not in others (198, 203). Since HRV is known to have long shedding period, therefore the 
co-detection may be due to successive infections. However, patients with HRV co-detection 
in this study admitted to hospital earlier than those with HRV mono-detection or those 
positive with other viruses (2 vs. 3 days), suggesting the true co-detection is more likely. 
The present study indicates that HRV-A predominated over HRV-C while HRV-B 
was not detected. Similar findings were also reported with HRV-A being the most prevalent 
(191, 193). The absence of HRV-B may be due to either it is a minor species or its milder 
nature which does not lead to hospitalization. In the recent study, HRV-A was reported more 
common during infancy, while HRV-C was the most common species in older age group 
(186). Since the enrolled patients were almost young infants, it may explain why HRV-A was 
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found more frequent than HRV-C. The clinical features of children with HRV-A were similar 
to those with HRV-C. Moreover, there were no significant differences between both species 
in terms of severity, comparable with previous studies (186, 198). In contrast, other authors 
have suggested HRV-C might be responsible for more severe disease (184, 185, 191). The 
variations could be attributed to the difference either in viral load or in studied population and 
study designs. Therefore, these data should be treated with caution. 
Consistent with other studies, HRV was circulating throughout the year with several 
peaks of activity in this study (184, 193, 196, 197). Although seasonal variation is a common 
feature of many respiratory viruses, its causes are largely unknown. To some extent, the year-
round circulation of HRV may be explained by the great genetic diversity of HRVs. This 
speculation was supported by the rapid changing of HRV types from month to month. Even 
in some types that lasted for several months (e.g. HRV A12), the strains of the same type 
were often different (Fig. 15). Moreover, the peaks of HRV activity are likely due to the 
introduction of more HRV types into the community at the same time. These findings imply 
that HRV strains may circulate in the time-limited manner. On the other hand, the 
transmission of HRV may explain for the sustainability of HRV epidemics. First, HRV has 
long shedding period, typically 2-3 weeks (201). Second, the mild or asymptomatic HRV 
infection may be more likely to transmit the virus from one to others (204). Third, the non-
enveloped virion structure of HRV may increase the indirect transmission through surfaces 
(205). 
The using of VP4/VP2 sequences for classification and typing has been shown to 
agree well with the more reliable typing method using VP1 sequences. However, it is not 
sufficient for the identification of new types. Therefore, sequencing the VP1 of the novel type 
HRV Apat5 identified here is required for confirmation (190). 
104 
 
In summary, this study indicated HRV was associated with significant morbidity and 
severe LRTIs in hospitalized children. There were no differences between HRV-A and HRV-
C in terms of disease severity. The genetic diversity and changing of HRV types over time 
were observed and may be responsible for the year-round circulation of HRV. However, 
additional studies with healthy controls using quantitative PCR methods are needed to 
understand better the role of HRV in LRTIs. Moreover, as the impact of HRV becomes better 
defined, the preventive and therapeutic interventions for HRV infections should be implicated 
in clinical practice. 
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CHAPTER 7 
SUMMARY AND FUTURE WORK 
Acute respiratory infections remain a leading cause of morbidity, mortality among 
children worldwide. While epidemiological data is available from industrialized nations, 
limited information about etiologies of ARIs makes it difficult to improve the prevention, 
diagnosis and treatment in developing and tropical countries. Therefore, it is necessary to 
know the epidemiological and clinical features of agents associated with ARIs in these areas.  
By using PCR method to screen for respiratory viruses in nasopharyngeal swabs from 
hospitalized children in Vietnam, this study demonstrated that viruses were detected in 64.6% 
of cases. HRV (30%), RSV (23.8%), and HBoV (7.2%) were the most frequently detected 
viruses, followed by other viruses.  HRV was detected all year round, while RSV epidemic 
occurred mainly in the rainy season. FLU A was found in both the rainy and dry seasons with 
seasonal H3N2 in the former and H1N1pdm09 in the latter. Other viruses were predominant 
in the dry season. HRV was identified in all age groups. RSV predominantly affected 
children < 6 months, while the highest FLU A detection was found among children > 24 
months. PIV3 was detected mostly in the 6 – 12 month-old group, whereas the highest peak 
of PIV1 and HBoV detection was in the 12 – 24 month-old group. PIV1 was associated with 
croup and RSV was associated with bronchiolitis (p<0.005). Detection of HBoV and HRV 
was associated with hypoxia and RSV detection with chest retraction (p<0.05). These data 
show that a high incidence of virus-associated ARIs was found among hospitalized children 
in Vietnam. HRV, RSV, and HBoV were the most commonly detected agents and may 
increase the severity of ARIs in children. This demographic, epidemiological and clinical 
information is very useful to improve the diagnosis, prevention and treatment activities 
especially in resource-limited countries. 
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The genetic characteristics of leading viruses were further analyzed. Phylogenetic 
analyses showed that Vietnamese H1N1pdm09 sequences in 2010-2011 formed the distinct 
cluster, with other contemporary Asian and 2012-American sequences, suggesting a possible 
common ancestor. The Vietnamese H3N2 viruses in mid-2010 belonged to the emerging 
subclade Perth10/2010, which then spread worldwide in 2011. These results confirm that 
Southeast Asia may be the hot spot for influenza viruses to evolve before spreading 
worldwide. Although Vietnam locate in the Northern Hemisphere and are using the Northern 
Hemisphere vaccine formulation in private sectors, the Vietnamese influenza viruses in this 
study were well matched with the Southern Hemisphere vaccine formulation. Together with 
the bimodal seasonality of influenza found in this study, this information is useful for policy-
makers in development of the national vaccination program. Two strains carrying S247N and 
D199N in NA which reduced the neuraminidase inhibitor susceptibility were found. 
Mutations at antigenic sites were also identified in these viruses. One case was detected with 
the swine H3N2 variant. Surveillance of influenza viruses in tropical countries is important 
not only for the development of their prevention and control strategies but also for earlier 
identification of the emerging new strains that may be selected for future vaccine. 
RSV is a major cause of ARIs in children but information on the clinical and 
molecular characteristics of RSV infection in developing countries is limited. In this study, 
RSV A was the dominant subgroup, accounting for 91.4% (235/257), followed by RSV B, 
5.1% (13/257), and 3.5% (9 cases) had a mixed detection of these subgroups. The 
phylogenetic analysis revealed that all group A strains belonged to the GA2 genotype. All 
group B strains belonged to the recently identified BA genotype, and further clustered into 2 
new subgenotypes BA9 and BA10, firstly described in Japan. One GA2 strain had a 
premature stop codon which shortened the G protein length. This is the first time this mutant 
strain was identified directly from a clinical sample. RSV detection was significantly 
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associated with younger age and higher severity score than those without (p<0.005). Patients 
with RSV co-detection were more likely to be hypoxia than those with RSV single detection 
(p=0.038). RSV A detection was associated with more severe disease than RSV B detection, 
implying that determination of the subgroup at presentation would be useful for appropriate 
management and group A may have more priority than group B in choosing candidate strains 
for vaccine development. This is the first time the molecular features and disease severity of 
RSV were described in Vietnam. These results will not only contribute to the growing 
database on the molecular diversity of RSV circulating worldwide but may also be useful in 
clinical management and vaccine development. 
HBoV, a novel virus, is recognized to increasingly associate with respiratory 
infections of previously unknown etiology in young children. In this study, HBoV was the 
third most common detected virus (7.2%). HBoV was associated with severe diseases, as the 
rates of hypoxia and pneumonia were higher, and hospitalization duration was longer in 
patients with HBoV detection than in those without (p<0.05). The phylogenetic analysis of 
partial VP1 gene showed minor variations and all HBoV sequences belonged to species 1 
(HBoV1). These results imply that HBoV1 may have an important role in ARIs among 
children. 
HRV has been recently identified as the leading cause in asthma exacerbation, severe 
bronchiolitis and pneumonia. In this study, HRV was the most frequently detected virus 
(30%). Among HRV mono-detected children, 70% were diagnosed as either pneumonia or 
bronchiolitis, and 12.4% had hypoxia that needed oxygen supplementation. Children with 
HRV were more likely to have difficult breathing and abnormal chest X-ray (p<0.05). 
Children hospitalized with HRV had less fever but more hypoxia and high blood eosinophil 
count than those positive with other viruses (p<0.001). Co-detection of HRV had more 
difficult breathing than mono-detection (p<0.05). During the weak season of RSV (dry 
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season), HRV replaced RSV to become the most common virus associated with bronchiolitis 
and pneumonia. Among 58 randomly selected HRVs for sequencing, only 2 species were 
detected with HRV-A being more common (44/58) than HRV-C (14/58). The clinical 
symptoms of HRV-C were similar to those of HRV-A. Phylogenetic analysis revealed 
diversity of circulating HRV types including 21 types of HRV-A and 10 types of HRV-C. Of 
note, one strain of HRV-A showed a high nucleotide difference exceeding the defined 
threshold and proved to be new type. These results provide new insights into the burden and 
severity of HRV and highlighted the need for its routine diagnosis in hospital settings. 
In summary, this study confirmed the diversity and the importance of respiratory 
viruses associated with ARIs required hospitalization in Vietnamese children. Specific 
viruses were frequently associated with specific clinical syndromes, specific seasonal patterns 
and age distributions. The demographic, epidemiological and clinical information from this 
study is useful to improve the diagnosis, prevention and treatment activities especially in 
resource-limited countries. The molecular characterization of common respiratory viruses 
was determined for the first time in Vietnam, and some interesting results were found such as 
new type of HRV, new strain of RSV, and drug resistant strain of FLU A. 
However, many challenges still remain to be done in the future. First, new strains of 
RSV, abnormal swine H3N2 variant in humans, and new type of HRV were identified. 
Research on the full genome of these new strains is obviously necessary. Second, HRV and 
HBoV are among the most commonly detected viruses in patients with ARIs. Recently, 
increasing evidence shows a strong association of HRV and HBoV detection with severe 
LRTIs. Thus, identifying these viruses at presentation is very useful for physician to give 
appropriate treatment, prognosis, and prevention. Although a PCR assay used for the 
detection of HRV and HBoV has been developed, it requires skilled technicians and 
specialized instrumentation and is not suitable for the detection of these viruses in the field. 
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Therefore, a simpler, more rapid, and more sensitive diagnostic assay is needed. Since HRV 
has more than 100 serotypes, develop the rapid detection method such as Loop-mediated 
Isothermal Amplification assay (LAMP) is required. Also, develop a LAMP or an 
immunochromatography (IC) assay to detect HBoV is necessary. Third, more studies should 
be done to acquire the better information on bacterial ARIs. Bacteria and viruses are the most 
common pathogens causing pneumonia in children in developing countries. Laboratory 
confirmation of bacterial or viral pneumonia is often ether time-consuming or not available in 
some clinical settings. The management of pneumonia is often based on physician judgment 
using clinical, radiographic, and laboratory data. Using the combination of these data is 
possible to distinguish bacterial from viral pneumonia. However, the lack of validated clinical 
prediction rules in children has led to overprescribe of antibiotics in clinical practice, 
especially in developing countries. Therefore, there is the need to develop and validate a 
clinical prediction rule to distinguish bacterial from viral pneumonia in children. This project 
is in progress and has finished collecting samples (blood and naso-tracheal aspirate samples). 
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Appendix 1: Information sheet (English) 
Children’s Hospital 2  
Ho Chi Minh City 
INFORMATION FOR PATIENTS 
Tel: 84-8-38295723 
Fax: 84-8-38232137 
 
The study: Epidemiology and identification of causative agents among infants and 
children admitted to Respiratory department of Children’s hospital 2 with acute 
respiratory infections. 
 
Your child is invited to survey research on the epidemiology and identification of causative 
agents among infants and children with acute respiratory infections. First, it should be clear 
that: 
       It is up to your own willingness to join the research. 
       Even after joining, it is also your right to withdraw from the research at any time. And 
your child will still receive standard health care. No action will be taken against you. 
Please read this information sheet or ask a reliable person help to read. A copy of this 
information sheet will be given to you. Before agreeing to join the research, please take the 
time to ask for any further questions and discuss with your relatives, friends, doctor or the 
medical staff about this research. 
 
Overview of Research 
Acute respiratory infections (ARIs) are leading cause of morbidity and mortality among 
children worldwide. About 2 million children under 5 years of age died from pneumonia each 
year, and most of these deaths occurred in developing countries. Viruses are the most 
common cause of ARIs and the major reason for hospitalization of young children. However, 
due to limited resources and facilities, the role of individual respiratory virus in developing 
countries has not been well studied.  
 
Purposes 
To establish an effective prevention and treatment measures, better understanding of clinical 
and epidemiological characteristics of ARIs is needed. Moreover epidemiological study 
including molecular level is needed. For these purposes, clinical samples and data are 
examined. 
 
Methods  
Nasopharyngeal samples are collected from patients. Disinfected samples are transported to 
Nihon University for further molecular epidemiological studies. Other clinical information 
are recorded and sent to Nihon University. They are analyzed anonymously. The results are 
sent to your hospital after examined. 
 
Protection of privacy 
Clinical data and examined data are analyzed and reported to meetings and submitted to 
journals. Your personal data are anonymously recorded. Your private information will never 
leak to outside. 
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Risk 
There is very small risk for your child in this research. Obtaining nasopharyngeal swab 
sometimes may cause nausea or vomit, and no other risk.  
 
About bearing the expenses 
If you join the research, it will not cost you anything at all. There is also no payment for your 
nasopharyngeal swab donation. 
 
Withdraw of joining research 
Although you agree to join the research, you can withdraw from the research at any time. 
Your child will still receive the standard health care and no action will be taken against you. 
 
Enquiries 
Should you need any information, please do not hesitate to contact your doctor or the 
following address as given below: 
 
Please read the Informed Consents and if you agree, then sign the document. If you feel 
comfortable and allow us, we can start taking sample. We will highly appreciate your 
support. 
 
Thank you for your cooperation 
 
 
 
Dr. Tran Dinh Nguyen 
Cardiology department, Children’s Hospital 2 
14 Ly Tu Trong St., Ward Ben Nghe, District 1, Ho Chi Minh City 
Tel: 84 0908659102 
Email: dinhnguyentran@yahoo.com 
The project leader:  Prof. Satoshi Hayakawa, Nihon University, Japan 
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Appendix 2: Information sheet (Vietnamese) 
Bệnh viện Nhi Đồng 2 
Thành phố Hồ Chí Minh 
THÔNG TIN CHO BỆNH NHÂN 
Tel: 84-8-38295723 
Fax: 84-8-38232137 
 
Nghiên cứu: Dịch tễ học và xác định các tác nhân gây bệnh ở em nhập khoa hô hấp 
Bệnh viện Nhi Đồng 2 với bệnh nhiễm trùng đường hô hấp cấp tính. 
 
Con của Ông/Bà được mời vào nghiên cứu về đặc điểm dịch tễ học và tác nhân gây nhiễm 
trùng hô hấp cấp. Trước tiên, chúng tôi muốn Ông/Bà hiểu rằng: 
 Việc tham gia vào nghiên cứu này là hòan tòan tự nguyện. 
Ông/Bà có quyền từ chối không cho con của Ông/Bà tham gia vào nghiên cứu hoặc 
rút ra khỏi nghiên cứu bất kỳ lúc nào Ông/Bà muốn. Và con của ông bà vẫn được 
chăm sóc theo tiêu chuẩn của bệnh viện dù không tham gia vào nghiên cứu. 
Xin Ông/Bà đọc kỹ phiếu thông tin này hoặc nhờ một người tin cậy của Ông/Bà đọc giúp. 
Một bản sao của phiếu thông tin này sẽ được đưa cho Ông/Bà. Trước khi Ông/Bà chấp thuận 
đồng ý cho con của Ông/Bà tham gia vào nghiên cứu này, xin hãy dành thời gian để đặt câu 
hỏi cho bất kỳ thắc mắc nào và bàn bạc cùng người thân, bạn bè hoặc bác sỹ riêng hoặc các 
nhân viên y tế về nghiên cứu này. 
 
Tổng quan về nghiên cứu 
Nhiễm trùng đường hô hấp cấp tính là nguyên nhân hàng đầu gây bệnh tật và tử vong ở trẻ 
em trên toàn thế giới. Khoảng 2 triệu trẻ em dưới 5 tuổi chết vì viêm phổi mỗi năm, và hầu 
hết các trường hợp tử vong xảy ra ở các nước đang phát triển. Virus là nguyên nhân phổ biến 
nhất của nhiễm trùng đường hô hấp cấp và là lý do nhập viện chính của trẻ nhỏ. Tuy nhiên, 
do nguồn lực và cơ sở vật chất hạn chế, vai trò của các vi rút đường hô hấp ở các nước đang 
phát triển đã không được nghiên cứu kỹ. 
 
Mục đích 
Để thiết lập một biện pháp điều trị dự phòng hiệu quả, cần hiểu biết tốt hơn về đặc điểm lâm 
sàng và dịch tễ học của nhiễm trùng đường hô hấp cấp. Hơn nữa, nghiên cứu dịch tễ học ở 
cấp độ phân tử là cần thiết. Đối với mục đích này, các mẫu bệnh phẩm và dữ liệu lâm sang 
được khảo sát. 
 
Phương pháp 
Mẫu mũi họng được thu thập từ các bệnh nhân. Mẫu khử trùng được vận chuyển đến Đại học 
Nihon để nghiên cứu sâu hơn về dịch tễ học phân tử. Thông tin lâm sàng khác được ghi lại và 
gửi đến Đại học Nihon. Thông tin này được phân tích ẩn danh. Các kết quả được gửi lại bệnh 
viện sau khi kiểm tra. 
 
Bảo vệ sự riêng tư 
Dữ liệu lâm sàng và dữ liệu sau khảo sát được phân tích và báo cáo tại các hội nghị và gửi 
đến các tạp chí. Dữ liệu cá nhân của con Ông/Bà được ẩn danh. Thông tin cá nhân của con 
Ông/Bà không bao giờ bị rò rỉ ra bên ngoài . 
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Rủi ro 
Có rất ít nguy cơ xảy ra cho con Ông/Bà khi vào nghiên cứu này. Lấy phết mũi họng gây 
nhợn, đôi khi có thể gây nôn. Ngòai ra không có một nguy cơ nào khác. 
 
Về chi phí 
Nếu con Ông/Bà tham gia vào nghiên cứu, Ông/Bà sẽ không phải trả bất kỳ chi phí nào cho 
nghiên cứu này. Cũng không có thanh toán cho phết mũi họng Ông/Bà tặng cho chúng tôi. 
 
Từ chối tham gia nghiên cứu 
Mặc dù đã đồng ý tham gia nghiên cứu, Ông/Bà có thể rút ra khỏi nghiên cứu bất kỳ lúc nào. 
Cho dù con Ông/Bà không tham gia vào nghiên cứu, con Ông/Bà vẫn được điều trị và chăm 
sóc y tế theo đúng tiêu chuẩn. 
Thắc mắc 
Nếu Ông/Bà có bất kỳ thắc mắc nào về nghiên cứu này, xin vui lòng gặp bác sỹ điều trị hoặc 
bác sỹ có tên dưới trang thông tin này để được giải đáp. 
Xin vui lòng đọc các văn bản chấp thuận và nếu Ông/Bà đồng ý, sau đó ký tên vào tài 
liệu. Nếu Ông/Bà cảm thấy thoải mái và cho phép, chúng tôi có thể bắt đầu lấy mẫu. 
Chúng tôi rất cảm ơn sự hỗ trợ của Ông/Bà. 
 
Cảm ơn Ông/Bà đã hợp tác. 
 
 
 
BS. Trần Đình Nguyên 
Khoa Tim mạch, Bệnh viện Nhi Đồng 2 
14 Lý Tự Trọng, Phường Bến Nghé, Quận 1, Thành phố Hồ Chí Minh 
Tel: 84 0908659102 
Email: dinhnguyentran@yahoo.com 
 
Chủ nhiệm dự án: Giáo sư Satoshi Hayakawa, Đại học Nihon, Nhật Bản 
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Appendix 3: Informed consent (English) 
Children’s Hospital 2 
Ho Chi Minh City 
INFORMED CONSENT 
Tel: 84-8-38295723 
Fax: 84-8-38232137 
 
The study: Epidemiology and identification of causative agents among infants and 
children admitted to Respiratory department of Children’s hospital 2 with acute 
respiratory infections. 
 
Consent from parents or relatives: 
 
I was explained information about research and understood the points given below and I 
agree to join this research. 
 
I was explained the following points (check box). 
□Overview of the research 
□Purposes 
□Methods 
□Protection of privacy 
□Risk 
□About expenses which will be covered by the research project 
□Voluntariness and option to withdraw from research 
□Enquiries 
 
I agree to join the research and that sample is used for the research. 
Name of patient: _____________________________________________________________ 
Name of Relative: _______________________________ Signature: ___________________ 
Relationship to patient: ____________________________ Date: ______________________ 
Name of doctor who explained: ______________________ Signature: __________________ 
Date: ____________________________ 
 
Withdrawal of joining research 
 
Although I agreed to join the research, at this time I would like to withdraw. 
 
The study: Epidemiology and identification of causative agents among infants and 
children admitted to Respiratory department of Children’s hospital 2 with acute 
respiratory infections. 
 
Name of patient: _____________________________________________________________ 
Name of Relative: ________________________________ Signature: __________________ 
Relationship to patient: ____________________________ Date: ______________________ 
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Appendix 4: Informed consent (Vietnamese) 
Bệnh viện Nhi Đồng 2 
Thành phố Hồ Chí Minh 
ĐỒNG Ý THAM GIA NGHIÊN CỨU 
Tel: 84-8-38295723 
Fax: 84-8-38232137 
 
Nghiên cứu: Dịch tễ học và xác định các tác nhân gây bệnh ở em nhập khoa hô hấp 
Bệnh viện Nhi Đồng 2 với bệnh nhiễm trùng đường hô hấp cấp tính. 
 
Đồng ý của cha mẹ hoặc người thân: 
 
Tôi đã được giải thích thông tin về nghiên cứu và hiểu rõ những điểm dưới đây và tôi đồng ý 
tham gia nghiên cứu này. 
 
Tôi đã được giải thích những điểm sau đây: 
□ Tổng quan về nghiên cứu 
□ Mục đích 
□ Phương pháp 
□ Bảo vệ sự riêng tư 
□ Rủi ro 
□ Về chi phí sẽ được chi trả bởi các dự án nghiên cứu 
□ Tự nguyện và tự do rút khỏi nghiên cứu 
□ Thắc mắc 
 
Tôi đồng ý tham gia nghiên cứu và mẫu được sử dụng cho các nghiên cứu. 
Tên bệnh nhân: ______________________________________________________________ 
Tên của người nhà: ________________________________ Chữ ký: ___________________ 
Mối quan hệ với bệnh nhân: ________________________ Ngày: ______________________ 
Tên của bác sĩ giải thích: ______________________ Chữ ký: _________________________ 
Ngày: ____________________________ 
 
Rút khỏi nghiên cứu  
 
Mặc dù tôi đã đồng ý tham gia nghiên cứu, vào thời điểm này, tôi muốn rút lui. 
 
Nghiên cứu: Dịch tễ học và xác định các tác nhân gây bệnh ở trẻ em nhập khoa hô hấp 
Bệnh viện Nhi Đồng 2 với bệnh nhiễm trùng đường hô hấp cấp tính. 
 
Tên bệnh nhân: ______________________________________________________________ 
Tên của người nhà: ________________________________ Chữ ký: ___________________ 
Mối quan hệ với bệnh nhân: ____________________________ Ngày: __________________ 
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Appendix 5: Ethical approval (Children’s Hospital 2) 
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Appendix 6: Ethical approval (Nihon University School of Medicine) 
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Appendix 7: Questionnaire (English) 
ACUTE RESPIRATORY INFECTIONS QUESTIONNAIRE 
No. …………….                                                     Record No: ………………......... 
I. GENERAL INFORMATION 
    1. Name               :…………................………………………….        Male       Female  
    2. Date of birth           :…………………………................… Age: …… year …….. month        
    3. Address                  :…………………...........…………      Rural       Urban      
    4. Date of Examination :….......-……..-201 
    5. Date of Admission   :...……-…..…-201           Date of Discharge: …….…-……….-201 
    6. Name of Mother/ Father    :…………………………………………………………….. 
II. CURRENT ILLNESS 
    1. Chief complaint:…………………………………………………………………………. 
    2. Duration from onset of symptoms to admission:………………………………………… 
3. Symptom Yes No Unknown How many days? 
Fever     
Cough     
Rhinorrhea     
Sore throat     
Dyspnea     
Wheezing     
Red eyes     
Rash     
Headache     
Myalgia     
Nausea/Vomiting     
Diarrhea     
Others     
     4. Antibiotics before admission . 
 Antibiotic names:………………………………….…………How many days…………… 
III. PAST MEDICAL HISTORY 
1. Birth history: 
        - Number of babies in family: ……………/………….. 
        - Gestational age: ……………… weeks            < 37 weeks             ≥ 37 weeks       
        - Birth weight: ……………… g   < 2500 g            ≥ 2500 g  
        - Vaginal delivery  Vacuum extraction  Forceps  Cesarean delivery  Other  
………………………… 
        - Birth Asphyxia               Breast-feeding  . When to stop breast-feeding..................... 
        - Vaccination Diphtheria-Pertussis . How many shots and When……………………… 
                         Measles                     . How many shots and When……………………… 
                              Flu                             . How many shots and When……………………… 
2. Diseases: 
        - Congenital heart defect . Diagnosis of Congenital heart defect: …………………… 
        - Pulmonary hypertension       -Heart failure       - Ever needed ventilatory support  
        - Bronchopulmonary dysplasia                                - Neuromuscular disorders  
        - Immunodeficiency disorders  
        - Wheezing episodes . How many times: ………………………………………. 
        - Respiratory infections . How many times/year…….When was the last episode:.......... 
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        -   Other disorders (Down’s syndrome, cystic fibrosis, etc): …………………………… 
        -   Exposure to ARIs within 3 weeks :  At home   At school  Other:………… 
3. Family:  
         - Who is caregiver: ………………………………………………… 
         - Attending day care center  
         - Number of siblings at home: …………………          - House’s surface area: ………m2 
         - Any smoker at home  
         - Wood-burn stove  Oil-burn stove  Gas-burn stove  Other: ………………… 
         - Father: Occupation: …………………………… - Educational level: …………… 
         - Mother: Occupation: …………………………… - Educational level: ……………. 
         - Family Atopy  Type of Atopy: Allergic Rhino-conjunctivitis  Allergic Sinusitis      
                                                                 Food allergy         Drug allergy   
                                                                 Asthma                 Eczema          Other allergy  
         - Tuberculosis                 -Genetic disorders          - Immunodeficiency disorders    
IV. SYSTEMS EXAMINATION 
1. Vital signs: 
        - Consciousness:     Awake and Alert       Irritable        Lethargy  Other  
        - Central cyanosis        
        - Pulse: ………bpm    – Axillary temperature: ……oC   – Respiratory rate: ………rpm 
        - Weight: ………Kg   - Height: …… cm                       -  SpO2 = ….…..% /FiO2 =…….%                    
            - Malnutrition                     mild            moderate         severe              
2. Respiratory system:  
        - Cough                 - Rhinorrhea                                - Sneezing                                                         
        - Rash                    - Wheezing                                 - Stridor (when in rest)          
        - Tachypnea          - Lower chest retraction              - Nasal flaring                               
        - Abdominal and accessory muscles retraction            - Apnea >15 second              
Signs Left lung Right lung Signs Left lung Right lung 
Rales   Decrease breath sounds   
Ronchi   Dull sound   
Stridor   Overinflated   
Other   Other   
 
Other systems Normal Abnormal Abnormal signs 
ENT    
Cardiovascular    
GI    
Orthopedic    
Neurological    
Others    
Severity score    
V. INVESTIGATIONS 
1. CBC: 
       -WBC = .......... Neu/Gran=.........%. L=........%  Mono=........% E= ........% Baso=...........%. 
       - RBC = …....….M/mm3                           Hb     = ...……..g%             Hct    = ........…..%                          
       -MCV = ……...fl    MCH  = …..pg       MCHC = ………...g%            PLT = ..…..K/mm3 
       - Anemia  mild         moderate         severe      
CRP  mg/L Na+  mmol/L 
Urea  g/L K+  mmol/L 
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Creatinin  mg/L Ca++  mmol/L 
ALT  U/L Cl-  mmol/L 
AST  U/L Other   
2. Blood gas: 
pH   SaO2  % 
PaCO2  mmHg HCO3  meq/L 
PaO2  mmHg Base excess (BE)  meq/L 
3. Chest X-ray: Date: ……../………/201 
Normal      Abnormal     Not done  
Abnormal signs Upper R Middle R Lower R Upper L Lingular Lower L 
Interstitial opacity       
Brochial wall thickening       
Airspace opacity       
Consolidation       
Cavity syndrome       
Pleural effusion       
Pneumothorax       
Focal hyperinflation       
Diffused hyperinflation       
Collapse       
Bronchiectasis       
Pneumomediastinum       
Other       
Other  
Cardiomegaly , Cardio-thoracic rate =……………………………. 
Chest X-ray diagnosis:………………………………………………………………………… 
4. Sputum bacterial culture: Done  Neg  Pos . Bacteria name: ……………………… 
5. Blood bacterial culture:     Done  Neg  Pos . Bacteria name: …………………….. 
6. PPD test: Done       Pos ≥10mm         Neg  
7. HIV:        Done        Neg        Pos  
8. Pleural fluid:  Transudative      Exudative          Pus  
9. CSF:                                   Done  Normal  Abnormal  
10. Urinalysis:                       Done  Normal  Abnormal  
11. Urine bacterial culture: Done  Neg  Pos . Bacteria name: ……………………… 
12. Stool bacterial culture:  Done  Neg  Pos . Bacteria name: ……………………… 
13. ECG:                               Done  Nornal  Abnormal  
14. Echocardiogram: …………………………………………………………………… 
15. Other: ………………………………………………… 
16. Nasopharyngeal PCR result: ………………………………………………. 
VI. DIAGNOSTIC CATEGORIES 
Upper respiratory infections         
Croup                                               
Bronchiolitis                                   
Pneumonia                               
Other diagnosis along with: ………………………………………………………….. 
Other note: ………………………………………………………….. 
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VII. TREATMENT 
1. Oxygen: Canullas mask NCPAP Ventilator Max FiO2=...% Max PEEP=…cmH2O 
2. IV fluid . Type:……………………………………………………. 
3. Bronchodilator: Not use             
Nebulizer       Name:…………………………………….. Duration (d):…… 
Oral               Name:…………………………………….. Duration (d):…… 
IV                   Name:…………………………………….. Duration (d):…… 
4. Antibiotics: Not use             
Oral                Name:…………………………………….. Duration (d):…… 
IV                  Name:…………………………………….. Duration (d):…… 
IV                  Name:…………………………………….. Duration (d):…… 
IM                 Name:…………………………………….. Duration (d):…… 
5. Corticosteroids: Not use             
Nebulizer      Name:…………………………………….. Duration (d):…… 
Oral               Name:…………………………………….. Duration (d):…… 
IV                  Name:…………………………………….. Duration (d):…… 
6. Mucolytic .  Name:…………………………………………………………. 
7. Other          Name: …………………………………………………………….. 
8. Other:………………………………………………………………………. 
9. Physiotherapy  
VII. COMPLICATIONS:       
Respiratory failure                  Pulmonary superinfection     Sepsis              
Pleural effusion                       SIADH                                  ARDS              
Baro/Volutrauma of lung         Pulmonary fibrosis      Pulmonary hypertension episode  
Pneumothorax/mediastinum    Death                                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Appendix 8: Questionnaire (Vietnamese) 
PHIẾU THU THẬP SỐ LIỆU ARI 
STT …………….                                                     Số hồ sơ: ………………......... 
I. PHẦN HÀNH CHÁNH 
    1. Họ và tên               :…………................……………………….            Nam       Nữ  
    2. Ngày sinh               :……………………................… Tuổi: ……… tuổi ……….. tháng         
    3. Địa chỉ                    :…………………...........…………      Nông thôn       Thành thị      
    4. Ngày khám            :….......-……..-201 
    5. Ngày nhập viện     :...……-…..…-201                             Ngày XV: …….…-……….-201 
    6. Họ tên cha/mẹ       :………………………………………………………………….. 
II. BỆNH SỬ 
    1. Lý do nhập viện:…………………………………………………………………………. 
    2. Ngày bệnh trước khi nhập viện:…………………………………………… 
3. Triệu chứng Có Không Không thông tin Mấy ngày? 
Nóng/ Sốt     
Ho     
Chảy mũi     
Đau họng     
Khó thở     
Khò khè     
Đỏ mắt     
Nổi ban     
Nhức đầu     
Đau nhức cơ     
Buồn nôn/nôn     
Tiêu chảy     
Triệu chứng khác     
     4. Điều trị KS trước nhập viện . 
 Loại KS:……………………………………………….…………Số ngày………………. 
III. TIỀN SỬ 
1. Sản khoa: 
        - Con thứ mấy: ……………/………….. 
        - Tuổi thai: …………………….. tuần            < 37 tuần                 ≥ 37 tuần       
        - Cân nặng lúc sinh:……………… Kgram   < 2500 gram            ≥ 2500 gram  
        - Sanh thường   Sanh hút   Sanh kềm   Sanh mổ   Khác  ……………… 
        - Ngạt sau sanh                   Bú sữa mẹ  . Ngưng sữa mẹ lúc..................... 
        - Tiêm ngừa Bạch hầu-Ho gà   . Cách nay bao lâu……………………………… 
                         Sởi                      . Cách nay bao lâu……………………………… 
                              Cúm                    . Cách nay bao lâu……………………………… 
2. Bệnh lý của trẻ: 
        - Tim bẩm sinh  . Tật tim bẩm sinh: …………………………………………………… 
        - Cao áp phổi          -Suy tim                     - Có giúp thở  
        - Loạn sản phế quản phổi                             - Bệnh lý thần kinh cơ  
        - Suy giảm miễn dịch  
        - Khò khè . Số lần khò khè: ………………………………………. 
        - Nhiễm trùng hô hấp . Bao nhiêu lần ……/năm. Lần cuối cách nay bao lâu:........tháng 
        - Bệnh lý khác: ……………………………………………………. 
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        - Tiếp xúc ai bị bệnh hô hấp trong 3 tuần qua :  Ở nhà   Trường học  Khác:……… 
3. Gia đình:  
         - Người chăm sóc: ………………………………………………… 
         - Nơi sinh hoạt: Gia đình     Trường học  
         - Số người trong gia đình: …………………               - Diện tích nhà: ……………. 
         - Có ai trong nhà hút thuốc lá  
         - Nấu bếp củi          dầu hỏa              gas             Khác: ……………………… 
         - Cha: Nghề nghiệp: ……………………………………… - Trình độ học vấn: ……… 
         - Mẹ: Nghề nghiệp: …………………………….………… - Trình độ học vấn: ……… 
         - (Gia đình) Tạng dị ứng   Dạng dị ứng: Viêm mũi dị ứng            Viêm xoang           
                                                                             Dị ứng thức ăn                Dị ứng thời tiết  
                                                                             Dị ứng thuốc           Suyễn          Chàm  
         - Lao                                                 -Bệnh di truyền          - Suy giảm miễn dịch    
IV. KHÁM 
1. Sinh hiệu: 
        - Tri giác:     Tỉnh       Kích thích        Lơ mơ  
        - Tím trung ương        
        - Mạch: ……………l/p   .     - Nhiệt độ nách: ……………oC      – Nhịp thở: ………l/p 
        - Cân nặng: ……  Kg         - Chiều cao: …… cm            -  SpO2 = ….…..% /FiO2 =…….%                    
            - Suy dinh dưỡng                     nhẹ            trung bình         nặng              
2. Triệu chứng hô hấp:  
        - Ho                            - Chảy mũi                              - Hắt hơi                                                           
        - Nổi ban                    - Khò khè                                - Thở rít khi nằm yên          
        - Thở nhanh              - Co lõm ngực                   
        - Co kéo gian sườn    - Phập phồng cánh mũi           - Cơn ngưng thở >15 giây   
Triệu chứng Phổi Trái Phổi Phải Triệu chứng Phổi Trái Phổi Phải 
Ran ẩm/nổ   Phế âm giảm   
Ran ngáy   Gõ đục   
Ran rít   Ngực căng phồng   
Khác   Khác   
 
Cơ quan Bình thường Bất thường Dấu hiệu bất thường 
Tai mũi họng    
Tim mạch    
Tiêu hóa    
Da cơ xương khớp    
Thần kinh    
Khác    
Điểm LS    
V. CẬN LÂM SÀNG 
1. Máu: 
    - BC    = ..............Neu/Gran=.........%. L=........%  Mono=........% E= ........% Baso=...........%. 
    - HC    = ….....….triệu/mm3                           Hb     = ...……..g%             Hct    = ........…..%                     
    - MCV  = ……...fl     MCH  = …..pg       MCHC = ………...g%              TC = ..…..K/mm3 
    - Thiếu máu  nhẹ         trung bình         nặng      
CRP  mg/L Na+  mmol/L 
Ure  g/L K+  mmol/L 
Creatinin  mg/L Ca++  mmol/L 
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SGPT  U/L Cl-  mmol/L 
SGOT  U/L Khác   
2. Khí máu động mạch: 
pH   SaO2  % 
PaCO2  mmHg HCO3  meq/L 
PaO2  mmHg Base excess (BE)  meq/L 
3. X quang phổi: Ngày làm: ……../………/201 
Bình thường      Bất thường     Không làm , lý do:…………………………………… 
Bất thường Trên P Giữa P Dưới P Trên T Lưỡi Dưới T 
Thâm nhiễm mô kẽ       
Dày thành phế quản       
Thâm nhiễm phế nang       
Đông đặc       
Hình ảnh hang       
Tràn dịch màng phổi       
Tràn khí màng phổi       
Ứ khí khu trú       
Ứ khí lan tỏa       
Xẹp phổi       
Dãn phế quản       
Tràn khí trung thất       
Khác       
Khác  
Bóng tim to , chỉ số Tim/Lồng ngực=……………………………. 
Chẩn đoán Xquang:…………………………………………………………………………… 
4. Soi cấy đàm: có làm  Am tính  Dương tính . Loại vi trùng: ……………………… 
5. Cấy máu:      có làm  Am tính  Dương tính . Loại vi trùng: ……………………..… 
6. IDR: có làm       Dương tính ≥10mm         Am tính  
7. HIV: có làm        Dương tính        Am tính  
8. Dịch màng phổi:  Thấm      Tiết          Mủ  
9. Dịch não tủy: có làm        Bình thường        Bất thường  
10. TPTNT: có làm        Bình thường        Bất thường  
11. Cấy nước tiểu: có làm    Am tính         Dương tính . Loại vi trùng: …………… 
12. Cấy phân:         có làm    Am tính         Dương tính . Loại vi trùng: …………… 
13. ECG: có làm        Bình thường        Bất thường  
14. Siêu âm tim: …………………………………………………………………… 
15. Khác: ………………………………………………… 
16. PCR phết mũi họng: ………………………………………………. 
VI. PHÂN LỌAI CHẨN ĐOÁN 
Các lọai viêm hô hấp trên                      
Viêm thanh quản                   
Viêm tiểu phế quản                        
Viêm phổi                                        
Chẩn đoán khác đi kèm: ………………………………………………………….. 
Ghi chú khác về chẩn đoán: ………………………………………………………….. 
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VII. ĐIỀU TRỊ 
1. Thở oxy: canulla mũi mask NCPAP thở máy Max FiO2=..%Max PEEP=...cmH2O 
2. Dịch truyền tĩnh mạch . Tên:……………………………………………………. 
3. Dãn phế quản: không dùng             
Khí dung      Tên:…………………………………………….. Số ngày:…… 
Uống            Tên:………………………………………..         Số ngày:……. 
TM               Tên:………………………………………..         Số ngày:…… 
4. Kháng sinh: không dùng             
Uống            Tên:……………………………………….…       Số ngày:…… 
TM               Tên:……………………………………..……..    Số ngày:…… 
TM               Tên:…………………………………………..      Số ngày:…… 
TB                Tên:………………………….……………..         Số ngày:…… 
5. Corticosteroids: không dùng             
Khí dung      Tên:………………………………………         Số ngày:…… 
Uống            Tên:………………………………………..       Số ngày:…… 
TM               Tên:……………………………………….        Số ngày:…… 
6. Loãng đàm .  Tên:…………………………………………………………. 
7. Thuốc tim mạch  Loại thuốc: …………………………………………………………….. 
8. Khác:………………………………………………………………………. 
9. VLTL hô hấp  
VII. BIẾN CHỨNG:      
Suy hô hấp                                  Bội nhiễm phổi                               Nhiễm trùng huyết  
Tràn dịch màng phổi                Tăng tiết ADH không thích hợp       ARDS                      
Chấn thương áp suất, thể tích        Xơ hóa phổi                                  Cơn CAP                
Tràn khí màng phổi, trung thất, dưới da                                                 Tử vong                  
 
 
